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ABSTRACT
Approximately 0.3-0.4% of the general population has moderate or severe mental
retardation (MR) and X-linked mental retardation (XLMR) comprises -20-50% of all
forms of MR. The existence of XLMR has been recognised since 1929 and surveys
since then have confirmed the male excess of MR. In 1943, Martin and Bell reported
a family with MR and an unusual pattern of inheritance; the condition they described
is now known as fragile X syndrome and accounts for -40% of all XLMR. More
than 99% of fragile X syndrome is caused by expansion of a CGG repeat in the 5'
UTR of the FMR1 gene, and measurement of CGG repeat length is a diagnostic test
for the syndrome. Since the cloning of the FMR1 gene in 1991, many methods for
PCR amplifying across the repeat have been published. I evaluated some of these in
this laboratory and made several minor adjustments which resulted in some
improvements in terms of yield of product and reduction in lane background. I
concluded that the most reliable method for amplifying CGG repeats in the normal
and low premutation size ranges is PCR using a fluorescent primer.
In order to determine the proportion of MR due to fragile X, CGG repeat analysis
was carried out by both Southern blotting and PCR on DNA from 723 mentally
retarded patients in S.E. Scotland. This resulted in the identification of 8 new cases
of fragile X syndrome (-1% of the total number of referrals for developmental
delay). This developmentally delayed cohort was also compared to normal and high
1Q cohorts to address the possibility of a relationship between CGG repeat number
and IQ variation in the general population. Three interesting prenatal diagnostic
cases were studied in detail to answer important practical questions concerning the
nature and timing of repeat expansion.
Well over 100 other XLMR conditions have been described, of which approximately
50% have been regionally mapped. Some of these are non-specific forms of XLMR
in which MR is the only manifestation; others are XLMR syndromes with a
characteristic and well defined phenotype. A family with non-specific XLMR is
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described in which the proband presented as a non dysmorphic male with
unexplained MR, for exclusion of fragile X syndrome. He had a CGG allele in the
normal range and the MR segregating in the family was shown not to be linked to
FMR1. Subsequent analysis of polymorphic X-linked markers showed linkage to
Xq21.
A new XLMR syndrome is represented by a large family with severe MR and spastic
diplegia which was previously thought to be MASA syndrome, a condition caused by
mutations in the L1CAMgene in distal Xq28. Negative LOD scores with Xq28
markers led to a search for linkage to other regions; this was found in Xp22 where
several other XLMR loci are located, although the clinical features of this family
differ from that of other XLMR syndromes and conditions in Xp22.
Like MASA syndrome, X-linked hydrocephalus (HSAS) is caused by L1CAM
mutations. Linkage analysis of a Scottish HSAS family, however, indicated that a
second locus for the disease was located in Xq27.3, close to FRAXA. Despite this,
an L1 CAM mutation was later identified in the proband which segregated with the
disease in other family members. The most likely explanation for the discordant
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1. X-Iinked mental retardation
1.1 CLASSIFICATION OF MENTAL RETARDATION
Mental retardation is defined by the World Health Organization as "incomplete or
insufficient general development of mental capacities". The classification of mental
retardation assigns a performance index on two criteria; intelligence quotient (IQ)
and overall socio-adaptive behaviour, the latter taking into account the individual's
relative performance in school, at work, at home and in the community. Adaptive
functioning in people with mental retardation is influenced by personality
characteristics, motivation, education, and social and vocational opportunities and
may improve with remedial efforts whereas the IQ is likely to remain stable. Mental
retardation (MR) is divided into four groups ranging from mild to profound (Table
1), classified according to IQ. This is obtained by assessment with one or more
general intelligence tests; the most widely used today are the Stanford-Binet (which
tests children from 2 years of age to adolescence) and the Wechsler Intelligence
Scale for Children (WISC-R) which is applicable to children in the age range 6 to 16
years.
Classification Former classification Stanford-Binet Wechsler
Mild mental retardation Dull 52-67 55-69
Moderate mental retardation Simpleton/feeble-minded 36-51 40-54
Severe mental retardation Imbecile 20-35 25-39
Profound mental retardation Idiot <20 <25
Table 1. Psychological classification of mental retardation (according to the American
Association on Mental Deficiency).
1.2 HISTORICAL PERSPECTIVE OF X-LINKED MENTAL
RETARDATION
The excess of males among mentally retarded individuals was first recognised by
Lewis in 1929. He was appointed by the Board of Education to ascertain the extent
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of mental retardation in children, so that adequate education and care could be
provided for them under The Mental Deficiency Act of 1913 and The Education Act,
1921. At an early stage in the proceedings it became clear that the study should be
extended to include mentally retarded adults as well. His three and a half year
investigation involved studying children and adults living at home, children in
special schools, and residents of mental institutions and covered six different
geographical areas in England and Wales. Each of the areas contained a population
of about 100,000, (the six areas comprising one-sixtieth of the total population) and
represented different industrial groups and social strata. He observed from his study
that in children, a) "the mean incidence ofall grades ofdefect is about 17per
cent higher among boys than girls " and b) "the incidence of imbecility and idiocy
(severe and profound mental retardation) is about 30 per cent higherfor boys than
girls, whereas feeble-mindedness (moderate mental retardation) is only 14 per cent
higher". In adults, he noted that "the marked sex difference in the incidences ofthe
lower grade defect is again shown by the figuresfor adults; the mean incidence
among males is 33 per cent higher than thatforfemales, whereas the mean incidence
offeeble-mindedness is practically the same among men and women". He also
investigated the family histories of mentally retarded individuals to find out how
many of the families had two or more mentally defective individuals and noted that
the mother-son, mother-daughter pairs for all grades of mental retardation
outnumbered the father-son, father-daughter relationships by more than 2:1. This
ratio was 1.5:1 for severe and profound mental retardation. Although he made these
observations he confessed that he was unable to offer any satisfactory explanation for
the sex differences.
Another survey on the incidence of mental retardation was conducted in 1938 by
Penrose who published the results of a 6 year clinical and genetic study of 1,280
patients (710 males and 570 females) who resided in a mental institution in southern
England. During this intensive study, he recorded the patient's age, sex, "mental
grade", mental grade of the patient's father and mother, the relationship between the
parents, the number of brothers of each mental grade, the number of sisters of each
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mental grade, and the clinical diagnosis of the patient. Although his data showed a
26% excess of males in the profoundly mentally retarded and a 14% excess in the
severely retarded he stated that "zY is doubtful howfar this excess ofmales among the
idiots (profound MR) represents a real excess ofmale idiots in the general
population " and concluded that "unequivocal evidence for the significance ofsex-
linked genes in the causation ofmental defect was notforthcoming.
A few years later, however, Martin and Bell (1943), accepted "sex-linked"
inheritance as the explanation for the presence of severe mental retardation in a
family with 11 affected males in 2 generations; theirs was the first report of X-linked
inheritance in which mental retardation appeared as the primary manifestation. The
mode of transmission was unusual in that all the affected individuals were derived
from three sibs: two normal brothers and a normal sister. They suggested that some
controlling factor caused suppression of the disease in the normal brothers without
affecting their liability to transmit it. There were also two females in the family with
"slight mental deficiency" which the authors proposed was caused by an
incompletely recessive gene. Seven of the affected males in this family were re¬
examined in 1981 by Richards et al. and five were shown to have a fragile site in
Xq27.3 (two cultures failed). Some of the males had the typical facial appearance of
fragile X syndrome and some had macro-orchidism, although no mention of an
abnormal physical appearance was made in the original paper of Martin and Bell,
apart from one affected man who was described as having a "big face and jaw".
Richards et al., (1981) suggested that the condition should be designated "The
Martin-Bell Syndrome". Since the discovery of mental retardation in association
with a fragile site on the X chromosome (Lubs, 1969) other families have been
restudied and found to have fragile X syndrome. The family studied by Dunn et al.
in 1963, in which the authors concluded that ''the condition is determined by a sex-
linked gene ofvariable penetrance which appears to have entered the family through
the phenotypically normal male ancestor'" and that "the gene may be incompletely
recessive causing low-normal intelligence in heterozygous females" was restudied by
Fox et al. in 1980. This family was also found to have fragile X syndrome.
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A second family with X-linked mental retardation (XLMR) was reported by Allan et
al. in 1944, in which severe mental retardation was present in 24 males in six
generations. Affected males appeared normal at birth except for hypotonia but by six
months of age, they were unable to hold up their heads which led to the family's
description of the patients as "limber neck". They also had spastic paraplegia, ataxia,
dysarthria, athetoid movements, muscle hypoplasia and were incapable of speech.
Macro-orchidism was not present. At the time of the initial study in 1944, at least 15
women of reproductive age or younger were potentially carriers of this condition.
The family was re-investigated in 1990 (Schwartz et al.; Stevenson et al.) when three
subsequent generations were added to the pedigree and five additional affected males
identified. In total, 29 males were affected in 7 generations. Additional clinical
features included scoliosis, pectus excavatum, foot deformities, joint contractures,
elongated facies with normal head circumference, bitemporal narrowing, and large,
simple ears. In 1990, Schwartz et al. presented linkage data suggesting that the gene
for the "Allan-Herndon-Dudley syndrome" (AHDS) is located in Xq21 (peak LOD
score obtained with DXYS1). Bialer et al. (1992) also studied a large XLMR family
with clinical features closely resembling AHDS in which tight linkage to DXS72 also
placed the locus for the disease segregating in their family to Xq21. It appears
therefore, that this family also has AHDS. A third family with AHDS has since been
ascertained (Schwartz et al., 1994a) and studied using markers located in Xql2-
Xq22. Multipoint analysis indicated that the AHDS locus is 0.6 cM distal to
DXS326. All three families are presently being analysed with all available
microsatellite markers between DXS1 111 and DXS3 in an attempt to further refine
the region of localisation of AHDS.
After the paper of Allan et al. (1944), XLMR publications did not appear again until
1961 when Losowsky studied a family with 12 severely mentally retarded members
in four generations and 2 less severely affected females. It is suspected that this
family, too, had fragile X syndrome although they have since been lost to follow-up
(Stevenson et al., 1994). Probably the best known of the early XLMR reports is that
of Renpenning et al. (1962) who, as a medical student in Canada, studied a large
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family of Dutch Mennonite extraction consisting of 20 affected males with head
circumferences at the lower end of the normal range, prominent ears and short
stature, in addition to severe mental retardation. Two of the affected males had
seizures. This family has been restudied by Fox et al. (1980) and Schwartz et al.
(1993) and a locus for Renpenning syndrome has been shown to map to Xp21.1-ql2.
Renpenning syndrome has, in the past, also been used to describe fragile X syndrome
and non-specific XLMR as well as the syndrome described above, but it is evident
from the localizations of these conditions and the clinical dissimilarities between
them that they are very distinct disorders. Turner et al. (1971) suggested that
approximately 10% of all moderately retarded males could have Renpenning
syndrome although they accepted that different loci may be involved. In 1969,
Snyder and Robinson published a family with nine males with mental retardation
over three generations. None of the males had any specific facial characteristics, but
they had hypotonia and disequilibrium, and the authors concluded that the family had
a non-specific form of XLMR. The family was restudied 23 years later in 1992
(Arena et al., 1994), when clinical and DNA studies were conducted on 17 family
members. It now appears that the family has a syndromic rather than a non-specific
form of XLMR with affected males exhibiting the following features: mild to
moderate mental retardation; large head; wide-based gait; marfanoid habitus;
diminished muscle bulk; nasal voice; long thin face and high narrow palate and mild
scoliosis. Linkage analysis placed the locus for Snyder-Robinson syndrome at Xp22
with a peak LOD score being obtained with DXS41.
The delay in recognising XLMR may have been due to inadequate ascertainment;
many of the earlier surveys were carried out in mental institutions where the patients
were largely severely mentally retarded, but most XLMR is actually of the
"community based" mild-moderate type. The fact that the contribution of X-linked
genes to mental retardation is greatest in the mild-moderate categories is shown by
the greater recurrence risk for male sibs with mild-moderate mental retardation than
with severe-profound mental retardation (Turner et al., 1971, Bundey et al., 1989).
Priest et al. (1961) found more males than females in state institutions (although
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males are probably more likely to be institutionalized because of uncontrollable or
violent behaviour) and found that affected sibs were more often male. A population
survey of mental retardation in 1965 (Reed and Reed) found a 49% excess of
mentally retarded males and showed that a retarded female with a normal male
partner was twice as likely to have retarded children as was a normal female with a
retarded partner. Further support for XLMR came from the observation that there
was a disproportionate number of families with only retarded boys (Wortis et al.,
1966); since then other similar surveys have consistently observed a male excess
(Moser and Wolf 1971; Turner and Turner 1974; Laxova et al., 1977; Blomquist et
al., 1981; Bundey et al., 1989). To account for this male excess, Lehrke (1972)
hypothesised that 25% to 50% of all mental retardation was X-linked whilst others
have estimated the proportion to be between 10% and 20% (Turner et al., 1971,
Turner, 1982).
1.3 PREVALENCE OF XLMR
Herbst and Miller (1980) calculated an incidence of XLMR in British Columbia of
1.83 per 1,000 live male births and a carrier frequency of 2.44 per 1,000 live female
births, which corresponds to a mutation rate of 6.1 x 10"4. Assuming a mutation rate
of 3-9 x 10° for X-linked loci (taking the mutation rates of 3.2 x 10~5 for
haemophilia A and 9.2 x 10"5 for Duchenne muscular dystrophy), and a fitness of
zero for affected males, they estimated that 7-19 genes cause non-specific XLMR
(using Haldane's equation p. = q(l-f)/3, where p is the mutation rate, q is gene
frequency and f is genetic fitness). This is a similar figure to that obtained by
Morton et al. (1977) who estimated that there may be 18 X-linked loci for mental
retardation. If the mutation rate was 3.2 x 10"5 per locus, they calculated a possible
incidence of XLMR of 1.74 per 1,000 births. Opitz (1986) calculated a prevalence of
1/296 for XLMR for both sexes when fragile X syndrome is included (assuming that
40% of XLMR is fragile X syndrome) making the total incidence of all XLMR at
least double that of Down's syndrome (Schwartz, 1993).
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1.4 CLASSIFICATION OF XLMR
There are currently 127 X-linked conditions in which mental retardation is manifest
(Neri et al., 1994). 53 of these have been regionally mapped on the X chromosome,
although with the exception of fragile X syndrome, the individual frequency of each
of these conditions is relatively low. As the abnormal clinical findings of XLMR
conditions are documented, they are reclassified as specific diagnostic entries and
assigned a MIM number (McKusick 1994). There are now 80 entries with a MIM
number. The number of XLMR conditions has more than tripled since the Fourth
International Workshop on X-linked mental retardation in 1989 (Neri et al., 1991).
This is primarily due to changes in the inclusion criteria; all X-linked disorders
where mental retardation has been reported as a consistent finding are now included
in the classification system. XLMR conditions are divided into five classes as shown
in Table 1.
Conditions in which mental retardation is the primary manifestation (Class 1 and
Class 5) account for 62% of all XLMR; 39 of these have been mapped within the X
chromosome using linked markers. As XLMR is clinically and genetically
heterogeneous, linkage analyses can only be performed in families which are large
enough to produce significant LOD scores (>2) by themselves. LOD scores cannot
generally be added among families unless there is absolute certainty that the same
syndrome is involved. Kerr et al. (1991) have proposed that the definition of non¬
specific mental retardation (MRX) should be "mental retardation in persons of
normal physical appearance, who have no recognisable features apart from a
characteristic pedigree". They also recommend that the symbol MRX (introduced by
Suthers et al. in 1988) be reserved for gene localisations in families with non-specific
XLMR (Class 5 in Table 1). Herbst (1980) proposed that only a pedigree in which
there are affected males in two generations or in two maternally related sibships, and
in which the presence of a fragile site in Xq27.3 has been excluded, should be
classified as MRX. The revised nomenclature for MRX genes allocates a number to
every MRX family localized under specific guidelines (Mulley et al., 1992a); the
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prerequisite for assignment of an MRX or MRXS symbol is a minimum LOD score
or multipoint LOD score of 2 between the MR locus and at least one X chromosome
marker. The symbol MRXS was introduced to accommodate syndromal forms of
XLMR pending assignment of a specific name, usually that of the author who







1. Syndromes i.e. clinically recognizable conditions,
based on a characteristic pattern of physical
anomalies [designated MRXS, (Davies et al., 1991)].
Listed in Table 3.
57 24 4
2. Dominant disorders 6 4
3. Metabolic disorders 12 9
4. Neuromuscular disorders i.e. clinically recognisable
conditions, based on a characteristic neuromuscular
involvement. Listed in Table 4.
30 10 4
5. Non-specific mental retardation i.e. conditions where
mental retardation is the only consistent
manifestation [designated MRX, (Davies et al.
1991)]. Listed in Table 5.
22 18 1
Total 127 56 18
Table 2. Current status of XLMR conditions. Only conditions in which definite linkage to
the X chromosome is demonstrated, and where linkage analysis resulted in a LOD score of 2
or more are included in this table. (Adapted from Neri et al., 1994).
1.5 IDENTIFICATION AND MAPPING OF XLMR GENES
Mapping of XLMR loci has progressed rapidly over the last few years with the
availability of highly polymorphic microsatellites spanning the X chromosome
(Weissenbach et al., 1992; Schlessinger et al., 1993; Gyapay et al., 1994), new non¬
radioactive techniques and automated gel electrophoresis equipment (Mansfield et
al., 1994), and the ability to analyse archival material on deceased family members
(Jackson et al., 1991). Several overall maps of the X chromosome have been
constructed. The initial Genethon map included 25 X-linked "Afm" microsatellite
markers that are now well integrated with other markers in physical or genetic maps
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(Weissenbach et al., 1992). The second Genethon map contained 80 Afm markers
extending over 166 cM (Gyapay et al., 1994), although there were two large gaps in
this map: 13 cM in Xq24-25 and 17 cM in Xq27. Murray et al. (1994a) constructed a
genetic linkage map using genotypes available from the CEPH (Centre d'Etude du
Polymorphisme Humain) and the CHLC (Cooperative Human Linkage Centre).
They analysed 128 dinucleotide repeats in 15 families consisting of 185 individuals
and produced three linkage maps at varying degrees of resolution, i.e. of increasing
density, but decreasing confidence level. The "skeletal" map (total X chromosome
length 143 cM) included 23 loci; the "framework" map contained 35 loci (206 cM);
and the "comprehensive" map contained 150 loci (266 cM). The average distance
between markers varied from 5.7 cM for the framework map to 6.14 cM for the
skeletal map. Fain et al. (1995) used the method of crossover mapping to produce a
high density two-dimensional linkage map, by incorporating information from five
previously published linkage maps (NIH/CEPH Collaborative Mapping Group, 1992;
Buetow et al., 1994; Gyapay et al., 1994; Matise et al., 1994; Murray et al., 1994b).
They analysed 243 markers in 40 CEPH families and produced a map with an
average distance between markers of 5.4 cM (when ordered by two recombinants)
and 3.2 cM if the markers were ordered using information from one recombinant,
with an estimated total genetic length of 190 cM for the X chromosome.
Analysis of individual large MRX families using a dense map of highly informative
markers may result in a localization within a 10-15 cM interval (Kerr et al., 1992;
Mulley et al., 1992b; Hu et al., 1994), although an interval of this size could,
theoretically, contain approximately 150-400 genes (Mandel, 1994). An overlap
between the genetic intervals containing two MRX families does not imply that the
same gene is involved and cannot therefore be used to obtain a more restricted
localization. Each family must be treated as a separate disorder until the particular
genes are identified. The presence of phenocopies (about 1 or 2% of males are likely
to be mentally retarded even though they do not carry the mutation segregating in a
particular family) may result in mapping errors in some MRX families. The
identification of XLMR genes with a broad linkage based localisation will ultimately
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depend on systematic analysis of many affected males for mutations in candidate
genes. Mandel (1994) has proposed that a lymphoblastoid cell line and preferably
also a fibroblast cell line, on one proband and one obligate carrier female from each
XLMR family (both MRX and syndromic forms), should be deposited at a cell
repository.
By correlating gene location and clinical findings, it may be possible to diagnose new
syndromes in pedigrees which have previously been too small for a linkage based
classification alone. However, clinical reports are often incomplete, which makes it
difficult to determine whether two syndromes which appear similar are the same or
not. As the number and density of XLMR genes increases it will become even more
important that reports contain precise clinical information. It has been proposed
(Schwartz et ah, 1994b) that a minimum clinical dataset be used covering three
categories: physical measurements (height, weight, OFC, eye, ear, hand, testicular),
other clinical observations (developmental history, IQ, hearing, speech, vision,
malformations, minor anomalies, dermatoglyphics, spinal curvature), and
neurological signs (gait, reflexes, muscle tone and mass, seizures, involuntary
movements, behaviour) and that measurements should be reported as percentiles as
well as absolute measurements. In addition, for the non-specific XLMR conditions,
some normal males should be subjected to the same clinical investigation to ensure
that subtle changes noted in the affected males do not represent unrelated familial
characteristics (Schwartz et ah, 1992). Females should also be studied to note the
presence of manifesting carriers in the family.
This thesis is composed of molecular and linkage studies on eight fragile X
syndrome families and three other XLMR families in S.E. Scotland which were









Xql2-q21.3 Microcephaly, "coarse" face, genital and
skeletal abnormalities. FlbH inclusions.
303600 Coffin-Lowry Xp22.2-
p22.1




Xq28 Skin pigmentation, nail dystrophy,
leukoplakia of oral mucosa
305450 FG Macrocephaly, agenesis of corpus
callosum, gastrointestinal abnormalities,
deafness




Xq26-q28 Short stature, microcephaly, alopecia,
bullous dystrophy, hypogenitalism
309590 Juberg-Marsidi Xql2-q21 Growth retardation, small genitalia,
deafness






311300 Otopalato-digital Xq27-q28 Short stature, hearing loss, cleft palate,
characteristic face
309510 Partington (MRXS1) Xp22.1-
p21.3
Dysarthria, dystonic movements of hands,
ataxia, seizures
304340 Pettigrew (MRXS5) Xq26-
Xq27.1
Long "course" face, hydrocephalus,
hypotonia, spasticity, ataxia, seizures
Porteous Xpll.4-
Xql3






Peculiar face, dental anomalies, sacral






Xq24-Xq28 Macrosomia, "coarse" face, Polydactyly,
extra nipples, heart defect.
Snyder-Robinson Xp22.3-
Xp21.3
Macrocephaly, long thin face, high
narrow/cleft palate, asthenic body build,
scoliosis, marfanoid habitus
309470 Sutherland (MRXS3) Xp21.1-
Xq22






Obesity, gynecomastia, tapering fingers,
emotional lability


















Xp21.3-1 Pseudohypertrophic muscular dystrophy
312920 Goldblatt Xql3-
q21.1
Spastic paraplegia, nystagmus, optic
atrophy
Gustavson Xq25-q26 Optic atrophy, hearing loss, epilepsy,
spasticity, restricted joint mobility, early
death
307000 HSAS Xq28 Hydrocephalus, stenosis of the aqueduct of
Sylvius
303350 MASA Xq28 Macrocephaly, aphasia, shuffling gait,
adducted thumbs, growth retardation
312900 SPG1 Xq28 Spastic paraplegia, ataxia
lonasescu Xp22.3-1 Motor-sensory neuropathy
304700 Mohr-
Tranebjaerg
Xq22 Hearing loss, visual impairment, ataxia,
spastic paraplegia









Spasticity, cerebellar ataxia, Parkinsonism
311510 Waisman-Laxova Xq27.2-
q28
Parkinsonism, seizures, apparent basal
ganglia degeneration
314580 Wieacker-Wolff Xql l-q22 Contractures, distal muscular atrophy,
dyspraxia of ocular and facial muscles
Table 4. Neuromuscular disorders (Class 4). (Adapted from Neri et al., 1994)
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Class 5
Name Locus Description Reference
MRX1 Xpl 1.4-q21.31 Mental retardation only Suthers et al., (1988)
MRX2 Xp22.2-3 Macrocephaly, square face,
macro-orchidism, short
stature
Arveiler et al., (1988)
MRX3 Xq28 Mental retardation only Gedeon et al., (1991)
MRX4 Xpl 1.22-q21.31 Speech delay, learning
disability
Arveiler et al., (1988)
MRX5 Xp21.1-q21.3 Hyperactive behaviour,
speech delay
Samanns et al., (1991)
MRX6 Xq27 Short stature, "coarse face",
short broad hands
Kondo et al., (1991)
MRX7 Xpl 1.4-q21.3 Mental retardation only Jedele et al., (1992)
MRX8 Xpl 1.3-q21.22 Mental retardation only Schwartz et al., (1992)
MRX9 Xp21.2-ql2 Mental retardation only Willems et al., (1991)
MRX10 Xpl 1.4-p21.3 Hypotelorism, large ears Kerr et al., (1992)
MRX11 Xpl 1.22-p21.3 Hypotelorism, large ears Kerr et al., (1992)
MRX12 Xp21.3-q21.1 Hypotelorism, large ears Kerr et al., (1992)
MRX13 Xp22.3-q21.22 Large ears Kerr et al., (1992)
MRX17 Xpl 1 -q21.3 Mental retardation only Gedeon et al., (1994)
MRX18 Xp21.1-pl 1 Mental retardation only Gedeon et al., (1994)
MRX19 Xp22.3-p21 Mental retardation only Donnelly et al., (1994)
MRX21 Xp22.3-p21.1 Mental retardation only Kozak et al., (1993)
MRX24 Xp22.2-p22.3 Mental retardation only Martinez et al., (1995)
FRAXE Xq28 FRAXE, mental retardation
only
Knight et al. (1993)
Table 5. Non-specific XLMR conditions (Class 5). (Adapted from Neri et al., 1994)
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2. X-linked mental retardation presenting as developmental delay;
DNA testing for fragile X syndrome.
2.1 INTRODUCTION
Mental retardation is global delay in the development of cognitive learning. The
term global is used to differentiate it from specific learning disorders such as dyslexia
and dyspraxia, and cognitive to distinguish between learning with understanding and
memory learning. Children with physical features suggestive of syndromes
associated with mental retardation may be identified at birth or during early infancy,
as in the case of Down syndrome, although these disorders represent only a small
percentage of the population of intellectually impaired children. The vast majority
are identified because of their failure to meet expectations at certain ages; delayed
achievement of developmental milestones is the cardinal feature of mental
retardation. Most mentally retarded children develop slowly from birth; children
with severe impairment show obvious psychomotor delay in the first year of life,
moderately retarded children usually exhibit normal motor development but present
with delayed speech and language abilities and mild retardation may not be detected
until the child attends school. Sometimes, language milestones are delayed
disproportionately in relation to motor development. The usual definition of mental
retardation is an IQ of 2 standard deviations or more below the general population
mean and relies on clinical validation of the child by standard psychometric tests. A
general scale of intelligence consists of a variety of tasks which measure different
aspects of intellectual functioning and estimate the child's overall ability, as
measured by a total score. Many tests are available; the following are a few of the
ones most commonly used in the UK.
Wechsler Intelligence Scale for Children (WISC) - age range 5 to 15 years. This
scale consists of 12 subtests, divided into verbal and performance subscales. WISC
scores are obtained by comparing test performances with those scores achieved by
children in the same age group as the patient (within a 3 month range). This scale
has been revised (WISC-R) and the age range is now 6-16 years.
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Wechsler Pre-school and Primary Scale of Intelligence (WPPSI) - age range 4 to
6Vi years. This scale is similar to the WISC test, but includes design copying and
sentence repetition tests for the younger age range.
Stanford-Binet Intelligence Scale - age range 2 years to adolescence. This scale
is a later version of one of the oldest and most widely used measures of intelligence.
Cattell Infant Intelligence Scale - age range 2 to 30 months. This was developed
as a downward extension of the Stanford-Binet test.
In addition to the general intelligence tests, there are also performance and non-
language tests, tests for physically handicapped children, blind, and deaf children.
2.1.1 Epidemiology of mental retardation
The distribution of intelligence in the general population is a bell shaped curve with
mentally retarded individuals belonging to the lower extreme of the distribution
(Figure 1). Approximately 3% of the population has an IQ below 70 and less than
0.5% of the population has moderate or severe mental retardation (IQ roughly 20-
50). There are more mentally retarded individuals in the population than would be
expected from a normal Gaussian distribution and this is attributed to the presence of
two groups of mentally retarded patients making up this 3%. The majority of
individuals (2.3%) have IQs between 50 and 70 with no demonstrable pathological
disease and the remainder (approximately 0.3% to 0.6%) with IQs less than 50 are
mentally retarded due to some pathological factor (Moser et al., 1983).
Because a diagnosis of mental retardation relies on an assessment of adaptive
behaviour in addition to IQ, the epidemiology of mental retardation varies with age.
The reported incidence of mental retardation increases sharply in the early school
years, when children are more likely to be detected as having learning difficulties,
and then declines in late adolescence as individuals with borderline or mild




Figure 1. Population distribution of intelligence. (Adapted from Moser et al., 1983) This
drawing is not to scale.
2.1.2 Etiology and pathogenesis of mental retardation
According to OMIM (Online Mendelian Inheritance in Man) at least 750 genetic
disorders include mental retardation as part of the phenotype. An etiological
classification groups mental retardation as: Genetic - chromosomal and single gene
disorders, multifactorial - disorders with both genetic and environmental
components, and environmental - infections, toxins, trauma etc.
2.1.3 Fragile X syndrome
Fragile X syndrome is the most common form of familial mental retardation and the
second most common cause of mental retardation after Down syndrome (which has
an incidence of ~1 in 600 to 1 in 800 live births; Shen et al., 1995). The incidence is
1 in 1,250 males, with a generally milder form of mental retardation occurring in 1 in
2,500 females. Fragile X syndrome constitutes 40% of XLMR (Schwartz, 1993).
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2.1.3.1 Historical background
In 1969, Lubs reported a three-generation XLMR family with four affected males
who had an X chromosome in which a small part of the tip was separated from the
main part of the long arm by a constriction. Four normal female carriers, including
the mother of two affected brothers, also had this "marker" X chromosome. Another
family with a marker chromosome was described in 1971 (Escalante) although the
importance of this observation was not realised until a few years later when two other
studies found the constricted X chromosome in 25 males and 1 affected female
(Giraud et al., 1976; Harvey et al., 1977). During the next few years, several
laboratories were unable to reproduce these findings until Sutherland (1977)
demonstrated that the expression of chromosomal fragile sites, including fragile X
(FRAXA), was dependent on the type of culture medium used, specifically one which
was folic acid and thymidine deficient. FRAXA was induced in Medium 199 but not
in other commercially available media tested. Following this discovery, a series of
families with XLMR were tested and many were found to have the fragile site
(Turner et al., 1978; Turner et al., 1980). The family investigated by Martin and Bell
in 1943, originally reported as a non-specific form of XLMR, was also reinvestigated
and shown to have fragile X syndrome (Richards et al., 1981).
2.1.3.2 Epidemiology
Several large surveys have been carried out in order to determine the prevalence of
fragile X syndrome. Blomquist et al. (1982; 1983) and Gustavson et al. (1986)
conducted prevalence studies of mild and severely retarded males in northern
Sweden and concluded from their data that approximately 0.1% of the general
population would be expected to have a fragile X chromosome. A survey conducted
by Webb et al. (1986) in England, found 16 fragile X positive boys among 219 boys
with idiopathic mental retardation (lin 14) and 10 out of 104 mentally retarded girls.
When these figures were extrapolated for the population studied, the prevalence of
fragile X syndrome became 1 in 1362 males and 1 in 2073 girls, equivalent to an
overall prevalence of 1 in 1634 (0.06%). Turner et al. (1986) conducted a similar
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survey in New South Wales which resulted in prevalence figures of 1 in 2610 for
males and 1 in 4221 for females. Taking these and other studies into consideration,
the estimates of the total prevalence of fragile X (mainly from European populations)
varied from ~1 in 2500 to 1 in 1100 for males and 1 in 5000 to ~1 in 1650 for
females (Webb, 1989). However, all these surveys were cytogenetically based and
therefore a proportion (~50%) of affected females will not have been detected (see
Cytogenetics, 2.1.3.6). In addition, the contribution of normal transmitting males
and mentally normal female carriers to the gene frequency could not be taken into
account because a) neither would be detected cytogenetically, and b) the surveys
investigated mentally retarded groups only, with extrapolation from their data to give
frequencies in the general population.
2.1.3.3 Clinical Phenotype
Fragile X syndrome is characterized clinically by three major features; moderate to
severe mental retardation, elongated, narrow facies with large everted ears, and
macro-orchidism. Although clinical macro-orchidism (> 2 times normal), is
uncommon prior to puberty, pre-pubertal boys have significantly larger mean
testicular volumes than non fragile X males (Lachiewicz and Dawson, 1994). After
the age of 8 there is a sharp increase in the number of fragile X boys with macro-
orchidism and it is present in almost 90 percent of post-pubertal males (Kirkilionis et
al., 1988). The phenotypic features of affected females tend to be more subtle and in
both males and females the phenotype can be extremely variable. The majority of
affected males have an IQ between 20 and 50 (Sutherland and Hecht, 1985), although
the degree of mental retardation can vary even within families. Additional physical
features may be increased head circumference in childhood, coarsening of facial
features, hypotonia, and prominence of the forehead and jaw. About 80% of adult
fragile X patients have mitral valve prolapse, which is thought to be due to a
connective tissue dysplasia. Longevity in fragile X patients appears to be normal; no
entity can be exclusively identified as a major cause of death (Partington et al.,
1992). No single physical feature is completely diagnostic and many of the features
overlap with other mental retardation syndromes; it is often the behavioural
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characteristics which alert clinicians to the diagnosis. These include hyperactivity,
tics, attention deficits, aggressive outbursts, unusual hand mannerisms such as hand
flapping and hand biting, poor eye contact and a reluctance to be touched (Hirst et
ah, 1992). Many of the behavioural abnormalities diminish as patients enter
adulthood. It is difficult to diagnose in newborn babies (apart from greater than
average birth weight, male neonates with fragile X syndrome appear normal) and the
features slowly accumulate with age.
Only 60% of fragile X males have the three main characteristics and 10% present
with mental retardation as the only clinical feature (Hirst et ah, 1992). Fragile X
syndrome is frequently ascertained through a language learning delay and is therefore
generally not suspected before the child reaches 2-3 years of age. Occasionally,
however, some fragile X cases are ascertained very early as illustrated by three new
cases who were diagnosed below the age of 2 years (discussed later in this chapter).
2.1.3.4 Fragile X syndrome and autism
Autism occurs in about 5 in 10,000 births with a 3-4:1 male predominance. In 2-3%
of families, more than one autistic child is found within the same family. There is
much controversy surrounding the issue of whether fragile X syndrome and autism
are associated. Einfeld et al. (1989) screened for autistic behaviour in fragile X
males and compared this result with the proportion of autism found in non fragile X
mentally retarded males. They concluded that the syndromes were not associated.
Cohen et al. (1991) however, came to the conclusion that there was an association
between the two and estimated that approximately 8% of autistic children have
fragile X syndrome and 16% of fragile X males are autistic. To account for the
discrepancies between earlier surveys, Einfeld et al. (1989) suggested that clinicians
may have been misled into believing that an association existed because two autistic-
like behaviours, hand flapping and gaze avoidance occur at a higher rate in fragile X
children, compared to other mentally retarded children. Fisch (1993) consolidated all
the reports in the literature and proposed the term "concurrence" rather than
"association" or "correlation" to describe the relationship between fragile X and
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autism. The overall consensus is that fragile X testing is appropriate for any autistic
male of undiagnosed etiology (Brown and Jenkins, 1992). 6.1% of males who were
referred to our laboratory for fragile X testing had autistic features as part of the
phenotype although all were subsequently found to be normal with respect to fragile
X syndrome (Figure 12, page 76).
2.1.3.5 Genetics
The inheritance patterns observed in fragile X syndrome are unique. It is transmitted
in an X-linked semi-dominant fashion, with incomplete penetrance. There are
several other unusual non-Mendelian properties of fragile X inheritance (Richards
and Sutherland, 1992):
1) 20% of males who inherit the fragile X mutation are not affected (normal
transmitting males, NTMs), but transmit the mutation to their daughters, who
are asymptomatic obligate carriers. Mothers ofNTMs are normal.
2) Daughters ofNTMs have a high probability (-40%) that offspring who inherit
the abnormal X chromosome will be clinically affected and this risk increases in
the next generation to 50%.
3) 35% of carrier females are mentally retarded but to a lesser degree than affected
males. Affected females receive the fragile X mutation from their mothers, not
their fathers.
The observation that the risk of a family member being phenotypically abnormal is
dependent upon his or her position in the pedigree is known as the Sherman paradox
(Sherman et al., 1985; Opitz 1986); this is illustrated in Figure 2.
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Figure 2. Illustration of the Sherman paradox in a hypothetical family. The figure below
each individual is the empirical risk of that person being mentally retarded, according to
Sherman et al. (1985). Filled symbols represent mentally retarded individuals (with lighter
shading for lower risk), symbols with a dot represent mentally normal carriers.
2.1.3.6 Cytogenetics
Fragile X syndrome is named after the characteristic fragile site in Xq27.3 which is
detected microscopically as a non-staining constriction in one or both chromatids in
metaphase chromosomes. It may also appear as a terminal deletion of Xq28 due to
the loss of the acentric fragment, which may be observed elsewhere in the metaphase
spread. Cells need to be cultured in medium deficient in folic acid and thymidine,
with excess thymidine (Sutherland and Baker, 1986), or in the presence of several
additives which disrupt folate metabolism (methotrexate or fluorodeoxyuridine
(FUdR)) in order for the fragile site to be induced. These additives must be present
during late S phase prior to the mitosis in which expression is observed. All
induction conditions appear to result in depletion of supplies of dTTP or dCTP
available for DNA synthesis.
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More than 87 common (i.e. found in most of the population) and 26 rare (found in
less than 1% of the population) other fragile sites have been described (Sutherland
and Ledbetter, 1989). Three other fragile sites have now been identified in distal Xq,
which could be confused with FRAXA. One of these, FRAXD (Sutherland and Baker,
1990), is a common fragile site which maps proximal to FRAXA, the other two are
rare fragile sites: FRAXE (600 kb distal to FRAXA) and FRAXF (more than 1Mb
distal to FRAXA). Cloning of the FRAXE and FRAXF regions has revealed, in both
cases, the presence of an unstable trinucleotide (CGG) repeat adjacent to a CpG
island (Knight et ah, 1993; Parrish et al., 1994). FRAXF is not associated with any
clinical phenotype. FRAXE expression, however, has been shown to segregate with a
mild form of mental retardation in some families (Flynn et al., 1993) but not in others
(Sutherland and Baker, 1992; Allingham-Hawkins and Ray, 1995).
Cytogenetic diagnosis of fragile X syndrome follows specific guidelines for
conditions and criteria (Jacky et al., 1991; Dewald et al., 1992). The principal
features recommend the use of two or more induction systems, the analysis of at least
50 - 100 cells in males and 75 - 150 cells in females, and the inclusion of a standard
chromosomal analysis to exclude other cytogenetic etiologies for the mental
retardation. When these guidelines are followed, the sensitivity of detection of
FRAXA in affected males is quite high, with virtually all affected males expressing
the fragile site (in 2% to 60% of cells). However, only 50% of carrier females can be
detected in this way, and the cytogenetic test is incapable of detecting carrier males
or phenotypically normal carrier females. In addition, the presence of the other
fragile sites, FRAXD, FRAXE and FRAXF, indicate that a positive cytogenetic test
may not be specific for fragile X syndrome and requires confirmation by molecular
testing. The role of cytogenetics in the diagnosis of fragile X syndrome has
diminished with the advent of cheaper and more accurate molecular detection and is
no longer justified in known fragile X families. Cytogenetic testing is still important,
however, among developmentally delayed children referred for fragile X testing, to
rule out other chromosomal abnormalities which may be responsible for the child's
learning disability. In prenatal diagnosis, there are specific difficulties associated
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with cytogenetic detection of the fragile site in chorionic villi and amniocytes with a
rate of misdiagnosis of about 5% due to false positives and more frequently, false
negatives (Sutherland et ah, 1991).
2.1.3.7 Isolation of the FMRJ gene
Genetic linkage studies
The first report of linkage of a DNA marker to fragile X syndrome was a study of the
segregation of the Factor IX gene {F9\ Camerino et ah, 1983) in which the disorder
was transmitted through a phenotypically normal grandfather. Although no
recombinants were identified in the large family described, several families were
later reported in which recombination was observed between F9 and the fragile X
locus. Brown et ah (1985; 1988) noted differences between families in which there
was tight linkage between F9 and fragile X, and families which gave negative LOD
scores. They suggested genetic heterogeneity as a possible explanation for the
discrepancy and subsequently divided their fragile X families into two types, those
with and without a normal transmitting male (the existence of non-penetrant males in
fragile X syndrome had been recognised since 1985 (Sherman et ah). Shortly after
the F9 studies were published, three new polymorphic probes were isolated (Figure
3) and reported to be close to the fragile site. These were: i) the highly polymorphic
VNTR probe Stl4 (DXS52; Oberle et ah, 1985), ii) 52A (DXS51; Davies et ah, 1985)
and iii) DX13 (DXS15\ Drayna and White, 1985). Further linkage analysis with
these new probes (Brown et ah, 1987) in addition to the F9 probe, was confounded
even more when linkage heterogeneity was still evident, irrespective of whether an
NTM was present in the family. Heterogeneity tests showed significant linkage
heterogeneity on the proximal side of the fragile X locus but not on the distal side.
The estimates of genetic distance between F9 and fragile X varied from 18 cM in the
"tightly linked" pedigrees to more than 35 cM in the "loosely linked" pedigrees.
New mapping techniques (Fain et ah, 1995, and see 1.5) have now established that
this distance is 24.5 cM. Following on from the F9 genetic heterogeneity studies,
Suthers et ah (1991a) conducted linkage analysis in 112 fragile X families with five
23
DNA markers in the interval from DXS369 proximally to DXS304 distally, although
they failed to find evidence of linkage heterogeneity in the region. The discrepancy
between these studies is not fully resolved but is presumably due in part to the
difficulties of estimating genetic distances in a syndrome with such unusual
inheritance patterns and reduced penetrance.
In the search for the fragile X mutation, many new closely linked polymorphic
markers were isolated. Between 1989 and 1991, four new probes were identified
which mapped to within approximately 5cM of FRAXA \ U6.2 (DXS304; Dahl et al.,
1989a,b), VK21 (DXS296\ Suthers et al., 1989), RN1 (DXS369; Oostra et al., 1991)
and VK23 (DXS293; Suthers et al., 1991b). Rousseau et al. (1991) isolated three
more polymorphic probes: St677 (DXS463), 2-35 (DXS477) and Do33 (DXS465)
which map between RN1 (DXS369) and the iduronate-2-sulphatase (IDS) locus and
which are still the closest dimorphic RFLPs to FRAXA. The order of these markers is









Figure 3. Genetic map of DNA probes in the vicinity of FRAXA. Distances between
markers are in centiMorgans (cM). Figures on the left are taken from Suthers et al.
(1991 a,b) and were converted (by the authors) to cM from recombination fractions using the
Haldane mapping function. For comparison, figures on the right were obtained from Fain et
al. (1995), who used the Kosambi equation.
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Somatic cell hybrids
In 1987, Warren et al. constructed somatic cell hybrids that contained either a human
fragile X chromosome or a normal X chromosome in a hamster background. Human
lymphoblasts from a fragile X male were fused with Chinese hamster ovary cells
deficient in both HPRT (Xq26) and G6PD (Xq28) activities and the cells cultured
under conditions for induction of fragile X expression. By screening for or against
HPRT or G6PD activity, they were able to isolate hybrids containing either
exclusively proximal (Xpter - q27.3, p21D) or exclusively distal (Xq27.3-qter, Q1X)
portions of the human fragile X chromosome. The hypothesis was that the fragile
site would be a preferential location for translocations between human and hamster
material - using a previous observation that chromosomal fragility occasionally
resulted in breakage and translocation (Warren and Davidson, 1984). The hybrid
panels were shown to have breakpoints within the fragile X site by hybridization
with proximal and distal markers (Warren et al., 1990). These hybrids enabled a
number of new polymorphic loci to be mapped relative to the fragile site and
confined the region containing the fragile X locus to 3 Mb (Suthers et al., 1990;
Rousseau et al., 1991; Hirst et al., 1991a).
Methvlation anomalies
The search for cloned DNA containing the fragile X site was not successful until new
DNA technology made available the technique of pulsed field gel electrophoresis
(PFGE). Areas in which non-methylated sites cluster - CpG islands - are frequently
associated with expressed genes and as the sites are relatively infrequent, the
fragments generated as a result of enzyme digestion tend to be very large (100-
lOOOkb) and can only be resolved with PFGE (Schwartz and Cantor, 1984). In early
1991, Vincent et al. reported methylation abnormalities in 22 fragile X patients
detected by PFGE using the probe Do33 (DXS465). Fragile X males showed
aberrantly large bands, larger than the 620kb fragment seen in 21 normal males but
similar to the large bands seen in female cell lines, suggesting a methylation anomaly
in the region. Bell et al. (1991) reported similar results; they observed significant
differences in the PFGE pattern after ffosHII digestion of DNA from fragile X males
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compared to normal male controls. In 19 out of 21 affected males, the normal 600kb
itasHII band was either absent or of reduced intensity, consistent with methylation at
the ZfasHII site. An NTM gave a normal pattern, but in 2 affected males, a normal
fosHII pattern was also observed. However, the authors failed to give a satisfactory
explanation for the discrepancy and suggested that the fragile site could be
methylated to an extent not detectable by their assay. It is not clear from the article
which criteria were used for classification as "fragile X positive" for inclusion in
their study. It is possible that the two males were detected cytogenetically and are
therefore false positives, in which case their mental retardation is not due to fragile X
syndrome (the authors did point out that these two males had no family history of
mental retardation). Alternatively, it is possible that the methylation status in
peripheral blood lymphocytes is different to that in other tissues and therefore may
not be correlated with mental retardation.
A few months later, further reports on the isolation, cloning and partial
characterization of the fragile X mutation were published. These appeared almost
simultaneously from groups in France (Oberle et al., 1991), Australia (Yu et al.,
1991) and an American/Dutch collaboration (Verkerk et al., 1991).
YAC cloning of the fragile site
Kremer et al. (1991a), constructed a YAC (yeast artificial chromosome) library from
DNA from the human/hamster somatic cell hybrid X3000-11 (Nussbaum et al.,
1986) which contained a fragile X chromosome from Xq24 to Xqter translocated
onto a hamster chromosome. The YACs were screened with DNA probes which
map close to the fragile site and XTY26, containing 275 kb of human DNA, was
isolated using VK16B3 (DXS293). Further analysis revealed that the DNA probes,
Do33 (DXS465) and 2-34 (DXS477) were also present in XTY26, confirming that it
contained DNA spanning the fragile site.
YACs crossing the fragile site were also identified simultaneously and
independently, in the CEPH library by Mandel (Heitz et al., 1991) and by the
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American/Dutch consortium (Verkerk et al., 1991). Regional mapping of YAC
clones containing DNA inserts derived from the distal human Xq (Nelson et al.,
1991), identified an 80 kb YAC (RS46) which mapped within Xq27.3, proximal to
the fragile X associated hybrid breakpoints. However, RS46 did not hybridize to
DNA of the distal translocation hybrids and therefore did not cross the breakpoints.
A CEPH YAC library was screened using RS46 specific oligonucleotide primers and
a 475 kb YAC was identified (209G4) which completely overlapped RS46 and
crossed the fragile site. Genetic linkage studies between a dinucleotide CA repeat
(DXS548) within RS46 and the fragile X locus in families which were previously
shown to have crossovers with tightly linked flanking markers, showed that DXS548
segregated without recombination with the fragile X locus. A CpG island containing
five rare restriction enzyme sites was identified 150 kb distal to DXS548. This was
the same CpG island identified independently by Heitz et al. (1991) and which
appeared hypermethylated on fragile X chromosomes (Vincent et al., 1991; Bell et
al., 1991).
Subcloning and fluorescent in situ hybridization
The Mandel group (Heitz et al., 1991) also independently identified the YAC 209G4
by screening with the linked probe St677 (DXS463); this YAC was found to contain
the proximal probe 2-34 (DXS47T) in addition to St677 and fluorescent in situ
hybridization on metaphases from five fragile X patients after induction with
fluorodeoxyuridine (FUdR) verified that 209G4 spanned the fragile site. A larger
YAC (141H5) containing 520kb of human DNA was isolated by screening with the
distal probe Do33; this YAC was also found to contain St677 and 2-34.
Further to the identification of YACs spanning the methylated CpG island, all three
groups used cosmid or lambda subclones to walk to the CpG island. Verkerk et al.,
(1991) constructed a cosmid library from the YAC 209G4 clone and identified a four
cosmid contig which spanned the fragile X related CpG island. From one of these
cosmids (22.3), a 7.4 kb EcoRI fragment was identified which was demonstrated to
contain the CpG island and to be a breakpoint cluster region where the majority of
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fragile X-associated breakpoints were positioned. The same EcoRl fragment, which
was equivalent to a 5.1 kb fragment in normal X chromosomes, showed a variable
increase in size in fragile X chromosomes when hybridized to E'coRI digested DNA
from normal and fragile X patients. The normal samples exhibited the expected 5.1
kb fragment, while all the affected fragile X males had larger fragments with variable
increases in size. In addition, a) in situ hybridization of cloned material from the
region mapped precisely within the isochromatid gap characteristic of the fragile site
and b) the 5.1 kb fragment contained the .fosHII site which had been previously
demonstrated to be hypermethylated in fragile X chromosomes (Vincent et al. 1991;
Bell et al., 1991). The same 5.1kb fragment (designated pfxal) was also identified
by Yu et al. (1991) and from this a 1 kb Pstl fragment (pfxa2). Similarly, Oberle et
al. (1991) identified three overlapping plasmid subclones (StB12, StX21 and StA22)
from YAC 209G4, which covered a 9 kb DNA segment including the CpG island.
The 7 kb clone StB 12 which mapped to the telomeric side of the CpG island was
further cloned after Pstl digestion and one of the resulting fragments (StB 12.3) used
as a probe on EcoRl digests of DNA from members of fragile X families. This probe
also showed increased bands of variable size in affected males, a slightly larger than
normal band in normal transmitting males and an increased band in affected females
(in addition to the normal band).
All three groups, therefore, had cloned the region encompassing the fragile site and
demonstrated differences between normal individuals and affected fragile X patients.
2.1.3.8 Identification of the FMR1 gene
Verkerk et al. (1991) used cosmid subclones of YAC 209G4 as hybridization probes
to screen a normal human fetal cDNA library. One of these cosmids (c4.1) identified
cDNA clone BC22, which was then used to identify related cDNAs from the same
library. From overlapping cDNAs, BC72 and BC22, more than 3.7 kb of mRNA
sequence and 657 amino acids of encoded protein were deduced. They named the
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gene from which the BC22 and BC72 cDNA clones were derived, FMR1' (fragile X
mental retardation 1).
At the 5' end of BC72, a repeated DNA sequence was found which consisted of 28
CGG triplets interspersed with 2 AGG triplets [(CGG)10AGG(CGG)9AGG(CGG)9],
Kremer et al. (1991) used PCR to amplify the variable region in the genomic clone
pfxa2 and also found that it contained a CGG trinucleotide repeat of 43 copies.
However, since pfxa2 was derived from XTY26 which was cloned from a fragile X
expressing cell line, it was clear that the CGG repeat is unstable during cloning as
well as in fragile X pedigrees. Comparison of pfxa2 with the original cell line,
X3000-11, demonstrated that its cloned counterparts (XTY26, 7,5 and pfxal) had lost
about 900 bp of sequence during the cloning process. Kremer et al. (1991b) also
showed that the CGG repeat region was the site of alterations in fragile X
chromosomes and that the somatic cell hybrids p21D and Q1X had breakpoints
within the repeat.
2.1.3.9 Expression studies
The first indication that the FMR1 gene was expressed in brain came from the
experiments of Verkerk et al. (1991) during the search for FMRL As described
earlier (2.1.3.8), the cDNA clone BC22 was identified by screening a cDNA library
derived from normal human fetal brain RNA with cosmid subclones of the YAC
209G4. Northern hybridization using BC22 as a probe detected an mRNA of
approximately 4.8kb in brain and placenta. Further analysis of other human tissues
demonstrated the existence of FMR1 mRNA in lymphocytes, although it appeared
absent in liver, fetal lung, or fetal kidney. In order to determine the normal
distribution of gene expression of FMR1, Hinds et al. (1993) carried out northern blot
analysis on various human tissues; heart, brain, placenta, lung, liver, skeletal muscle,
kidney, pancreas and testis. Brain and testis showed the highest levels, with
significant expression in placenta, lung and kidney, and low to negligible levels in
" The fragile X mental retardation gene is FMR1, the protein product of this gene is FMR1. The mouse
homologues are fmrl and fmrl respectively.
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liver, pancreas and skeletal muscle. Multiple transcripts in the region of 1.4 kb were
detected in the heart with no signal at 4.4 kb (no explanation is given by Hinds et al.
for the discrepancy in transcript lengths: 4.4kb vs. 4.8kb). The existence of multiple
species of mRNA may be a result of tissue specific splicing. The existence of
moderate levels of expression in human lung and kidney contrasts with the findings
of Verkerk et al. 1991, who found negligible levels in fetal lung and fetal kidney. It
is unknown whether there is a true variation in expression in these tissues with age or
whether the differences are due to experimental artefacts.
Variation in level of expression during development
Hinds et al. (1993) also studied expression of the mouse homologue of FMR1 (fmrl)
during various stages of development by in situ hybridization. They examined whole
uterus sections from pregnant mice at various gestations, and found high levels of
expression offmrl from day 7 (the earliest stage studied) until day 10 in all
embryonic tissues (except bone). After day 10 there was a reduction of the signal
and change in distribution, when expression became more heterogeneous between
organs, particularly in the brain and liver. There is a marked difference between the
level of expression in the embryonic heart (up to day 14) which showed uniformly
increased expression, and the adult heart where no signal was detected. A similar
study of human fetuses by Abitbol et al. (1993) localised the regions of expression
more precisely. They analysed the distribution of FMR1 mRNA by in situ
hybridization, in tissue sections from two normal fetuses at 8 and 9 weeks gestation,
and from the brains of normal monozygotic twin fetuses at 25 weeks gestation. In
the 8 and 9 week fetuses, FMR1 mRNA was present at a high level in the brain,
spinal cord and ganglia, with lower levels in some cartilaginous structures and liver.
In the older fetuses, FMR1 mRNA was restricted to differentiated structures of the
brain, especially the hippocampus.
Expression offmrl and FMR1 in testes
Because of the major involvement of human testes in the phenotype of fragile X
syndrome, mouse testes were studied at various stages of post-natal development
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(Hinds et al., 1993) and at the age of 4 weeks (Bachner et al. 1993), although with
conflicting results. Hinds examined testes at 1, 12, 17 and 28 days of age and found
that the signal was strong initially (in 1 day old mice) and spread uniformly
throughout the testis. Later it appeared to be concentrated in the epithelial cells of
the seminiferous tubules. In contrast, Bachner's results demonstrated that the level
offmrl expression was 30 to 40 times higher in the spermatogonia than in the
surrounding tissues. Devys et al. (1993) used FMR1 specific monoclonal antibodies
to ascertain where, in normal human testes, FMR1 was expressed and found that
expression in the cells within the seminiferous tubules was restricted to the
spermatogonia only. There was no expression in the spermatocytes or their
derivatives and also no expression in the supporting Sertoli cells.
Adult expression offmrl
In mouse, high levels of expression were observed in adult brain, ovaries, thymus,
oesophagus, and spleen; moderate to low levels in kidney, liver, colon, uterus,
thyroid and lung and none at all in adult muscle, heart or aorta. Expression in the
adult mouse brain was apparent throughout most of the brain with some specific
regions showing higher levels, particularly the hippocampus and cerebellum, with
intermediate expression in the cerebral cortex, and minimal expression in the corpus
callosum.
The mouse as an animal model
Since the expression pattern of FMR1 at the mRNA and protein level is similar in
different tissues of humans and mice (apart from the apparent discrepancy in heart
muscle), the mouse may be a good animal model in which to study fragile X
syndrome. Transgenic knockout mice have been constructed with an inactivated
fmrl gene and which show macro-orchidism, learning deficits and hyperactivity
(Dutch-Belgian Fragile X Consortium, 1994).
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In summary, there is widespread although variable expression offmrl and FMR1
during early development, after which expression becomes more heterogeneous and
in adults is confined to the brain and testes.
2.1.3.10 Expression of FMR1 in fragile X patients
Pieretti et al. (1991) studied expression of the FMR1 gene in lymphoblastoid cell
lines and leucocytes derived from patients and normal controls by PCR amplifying
from FMR1 cDNA. They analysed 20 affected males, 10 carrier females and 14
normal controls. Sixteen of the affected males had no detectable expression, all the
carrier females showed expression although to different extents and in the all the
normal controls, expression was observed. The four patients with FMR1 mRNA
showed atypical Southern blot patterns with pE5.1 (EcoRI/ZN.vHII double digests);
three of these were mosaic for a normal band and a smear of increased size fragments
indicating that the RssHII site was not fully methylated. The fourth patient had no
normal sized band but showed partial methylation. They concluded that incomplete
methylation of the CpG island correlates with the presence of FMR1 mRNA in
fragile X patients and suggested that, in some affected fragile X males, the level of
expression of FMR1 did not reach the necessary threshold to provide normal levels of
the protein in the relevant tissues at the appropriate time in development. The results
of Pieretti et al. (1991) are in agreement with those of Verheij et al. (1993) who
demonstrated complete lack of protein product in lymphoblastoid cell lines from four
of five affected males. They did, however, find FMR1 protein in one patient who by
DNA analysis was a mosaic for premutation and full mutation size alleles. Verheij et
al. (1993) and Ashley et al. (1993) also proved that the CGG repeat is within the 5'
untranslated region (UTR) and therefore not translated, and that translation starts at
an ATG codon 3' to the CGG repeat.
2.1.3.11 Characteristics of FMR1 and FMR1.
The FMR1 gene consists of 17 exons spanning 38 kb (Eichler et al., 1993),
determined both by PCR and restriction analysis, and the direction of transcription is
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towards the telomere. The average intron length (2.2kb) and average exon length
(112 bp) are similar to those of other vertebrate genes although the first intron is
unusually large (9.9kb). Alignment of the predicted protein sequence of human
FMRl (FMR1) with mouse fmrl reveals 97% identity and greater than 98%
similarity (Ashley et ah, 1993). The largest mRNA variant encodes a protein of 631
amino acids with a molecular weight of approximately 69 KDa, and the smallest
encodes a protein of 436 amino acids (Verheij et ah, 1995).
Alternative splicing in FMR1
FMR1 is subject to alternative splicing at the 3' end of the gene as shown by Verkerk
et al. (1993) who used RT-PCR (reverse transcriptase PCR) to study normal
transcription of FMR1 in different tissues. The alternative splicing could
theoretically result in 12 distinct mRNA products, each of which could be translated
into an FMR1 isoform. The presence of four different proteins has been confirmed
by using FMR1 specific antibodies (Verheij et ah, 1993). No alternative splicing has
been found in the first half of the FMR1 gene; the CGG repeat is in the same exon at
the initiation codon ATG (exon 1) and cannot be spliced out without removing this
codon. Two principal modes of alternative splicing have been described for FMR1
(Verkerk et ah,1993; Ashley et ah, 1993); alternative 3' acceptor sites have been
demonstrated for exons X, XV, and XVII, while exon skipping can occur with exons
XII and XIV.
Inter species homology of FMRl
The FMRl gene is highly conserved among vertebrates, and homologous sequences
have been observed in yeast, Caenorhabditis elegans and Drosophila (Verkerk et ah,
1991). The CGG repeat is also found in murine fmrl in an equivalent position,
except there are fewer repeats (approximately 10) which are relatively invariant
among mouse strains (Nelson, 1995a).
Similarity of FMRl and FMRl to other genes and proteins
Homology searches of the GenBank, SwissProt and EMBL databases with the FMRl
cDNA sequence, using the BLAST program, failed to reveal any similarities to
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previously cloned characterized cDNAs. However, a short repetitive stretch of
amino acids within FMR1 consisting of 19 amino acids with 42% identity and 63%
overall similarity was identified. One repeat is contained entirely within exon VIII
while the other spans exons IX and X. These repeats were shown by Siomi et al.
(1993) to have strong similarity to KH domains which are evolutionary conserved
domains found only in RNA binding proteins. Also identified within the carboxy
terminal portion of FMR1 was an RGG box (Arg-Gly-Gly) which is also implicated
in RNA binding and DNA binding, suggesting involvement of FMR1 in RNA
metabolism. Khandjian et al. (1996) investigated the subcellular localization of
FMR1 (which had previously been shown to be a cytoplasmic protein (Devys et al.,
1993)) and demonstrated that during ultracentrifugation of cytoplasmic fractions of
HeLa cells on a sucrose gradient, FMR1 cosedimented with polyribosomes. When
the polyribosomes were dissociated with EDTA and subjected to further
ultracentrifugation, FMR1 was found to be associated with the 60S large ribosomal
subunit. Immunofluorescence studies using monoclonal antibodies directed against
FMR1 also showed colocalization with ribosomes. From these data the authors
postulated that absence of FMR1 might affect the translational mechanism or alter
the normal rate of ribosomal assembly.
2.1.3.12 The CGG repeat in fragile X syndrome
The CGG repeat is highly polymorphic; normal X chromosomes have repeat sizes
ranging from 6 to 54 repeats with a mode of 30 repeats (Fu et al., 1991; Snow et al.,
1993). Within this normal range, alleles are stably inherited in families (Fu et al.,
1991; Kremer et al., 1991b). Normal transmitting males and their carrier daughters,
have CGG repeat lengths of 54-200 repeats (premutations); individuals with alleles
in this range show a non-penetrant phenotype and in these cases the CpG island is
non-methylated. Affected individuals have CGG repeat numbers greater than 200,
and often in excess of 1000 repeats (full mutations). Expansion of the CGG repeat is
also accompanied by methylation of the CpG island and cytogenetic expression of
the fragile site (Oberle et al., 1991; Verkerk et al., 1991; Fu et al., 1991). The
estimated number of repeats required for a phenotypic effect is approximately 230
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although methylation at the CpG island appears to be the critical factor in
determining the phenotype. The expanded allele in these patients frequently exhibits
somatic variation, resulting in either multiple fragments or a heterogeneous smear of
fragments on a Southern blot.
Although the number of repeats in the premutation range is somatically stable within
the individual, it is highly unstable upon transmission from generation to generation,
with expansion to a full mutation occurring only after transmission through the
female germline (see 2.1.3.16). Some rare cases of reduction in size have been
observed (Oberle et al., 1991; Yu et al., 1991). When the premutation is transmitted
from father to daughter the repeat either remains the same size or increases slightly,
and recent evidence has shown that decreases in repeat length between father and
daughter may occur quite frequently (Fisch et al., 1995). The degree of expansion
from premutation to full mutation may depend upon the sex of the child, according to
Loesch et al. (1995) who found that the difference in size between the mother's
premutation and the child's full mutation was greater in boys than girls.
2.1.3.13 Founder effects in fragile X syndrome
Since affected males rarely reproduce, a very high mutation rate has been proposed to
maintain the frequency of the disease (Brown, 1990). Haldane (1935) had shown
that for X-linked genes, a deleterious allele can be maintained in the population such
that the proportion of sporadic cases m = su/(2u + v) where s is the selection
coefficient in males and u and v are the male and female mutation rates. As fragile X
males almost never reproduce, 5=1, therefore one-third of all cases should be de
novo assuming equal mutation rates in both sexes. However, new mutations, in
which expansion of the CGG repeat is responsible for the phenotype, have not been
found and in all fragile X families where grandparents of probands were studied, one
grandparent was found to carry the mutation (Macpherson et al., 1994). Therefore,
carriers of mutant alleles must be present in the general population (Smits et al.,
1992). Initial evidence that a founder effect was involved in fragile X came from
linkage disequilibrium studies (Richards et al., 1992) using the dinucleotide repeats
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FRAXAC1 and FRAXAC2 which closely flank FMR1 (Richards et al., 1991). Three
haplotypes which accounted for only 15% of normal chromosomes were found in
58% of fragile X chromosomes. Similar studies by Hirst et al. (1993) using
FRAXAC1, Macpherson et al. (1994) using FRAXAC1, FRAXAC2, and DXS548, and
Oudet et al. (1993) with FRAXAC2 and DXS548 found a pronounced difference in
the distribution of flanking haplotype between fragile X and normal chromsomes.
Snow et al. (1994) carried out further haplotype analysis using DXS548 and
demonstrated enrichment of the 194 bp allele among fragile X alleles and depletion
of the 196 bp allele. The 204 bp allele, although not enriched on fragile X
chromosomes, showed a significant association with a number of repeats greater than
40. There was a high frequency of association of the most prevalent repeat number
(30) with the DXS548 194 bp allele.
2.1.3.14 Structure of the CGG repeat
Sequence analysis of the FMR1 CGG repeat (Snow et al., 1994) has shown that it is a
composite array with sets of CGG repeats interspersed by regularly spaced AGG
triplets. Sequencing across the repeat in four different cohorts: normal
chromosomes; premutation alleles; full mutation carriers and individuals with a
possible diagnosis of fragile X syndrome, showed that the majority of alleles
contained at least one AGG interruption within the CGG repeat. A typical array of
29 repeats had the structure (CGG)9AGG(CGG)9AGG(CGG)9 (designated
9.A.9.A.9). Among the normal alleles (< 52 repeats), 43 contained 1 AGG, 74 had 2
AGGs, 8 had 3 AGGs and 5 alleles were pure CGG repeats with no interspersed
AGGs. The frequency of uninterrupted CGG repeats was higher in the premutation
allele sample (8 alleles out of 14 had no interruption) and in fragile X chromosomes,
3 alleles out of 5 had AGG interruptions. For the latter, the authors concluded that
the sequence in these 5 cases was obtained from a subpopulation of cells containing a
premutation length allele, which was too faint to be detected on a Southern blot (the
technical difficulties of PCR amplifying and sequencing across the repeat in full
mutations precludes study of the nature of the repeat in these patients). Hirst et al.
(1994) sequenced across the FMR1 repeat in 102 normal males and found that 96 of
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these consisted of short CGG tracts interrupted approximately every tenth repeat by
an AGG triplet with a core unit of [AGG(CGG)9] added at the 3' end. They
identified five classes of array (types 0-4): type 0 arrays are non-interrupted repeats
and make up 6% of chromosomes; type 1 have one intervening AGG repeat with a
range in size of 16-36 repeats and make up 28% of chromosomes; type 2 have two
AGGs, a range of 28-45 repeats and are the most common form, being found on 64%
of chromosomes. Types 3 and 4 (three and four intervening repeats respectively)
were rare making up less than 1% of chromosomes. Sequencing of the CGG repeat
also demonstrated that pure CGG repeats occur predominantly at the 3' end
suggesting polarity for the loss of AGG interruptions (Eichler et al., 1995); this has
also been observed to be the case in the occurrence of new mutations in several
human minisatellite repeats (Jeffreys et al., 1994). Sequences with no AGG or with
the configurations 9.A.>20, 10.A.>20 and 11 .A.>20 may be predisposing alleles or
fragile X "protomutations" (Snow et al., 1994). Approximately 3-5% of the
population carry uninterrupted arrays with greater than 20 CGG triplets, either alone
or at the 3' end of the array. The data presented by Snow et al. (1994) indicate that
there may be an overlap range within which repeats may be stably or unstably
inherited.
2.1.3.15 Mechanism and models of CGG expansion
Instability of the CGG repeat is thought to be the result of slipped strand mispairing
during replication with expansion of the repeat region in repeat unit increments
(Snow et al., 1994), and pure CGG repeats being more prone to replication slippage.
This can be demonstrated in vitro as the presence of more shadow bands on
denaturing gels containing PCR products using primers flanking the repeat, assuming
that the shadow bands arise as a result of slippage of Taq polymerase during PCR
(Hauge and Litt, 1993). Comparison of the length of these arrays suggests that pure
CGG tracts may have arisen by the loss of the interspersed AGG triplets possibly by
deletion during replication slippage. The generation of uninterrupted arrays may be a
continuous and dynamic process by which precursor fragile X arrays can arise from
within the normal population (Hirst et al., 1994).
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Several models have been proposed to explain the behaviour of the fragile X
mutation. The model of Morton and Macpherson (1992) postulated that four types of
allele exist at the fragile X locus. Normal alleles (N) mutate at a rate of 2.5 x 10~4 to
stable alleles (S) which have 50 or more CGG repeats. S alleles are converted to
unstable alleles (Z) at a rate of about 1.1% per generation and the full mutation allele
(L) only arises from Z during female meiosis but at a rate of 74% per generation.
The pool of mutation chromosomes, which is constantly being lost from the
population due the decreased reproductive fitness of affected individuals, could
therefore be continually renewed from the normal population. If fragile X syndrome
is currently in population equilibrium, then a fairly large pool of mutant alleles would
be required to maintain the disease frequency. More recently, Ashley and Sherman
(1995) proposed a multistep/multipathway model which took into account both
meiotic and post-zygotic expansion. The mutation rate p was taken as the rate at
which an unstable allele arises from a stable allele was assumed to be equal in males
and females. Meiotic expansions were assumed to occur equally in oogenesis and
spermatogenesis, while mitotic expansions were limited to the maternally inherited X
chromosome. The model also assumed that decreases in size are not true reductions
but are due to lack of mitotic expansion in paternally derived alleles.
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2.1.3.16 Timing of expansion
It is not clear when amplification of an unstable repeat occurs although evidence is
mounting that the transition from premutation to full mutation occurs only after
transmission through the female germline, and then only for a short period during
early embryogenesis.
Fragile X affected fetuses are mosaic with respect to repeat number and following the
establishment of mosaicism the repeat becomes stably transmitted in somatic tissues.
Wohrle et al. (1993) showed that somatic variation of CGG repeat length is based on
a mosaic of cells with different but stable FMRl alleles. They cloned fibroblasts
from two affected individuals; a 13 week old positive male fetus, and an adult male
patient, both of whom showed typical somatic variation. Dilution plating of the cells
resulted in isolated colonies, each carrying only one particular repeat size. After an
estimated 22 rounds of DNA replication, the fragment lengths had not changed.
Another 13 week old affected male fetus revealed almost identical patterns of repeat
lengths in DNA isolated from different tissues indicating that mosaicism had already
been established and stabilized at this time of development. Wohrle et al. (1993)
concluded that if expansion of a premutated repeat does not start before the formation
of a zygote, parental imprinting must exist in the FMRl region to allow for the
distinction between paternally and maternally derived premutations. They suggested
that carrier parents transmit a premutated FMRl allele to offspring and that large
expansion to a full mutation takes place in a particular window of early development,
exclusively on maternally derived X chromosomes, giving rise to a mosaic of cells
carrying alleles with different expansions of the repeat.
Further evidence for post-conceptual expansion came from analysis of sperm from
four affected males (Reyniers et al., 1993). Sperm DNA exhibited only premutation
alleles while somatic cells (peripheral blood lymphocytes and Sertoli cells from a
testicular biopsy) displayed a full mutation. From these results, the authors
postulated that either the transition from premutation to full mutation does not occur
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in the gametogenic precursors or there is selection against the full mutation due to a
requirement for FMRl expression in spermatogonia and oogonia.
Additional evidence for the early establishment of somatic mosaicism has come from
a prenatal diagnosis carried out in our laboratory (2.3.1.2). Both male fetuses in a
monozygotic twin pregnancy were found to carry the full mutation. DNA analysis
after termination of the pregnancy revealed identical patterns in the CVS and in all
fetal tissues examined. Because the twins were monozygotic, the twinning event
occurred sometime between the third and the eighth day of development, suggesting
that, in this case, the somatic mosaicism was also established within this period.
Devys et al. (1992) obtained similar results when they studied two pairs of
monozygotic twins who had identical band patterns on Southern blotting. The twins
in their study were monochorionic and monoamniotic which is a later form of
twinning occurring between day 10-20. The timing of CGG expansion can be
deduced from the data presented by Devys et al. (1992) to be within day 5 and day 20
of development. If expansion only occurs mitotically then it must take place
sometime after day 5 when the gametogenic and somatic cell lineages separate and
before day 20 when the late form of twinning suggests that mosaicism is completed.
Although it has been established that males with a full mutation pass only a
premutation size allele to their daughters, it has not been proven conclusively (and
would obviously be very difficult to do so) that a full mutation carrier mother
transmits only a premutation sized allele which then undergoes post-zygotic
expansion, to her offspring. When a premutation is transmitted from father to
daughter, the allele can either remain unchanged in size, become smaller or become
slightly larger, although an allele which changes in size remains in the premutation
range. We studied a fragile X syndrome family (discussed in 2.3.3.3) in which a
normal transmitting male passed on premutation alleles which were successively
smaller in each of his four obligate carrier daughters (Figure 25), the eldest daughter
being 17 years older than the youngest. The difference between the largest and
smallest allele was estimated to be 20 repeats. Two possibilities could account for
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this observation: a) the NTM's sperm carried highly heterogeneous premutation
alleles and the reduction in size with time is a chance effect or b) there is continual
selection against sperm with large premutations during spermatogenesis. The NTM
was deceased at the time of DNA analysis on his offspring and therefore the size of
his premutation is unknown.
There is, as yet, no evidence which determines whether changes in premutation size
from father to daughter occur during or after meiosis; this might be resolved by
single sperm analysis. If separate spermatozoa were shown to carry different sized
premutation alleles it would suggest that expansion takes place during meiosis. This
has been demonstrated to be the case in spinocerebellar ataxia (SCA1), which is
caused by expansions in an unstable CAG trinucleotide repeat in the ataxin-1 gene.
Chong et al. (1995) analysed the SCA1 repeat in blood and sperm of two affected
individuals. Single sperm were separated using a micromanipulator and peripheral
blood leucocyte DNA was diluted out until approximately 2-5 genome equivalents
remained; the single sperm DNA and low copy leucocyte DNA were then PCR
amplified using nested PCR with primers flanking the CAG repeat. The results
showed that the expanded alleles in sperm were more heterogeneous than the
expanded alleles in blood. The normal allele in each case showed complete
homogeneity (apart from one sperm which the authors attributed to sample
contamination). To date, a study of this nature has not been carried out on sperm
from males with a fragile X premutation.
An alternative possibility to account for the observations in fragile X syndrome is
that somatic instability results from multiple independent transitions from pre- to full
mutation in many different embryonic cell lineages, resulting in mosaicism which is
unrelated to somatic instability of the full mutation itself. The currently available
experimental data cannot distinguish these possibilities.
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2.1.3.17 Methylation and X-inactivation in fragile X syndrome
When the FMR1 CGG repeat expands to approximately 230 repeats or more, the
entire 5' region of the gene becomes abnormally methylated. The methylation of
CpG residues extends from nucleotide position +71 (relative to the start of
transcription), includes the CpG island, the repeat itself, to just beyond the Xhol site
distal to the repeat (Hornstra et ah, 1993). The effect of methylation is the abolition
ofFMR1 transcription, concurrent absence of FMR1, and expression of the fragile X
phenotype. Normal transmitting males are unmethylated in the 5' region of FMR1.
The methylation pattern on the normal inactive X chromosome in females is
equivalent to that found in males with a full mutation (Kirchgnessner et al., 1995).
Carriers of the full mutation display methylation on both the inactive and the
mutation bearing X chromosomes, while premutation carrying females are
methylated only on the inactive X chromosome. In normal females, there appears to
be a range of X-inactivation ratios around the mean of 50:50, ratios of 60:40 and
70:30 are common and 10% of normal females have ratios of 80:20. In fragile X
syndrome, non-random X-inactivation alone cannot account for the fact that only
35% of females with a full mutation are mentally impaired, unless tissue specific
skewing of X inactivation occurs in the brain. Non-random X-inactivation may
account for the variability in severity and the observation that females are usually
less severely mentally retarded than affected males. It is also possible that a
threshold level of FMR1 is required for normal brain function. Monozygotic female
twins have been described in which one twin was intellectually normal and the other
was retarded, although both were heterozygous for the full mutation (Kruyer et al.,
1994) and both expressed the fragile site in 7% of cells. In the normal twin, the X
chromosome carrying the fragile X mutation was the active chromosome in only
30% of cells but in the retarded twin it was active in 85% of cells, suggesting that, in
this case, X-inactivation and mental retardation are correlated.
The patterns of methylation at the CpG island of FMR1 are variable between
embryonic and extra-embryonic tissues. In contrast to expansion of the CGG repeat
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between day 5 and day 20 of embryogenesis, methylation in CV tissue usually does
not occur until sometime after the 10th week of gestation. The majority of chorionic
villus samples have been shown to be undermethylated or unmethylated at the CpG
island, whereas tissues from affected fetuses only 6 weeks old were methylated in
this region (Luo et al., 1993). Sutcliffe et al. (1992) also demonstrated methylation
differences between chorionic villi derived from a male fetus with a full mutation and
tissues from the aborted fetus; the CV sample was unmethylated and the fetal tissues
were methylated. Devys et al. (1992), however, found that the abnormal methylation
patterns characteristic of the full mutation were present in 8 of 9 chorionic villi from
affected fetuses, while chorionic villi from 6 out of 7 normal females were
unmethylated at the CpG island on both chromosomes. The 7th case had patterns
equivalent to those seen in normal females, although the authors could not rule out
the possibility of incomplete digestion for the methylation sensitive enzyme. The
CpG islands of all genes except those which are active during embryogenesis (and
excluding the primordial germ cell genes which are demethylated in the third
trimester) undergo total demethylation at the morula stage, followed by gene specific
methylation at the time of implantation of the blastocyst (at 1-2 weeks gestation). In
the mouse, CpG islands in extra-embryonic tissues are known to escape this global
de novo methylation which is in accordance with the observation that methylation in
human CVS tissue is not always comparable to fetal tissues.
Evidence provided by three groups have indicated that it is not the expansion of the
CGG repeat which is responsible for the fragile X phenotype but the concomitant
methylation of the CpG island (McConkie-Rosell et al., 1993; Rousseau et al., 1994;
Smeets et al., 1995). Two phenotypically normal brothers with a full mutation, in
addition to cytogenetic expression of FRAXA (6% and 30%) were described by
Smeets et al. (1995). Methylation analysis showed that a mentally retarded member
of the family (a grandson of one of the brothers) was a mosaic for a methylated full
mutation and an unmethylated premutation, whereas the two normal brothers had
unmethylated full mutations. The type of mosaicism seen in the affected patient was
very unusual in that the heterogeneity was shown by a "ladder" of bands ranging
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from premutation range to full mutation. Levels of mRNA were normal in the two
brothers and absent in the affected boy. These findings have important implications
for prenatal diagnosis because methylation in CV tissue is not a reliable indicator of
methylation in the fetus and the size of CGG expansion is often used alone as a
predictor of intellectual outcome in a male fetus.
2.1.3.18 Fragile X syndrome not due to CGG amplification
Fragile X syndrome is an atypical genetic disease in that the vast majority (probably
more than 99%) of patients have a mutation in one specific region of the gene rather
than a variety of mutations (point mutations, deletions, rearrangements etc)
throughout the entire gene. However, there is a small group of patients who have the
classic phenotype, without expression of the fragile site, and without amplification of
the CGG repeat. These patients have mutations which, with one exception (De
Boulle et ah, 1993) result in complete absence of FMR1 protein. The mutations are
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De novo deletion Deletion spans at least 3Mb
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Family history of MR Inherited deletion Approx 1.4kb 5' of the CpG
island to the beginning of the




8 year old boy with
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6 year old boy with
MR plus some atypical
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Inherited deletion 9Mb from DXS105 to -160-




18 year old boy with
MR and cherubism
De novo deletion Mosaic for deletion of 8.7kb
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and flanking sequences, and
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Table 6. Summary of point mutations and deletions which involve FMR1. Numbers in the












Figure 4. Approximate locations of deletions and point mutations in the region of FMR1.
Numbers refer to Table 6. Not to scale.
The deletions and point mutations summarised in Table 6 and illustrated in Figure 4
were all found by Southern blotting using probes which detect expansions in the
CGG repeat at the 5' end of the gene. It is likely therefore, that other deletions and
point mutations may exist in other parts of the gene, which have yet to be detected.
The existence of deletions and point mutations in the 5' region of FMR1 which do
not involve expansion of the CGG repeat, but result in the fragile X phenotype, have
established that fragile X is a single gene disorder.
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The first point mutation of FMR1 (No. 3 in Table 6) was found in a patient with the
fragile X phenotype, no cytogenetic expression of FRAXA and a normal CGG repeat
length (De Boulle et ah, 1993). This patient had a particularly severe phenotype with
an IQ of less than 20, dysmorphism, macro-orchidism, and spastic paraparesis. He
was an affected member of a family with X-linked glycogenosis (XTG) due to
phosphorylase kinase deficiency although the symptoms of this disorder
(hepatomegaly, growth retardation, hypercholesterolaemia) diminish after
adolescence. Mental retardation is not a feature of XLG and none of the other family
members were mentally retarded (or had macro-orchidism). This increased severity
of the phenotype in this patient suggests that abnormal FMR1 is more deleterious
than complete absence of the protein.
One of the point mutations (No. 10 in Table 6) described by Lugenbeel et al. (1995)
resulted in a frameshift and predicted a premature stop codon 66 amino acids 3' to
the deletion. An mRNA transcript was detected (as indicated by reverse transcriptase
PCR) but Western blot analysis was unable to identity a protein product of the
expected size. The two base pair change (No. 11 in Table 6) was a splicing mutation
which resulted in two mRNA transcripts of reduced size (one as a result of splicing
out exon 2 and the other was created by splicing out exons 2 and 3). Even though
splicing out of exons 2 and 3 does not alter the reading frame and therefore a protein
of reduced size could be generated, Western blot analysis failed to detect any protein.
The authors concluded that these two patients provide strong evidence that absence
of FMR1 results in the fragile X phenotype.
The 1.6 kb deletion (No. 7 in Table 6) reported by Meijer et al. (1994) and the
deletion/expansion mosaics (No. 15 in Table 6) reported by De Graaff et al. (1995)
may have arisen by similar mechanisms with expansion of an unstable repeat being a
predisposing factor for a deletion. Studies of deletions in other human disorders have
shown that the deleted regions are flanked by short repeats which are presumed to
undergo replication slippage resulting in the formation of a loop between the repeats,
which is subsequently excised. A small region 5' of the CGG repeat has been
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proposed by De Graaff et al. (1995) to be a deletion hotspot; the deletions in the four
patients they described all had 5' breakpoints within 30 bp of each other. Although
Figure 4 is not drawn to scale, there is a suggestion that this may be the case.
2.1.3.19 Molecular diagnosis of fragile X syndrome
During the search for the FMRl gene, numerous probes spanning the CGG repeat
and the CpG island were developed from YACs containing the fragile site. Most of
the probes which are currently in use in diagnostic laboratories were derived from the
5.2kb fscoRI fragment isolated from the cosmid subclones BC22 and BC72 (2.1.3.8),
The fundamental test for fragile X syndrome is the measurement of the length of the
CGG repeat, often in conjunction with analysis of the methylation status of the
FMRl CpG island. This can be achieved by:
a) PCR amplification across the repeat
b) Southern blot analysis with DNA probes
c) Southern blot analysis of PCR products
PCR amplification across the repeat. The first PCR-based method for assessment of
length variation within the CGG repeat was developed by Fu et al. (1991) using
primers c and f as illustrated in Figure 5. This is a reliable method for amplifying
across the repeat in normal individuals although there are two major limitations to all
methods involving PCR amplification (discussed below). In their cohort of 492 X
chromosomes Fu et al. (1991) found that the overall heterozygote frequency was
63% with the most frequent allele (found in 30% of chromosomes) estimated at 29
repeats by comparison with size markers. Brown et al. (1993) sequenced across the
repeat and established that the most common allele actually consists of 30 repeats,
the high CG content of the repeat presumably caused mobility differences during
electrophoresis.
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LIMITATIONS OF THE PCR TEST
1) Failure of the full mutation to amplify. The high GC content of the repeat
makes it impossible to amplify (and sequence) across full mutation alleles and
large premutation alleles.
2) Preferential amplification in heterozygote females. This is defined as a
difference in the yield of amplified product in heterozygotes so that the larger
allele is always much weaker than the smaller one. It is generally related to the
size difference between alleles and therefore the premutation allele of a carrier
female is often difficult to detect. In addition, the premutation allele appears as an
indiscrete band with a spread of about 10 repeats, presumably as a consequence of
Taq polymerase slippage.
In order to improve the efficiency of the PCR assay, many groups have experimented
with different primers, cycling parameters, buffers (pH and components), other
additives (DMSO, glycerol, detergents), dGTP analogues (dITP, 7-deaza-dGTP),
nested PCR (Levinson et al., 1994), and various DNA polymerases including Pfu
(Chong et al., 1994). However, no group has yet been able to amplify across the full
mutation. One approach which may have potential is an adaptation of the
minisatellite variant repeat (MVR) PCR (Jeffreys et al., 1991). In this method a
forward primer is situated outside the repeat and a reverse primer consisting of a
string of repeats (which would be (GCC)6 for the fragile X repeat)), and a non¬
homologous "tail" is situated so that it anneals within the repeat itself. The reaction
is driven by a third primer which is complementary to the tail only. The tail is
designed so that it will not anneal anywhere in the genome. In theory, there should
be product from every repeat so that a ladder is produced with the final peak
representing the most distal repeat unit (depending on the orientation of the primers).
This method has worked successfully for amplification of the variant repeat in D1S8
(Yamamoto et al., 1994) and the CAG repeat in myotonic dystrophy (Warner et al.,
in preparation) and it is likely to prove useful in the other triplet repeat disorders.
Initial experiments with the FMR1 CGG repeat have not been successful although
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this may be due to the interspersed AGGs and the high GC content of the repeat
(CGG/GCC repeats are responsible for the phenotype in only two of the triplet
repeats disorders identified so far, fragile X and FRAXE mental retardation).
Southern blot analysis with DNA probes. Southern blotting analysis remains the
most reliable method for detection of an increase in repeat size. It is simple,
relatively inexpensive (through wise choice of enzymes), usually unambiguous and
has the additional advantage of providing a simultaneous assay for methylation status
at the CpG island. However, the time from receipt of blood to final result can be up
to 10 days. Four segments of DNA derived from the 5.2 kb EcoRl fragment, from
which FMR1 was isolated, are available as DNA probes (Figure 5):
a) StB12.3 and pfxa7 are 1.2kb Pstl fragments derived from either YAC 209G4 or
XTY26 (Oberle et ah, 1991; Kremer et al. 1991a). pP2 is a 1.2kb Pstl fragment
derived from pE5.1 (Oostra and Verkerk, 1992). These probes detect a normal
band of 5.2kb with EcoRl digests in addition to an unmethylated fragment at
2.8kb in a double digest (e.g. EcoRl + Eagl, .EcoRI + iNsHII). If Hindlll is used
instead of EcoRI, the methylated fragment is just under 5.0 kb and the
unmethylated fragment is approximately 2.5kb (Figure 5).
b) pE5.1 and pfxal are the same 5.2kb EcoRl fragment isolated from YACs 209G4
and XTY26 respectively (Verkerk et al., 1991;Yu et al. 1991). They span the
CGG repeat and the CpG island and detect a normal band of 5.2kb on EcoRl
digested DNA. In a double digest of EcoRl and Eagl, three bands are detected;
the methylated X gives a band at 5.2kb and on the unmethylated X chromosome,
this is cut into fragments of 2.4 and 2.8kb.
c) Oxl.9 is a 1.9 kb BamHl-EcoKl fragment (Nakahori et al. 1991) subcloned from a
cosmid derived from YAC141H5. Oxl.9 detects the same fragments as StB12.3,
pfxa7 and pP2.
d) pfxa3 and OxO.55 are essentially the same fragment (-500 bp) which lie
immediately distal to the CGG repeat. pfxa3 is a Pstl/Nhel fragment subcloned
from the 1.06kb Pst 1 fragment spanning the CGG repeat and the CpG island (Yu
et al. 1991). OxO.55 is generated by PCR amplification (Nakahori et al. 1991).
Hybridization with these probes results in a band of approximately lkb on Pstl
digests of DNA from normal chromosomes.
With the exception of the probes in d) which detect a full mutation as a smear greater
than ~1.6kb, all the probes detect a full mutation as a band greater than ~5.7kb. Full
mutations can appear as a discrete band of increased size, or as several bands, or as
heterogeneous smear. In about 12% of affected males (some reports state 15-20%)
and 6% of full mutation carrying females, a band is seen in the premutation range as
well as in the full mutation range (Rousseau et al., 1994). These individuals are
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Figure 5. Diagram of FMR1 in the region of the CGG repeat, showing restriction enzyme
sites and DNA probes used in the diagnosis of fragile X syndrome. PCR primers c and f (Fu
et al., 1991) and x and y are indicated. Not to scale.
Southern blot analysis of PCR products
A combination of PCR and Southern blotting was developed by Pergolizzi et al.
(1992) as a rapid method of identifying full mutations. PCR amplification was
carried out using primers which closely flank the repeat, the PCR products were
transferred to a nylon membrane and hybridized with a (CGG)5 probe. I tested this
method but with variable success. As expected, there was preferential amplification
of the normal allele in carrier females and some full mutation males still failed to
amplify. Male premutation alleles, however, amplified fairly well. The advantages
of this method over a traditional Southern/alkali blot are: a) results can be obtained
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within 2 days, b) it is cheap, and c) it can be carried out on DNA from mouthwash
samples. However, the sensitivity is not as high as with the Southern/alkali blot.
2.1.3.20 Prenatal diagnosis of fragile X syndrome
Since the discovery of the nature of the mutation causing fragile X syndrome,
prenatal diagnosis by direct DNA analysis of chorionic villi, is technically a
relatively simple procedure. Currently, in our laboratory, for each prenatal diagnosis,
the following are carried out:
a) Determination of fetal sex using primers at the pseudoautosomal boundary locus
(.PAB; Ellis et al., 1990) or the amelogenin locus (AMEL; Bailey et al., 1992).
b) PCR across the repeat using either primers c and f (Fu et al. 1991 and see 6.1.4.1),
or x and y (2.2.1.2) with detection of products by denaturing polyacrylamide gel
electrophoresis.
c) Southern/alkali blotting using both HindlW digests and Hindlll/Eagl double
digests irrespective of the sex of the fetus. The reason for this is that a
premutation in a male appears in the 2.7-3. lkb region of the gel where the
resolution is greater.
In certain circumstances, a closely linked CA repeat, such as DXS548 (Riggins et al.,
1992, FRAXAC1 or FRAXAC2 (Richards et al., 1991), may be useful.
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Table 7. Summary of possible outcomes of prenatal diagnoses.
The two outcomes which may give problems in the interpretation of the results occur
when a premutation carrier male or a full mutation carrier female are predicted. In
the former case, the male carrier could potentially be a mosaic with a large
proportion of cells having an unmethylated premutation in FMR1 and the remainder,
a methylated full mutation which is too faint and/or heterogeneous to be detected on
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a Southern blot. In addition, methylation at the CpG island cannot be used to
distinguish a large unmethylated premutation and a small full mutation because the
methylation status in CVS tissue is not equivalent to that in the corresponding fetal
tissue (as discussed previously in 2.1.3.17). A prenatal diagnosis carried out in our
laboratory which resulted in this dilemma is described in 2.3.3.3.
When a full mutation carrier female is diagnosed, it is not possible to predict the
intellectual outcome, either from the size of the expansion, methylation at the CpG
island, or by measurement of the degree of non-random X-inactivation. This is a
genetic counselling issue which may arise frequently in the context of prenatal
screening.
2.1.3.21 Prenatal and population screening for fragile X syndrome
Whether the time is right for prenatal screening of fragile X syndrome is a
contentious issue [Moore, (1992); Palomaki and Haddow, (1993); Bonthron and
Strain, (1993); Bundey and Norman, (1993); Howard-Peebles et ah, (1993);
Palomaki, (1994)] which has not yet been resolved in the UK. Fragile X syndrome
appears to be an obvious candidate for population-based prenatal screening for the
following reasons: it is a relatively common genetic disorder; the phenotype may be
severe; no treatment is available; and the new mutation rate (of a mother with alleles
in the normal range producing a child with full mutation) is probably nil. In a pilot
study in Canada, Rousseau et al. (1993) analysed DNA from 10,624 women and
found that 30 (1 in 354) carried a premutation sized allele. A later study by Rousseau
et al. (1994) found 3 premutation alleles among 164 couples suggesting that as much
as 0.9% of the general population may carry a premutation (although these 3 alleles
were found in male spouses and the sample number was small). The prevalence of
affected individuals (1 in 1,250 males and 1 in 2,500 in females) is similar to the
prevalence of cystic fibrosis for which prenatal screening programmes have been in
place in Edinburgh (Mennie et al., 1992) and other UK centres for several years. As
fragile X syndrome is an X-linked condition (even though it is semi-dominant,
56
affected males do not produce affected daughters) only pregnant women need to be
tested and therefore the partner can be ignored.
Population and prenatal screening is presently only being carried out for a few
genetic disorders worldwide; for |3-thalassaemia in some Mediterranean countries,
Tay-Sachs disease in Ashkenazi Jews in the USA, and sickle cell anaemia in certain
high risk racial groups in the USA. The effect of these programmes has been a
reduction in the birth incidence, sometimes as much as 95% in the case of P-
thalassaemia in Cyprus. In Edinburgh, prenatal screening of cystic fibrosis (CF) has
resulted in a two thirds decrease in the number of babies born with the disease.
However, a prenatal screening programme for fragile X syndrome would probably
not have such a dramatic effect on birth incidence because of the characteristics of
the disorder, such as the difficulty in predicting the degree of mental retardation in a
female fetus with a full mutation. In addition, since premutation alleles are thought
to be derived from large normal alleles, the gene pool of successive generations will
continually be added to (unlike the gene pool of CF mutations). The actual effect of
a prenatal screening programme for fragile X syndrome will only be shown by a pilot
study.
Screening a non-pregnant population would be an alternative method of detecting
carriers of fragile X in the population. This could be done in the neonatal period or
in school children, although there are ethical considerations involved in testing
children if the aim is to reduce the birth incidence of the disease in the next
generation, rather than to detect it in the present generation. Children under 16 can
consent to genetic testing only if they are able to understand why they are being
tested and the significance of the result (Clarke et ah, 1994). If they cannot, (which
may be the case in fragile X full mutation children) then the parents have the right to
decide for the child until he or she becomes 18. For this reason, testing for fragile X
is limited to testing through GPs or in antenatal clinics at the time of routine maternal
serological tests. There are advantages and disadvantages to both approaches.
Screening during pregnancy is known to create anxiety for the couple and also puts
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pressure on the laboratory carrying out the tests, although the uptake rates for testing
during pregnancy are higher than GP based screening.
Practical considerations
The nature of the repeat precludes amplification of large premutations and full
mutations by PCR, therefore it is impossible to distinguish a normal female who is
homozygous for two alleles of the same repeat number, from a carrier female with a
full mutation or large premutation. A female who has two clearly distinguishable
alleles in the normal range however, could be excluded from further testing, but a
female who shows only one discernible allele must proceed to Southern blotting.
The proportion which must be analysed further could be as high as 45%. The
reasons for this are discussed in 2.3.2.2,
2.1.3.22 Testing developmentally delayed children for fragile X syndrome
Fragile X testing is recommended for any child with mental retardation of unknown
etiology. The cytogenetic test has now been replaced by the more reliable DNA test
in most genetic centres in the UK, although the cytogenetic test is still necessary to
rule out any other chromosomal abnormality which may be a cause of the mental
retardation.
It is important to establish the cause of a child's learning or behavioural disability for
several reasons. Firstly, if a diagnosis of fragile X syndrome is made, then there are
implications for other family members, and relatives may request carrier testing or
prenatal diagnosis. Second, for some parents, it is important to be able to name the
condition responsible for their child's mental retardation. Third, a definite diagnosis
of fragile X syndrome may indicate that special schooling would be appropriate,
which could be beneficial, both for the child and for the rest of the family.
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2.1.4 Objectives of this study.
Prior to 1991, trinucleotide repeat expansion mutations were an unknown form of
mutation, but since the characterization of the fragile X mutation, eleven triplet
expansions (at ten loci) have been found to be associated with a specific disease
and/or fragile site (Willems, 1994). The repeat varies between diseases but generally
the neurodegenerative disorders (Huntington disease, SCA1, X-linked spino bulbar
muscular atrophy, dentatorubral-pallidoluysian atrophy and the allelic Haw River
syndrome, and Machado-Joseph syndrome) have repeats consisting of CAG triplets,
while the syndromes associated with fragile sites have CGG or CCG triplets.
Recently, Friedreich's ataxia was found to be caused by a GAA triplet repeat
expansion in an intron of the frataxin gene (Campuzano et ah, 1996). The GAA
repeat is polymorphic on normal chromosomes and is also unstable upon
transmission, although Friedreich's ataxia is unusual in that it is the only disease
caused by a triplet repeat expansion in which the inheritance is autosomal recessive.
The identification of the molecular basis of fragile X syndrome has clarified some of
the previously puzzling genetic features of the disorder and has also had a major
impact on laboratory diagnosis of the syndrome with most genetic centres currently
providing a DNA based service for carrier testing and prenatal diagnosis.
The aims of the study presented in this chapter were four-fold: a) to determine the
proportion of pre-school age children whose mental retardation was due to fragile X
syndrome, b) to provide a molecular fragile X test for older children and adults with
mental retardation for confirmation of diagnosis, c) to examine the possibility that
polymorphic variation of CGG repeat number is correlated with IQ, and d) to
address important practical issues concerning the nature and timing of repeat
expansions during transmission in a prenatal diagnostic situation.
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2.2 METHODS
2.2.1 Optimization of methods for DNA testing
Since the identification of the nature of the mutation causing the majority of fragile X
cases, many genotyping protocols have been published. As there are several different
classes of mutation, all affecting the same region of FMR1, a good diagnostic test
must be able to identify each type, with high specificity (proportion of unaffected
individuals who have a negative result on testing) and high sensitivity (proportion of
true positive results). After five years evaluation (since the identification of FMR1)
of several different methods in many different laboratories, the consensus appears to
be that Southern blotting with a double digest is the most reliable test with PCR
being a useful, though not essential, adjunct. Some approaches are better than others;
my experiences with Southern blotting and PCR are as follows.
2.2.1.1 Southern blotting
The choice of restriction enzyme and probe is determined by the diagnostic
information required. The most popular enzyme combinations in the literature are
EcoRl and Eagl or EcoRl and ZAvHII. although other methylation sensitive enzymes
such as Ban\ and Shell were used in early reports. I found Hindlll and Eagl to be the
best combination because they both digest DNA in Hindlll buffer (50mM Tris-HCl,
pH 8.3, 50mM NaCl, lOmM MgCl2, ImM DTT) at 37°C. BstZl, however, has an
incubation temperature of 50°C, which means that double digests of BstZ 1 and either
Hindlll or EcoRl have to be carried out in two steps. I have had relatively few
problems with incomplete digestion using the Hindlll/Eagl combination. In
addition, the low-medium salt composition of the Hindlll buffer allows good gel
resolution. The most popular probes in published reports appear to be StB12.3,
Oxl .9 and pE5.1. I have had comparable results with the first two (we do not have
pE5.1 in the laboratory) but preferentially use StB12.3 because it is a "cleaner" probe
(which may be important in detecting weak heterogeneous full mutation smears in
females). I have found the following probe/enzyme combinations to be the most
useful in our laboratory in the following situations:
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For routine screening of mentally retarded patients.
In males: a single digest of Hindlll or iscoRI and hybridization with StB12.3 or
Oxl.9.
In females: a single digest as above, in addition to a double digest of Hindlll or
EcoKl and Eagl or BstZl. These two digests are run side by side on the agarose gel
for comparison.
A typical Southern blot obtained in the testing of mentally retarded individuals
referred for fragile X testing is shown in Figure 9 (page 73).
For detection of the full mutation in an individual in a known fragile X family
As above, although in certain circumstances a single Bglll digest is useful as the
normal fragment is approximately 12kb - this has the effect of condensing a very
diffuse full mutation. In females carriers of a full mutation, a double digest will
determine the length of the CGG repeat as well as the proportion of active/inactive X
chromosomes carrying the mutation. A double digest in a male would detect
"methylation mosaics" who have a band in the unmethylated premutation range as
well as a methylated band/smear in the full mutation range. I would not recommend
the P5tl/pfxa3 or OxO.55 combination for detection of a full mutation because these
probes give a normal fragment at approximately lkb which means that a full
mutation is spread out and may be very difficult to detect, and in my experience this
probe also gives a lot of background signal.
For detection of the premutation in an individual in a known fragile X family
The smaller probes OxO.55 and pfxa3 are useful for detecting smaller premutation
alleles in Pstl digested DNA because the separation between alleles is greater.
However, Pstl digests do not provide information about the methylation status of
FMR1 which is important in distinguishing a large unmethylated premutation and a
small methylated full mutation. In this study the best combination has been found to
be Hindlll/Eagl digests in both males and females and hybridization with Oxl.9 or
StB12.3. With this enzyme/probe combination, a premutation appears in the
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2.7-3. lkb region of the gel where the resolution is almost as good as in the lkb
region with Pstl digests and OxO.55 or pfxa3 as a probe.
2.2.1.2 PCR across the CGG repeat
The advantages of the PCR test are that the number of CGG repeats can be
determined accurately and smaller amounts of DNA template are required. However,
DNA testing for fragile X by PCR across the CGG repeat is not straightforward.
There are several reasons for this: a) the high GC content of the repeat makes it
impossible to amplify full mutations; b) PCR additives (such as 7-deaza-dGTP)
whilst improving efficiency, reduce visibility of products after ethidium bromide
(EtBr) staining (by hindering intercalation of EtBr between DNA strands); c) the
inherent "slippage" properties of DNA polymerases which produce shadow bands
can make interpretation difficult. Another drawback of PCR is that the methylation
status of the CpG island cannot be assessed. This is necessary to distinguish large
unmethylated premutations and small methylated full mutations. The first PCR
method published for the FMR1 CGG repeat (Fu et ah, 1991) used primers c and f
(Figure 5 and 6.1.4.1) which flank the repeat and which gave a product of 308 bp for
an allele of 30 repeats. I tried this method and as it worked fairly well, continued to
use it routinely. A typical autoradiograph obtained in routine PCR testing for fragile
X syndrome is shown in Figure 10 (page 74).
In order to improve the efficiency of the PCR, particularly the yield of premutation
alleles, I made modifications to the PCR protocol by:
i) Adding 10% glycerol
ii) Increasing the amount of DNA template to 250-500 ng
iii) Increasing the number of cycles to 35
These changes had the effect of slightly increasing the yield, and the addition of
glycerol reduced the lane background.
PCRs were carried out with the addition of a-32P-dCTP (2p.Ci to each reaction).
Later, I adapted the radioactive method so that PCR products could be analysed using
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the automated laser fluorescence sequencer (A.L.F., Pharmacia). This involved using
a fluorescent primer (either forward or reverse) in the PCR reaction. One advantage
of this non-radioactive method, is that since only one DNA strand is being labelled,
scoring of alleles should be more reliable. However, the sensitivity of detection is
not as high as with the radioactive method and I found that premutation alleles
(particularly in females) appeared extremely weak because of the problems of
preferential amplification of the smaller allele. For this reason, I reverted to the
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radioactive method. Another advantage of using a- P-dCTP is that if a premutation
allele appears very faint on an autoradiograph, the same dried gel can be exposed to
another piece of X-ray film for a longer period. An increased amount of PCR
product can be run on another A.L.F. gel but the volume of reaction has to be limited
10pl or less. Even though I chose the internal radioactive labelling method for
routine PCR testing, it became apparent later that there were pros and cons for both
methods (discussed in 2.3.2.2).
In a further attempt to improve the efficiency of PCR across the repeat, I designed
primers x and y which, according to the base composition, should have been more
compatible with each other than c and f. After a limited number of trials it was found
that they offered no advantage over primers c and f in terms of yield of premutation
alleles. However, they were useful in that they resulted in a smaller product and
therefore required a shorter electrophoresis run on PAGE. The sequences which
were obtained from the EMBL sequence, HSFXDNA, the 5.2kb EcoKl fragment
isolated by Verkerk et al. (1991) and Kremer et al. (1991b) are:
x: 5' - TCA CTT CCG GTG GGA GGG CCG CCT CT - 3'
y: 5' - AGA GGT GGG CTG CGG GCG CTC GA - 3'
An allele of 30 repeats gives a product of 221bp and amplifies under the same
conditions as the primers c and f.
2.2.2 Fragile X testing for mental retardation
Fragile X testing in a mentally retarded individual is a simple determination of the
size of the repeat; the presence of a full mutation is diagnostic of the disorder. DNA
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testing of blood samples received from patients with unspecified mental retardation
was carried out using both Southern blotting (2.2.1.1 and 6.1) and PCR (2.2.1.2 and
6.1). Figures 9 and 10 show typical Southern blot and PCR autoradiographs (pages
73 and 74).
2.2.2.1 Testing developmentally delayed children for fragile X syndrome
A cytogenetically based screening programme to detect fragile X syndrome in
mentally retarded children has been operating in New South Wales since 1984
(Turner et al., 1992). Other screening programmes have been implemented in New
York State (Nolin et al., 1992) and south east Spain (Gabarron et al., 1992), although
the latter studies involved screening mentally retarded males only. The proportion of
fragile X cases identified were 3.5% of females and 10.1% of males in the Australian
study, 9% in New York State, and 14% in the Spanish study.
In order to determine the proportion of fragile X cases in S.E. Scotland, as detected
by DNA methods, a programme for testing mentally retarded children was initiated
in October 1991. General practitioners, community paediatricians and hospital
paediatricians in Lothian, Fife and the Border regions were informed that this service
was available for all cases of mental retardation of unknown etiology. The
requirements for the test were at least 3 mis of EDTA anticoagulated blood for
extraction of DNA and if possible a separate lithium heparin blood sample sent
directly to the Cytogenetics Laboratory for identification of the fragile site.
Clinicians were requested to enclose with the specimen, a form detailing the clinical
presentation, family history if any, degree of developmental delay, dysmorphism if
present, whether a duplicate sample had been sent for cytogenetic testing, and if a
previous cytogenetic analysis had been carried out.
2.2.2.2 Testing for fragile X syndrome in adolescents and adults with mental
retardation
Although the initial strategy was to test children with developmental delay (targetting
children under the age of 5% years), blood samples were also received from older
64
children and adults for confirmation of diagnosis. These made up a substantial
proportion of the total number of samples received (50.5%). A small number of
patients were referred from adult mental institutions in Lothian and Fife.
2.2.3 Analysis of the FMR1 CGG repeat in three intellectually different
populations; correlation of repeat number with IQ
As described previously, the distribution of intelligence in the general population is
an asymmetric bell shaped curve (Figure 1, page 16), with mentally retarded
individuals making up 3% of the area under this curve at the lower extreme of the
distribution. Patients with fragile X syndrome (males with a full mutation and
penetrant full mutation carrier females) fit into this 3% although the IQ range for
these patients is highly variable. FMR1 premutation alleles are thought to be derived
from large normal alleles at the upper end of the normal CGG repeat range, which,
after several generations have lost one or more of their interspersed AGG triplets and
become pure and unstable CGG repeat alleles (most normal alleles have two AGG
interruptions, most premutations have no interruptions, Zhong et ah, 1995).
Do males with premutations have any phenotvpic features of fragile X syndrome?
Although males with a premutation are generally considered to be clinically
unaffected, recent studies have suggested that normal transmitting males may have
mild features of fragile X such as behavioural problems (Dorn et al., 1994) and some
characteristic clinical features (Loesch et al., 1994). Hagerman et al. (1996)
described three males who presented with learning and behaviour problems who had
some characteristic clinical features of fragile X and FMR1 expansions in the
premutation range. Two of the three boys had a small degree of FMR1 methylation
and all three had reduced levels of FMR1 protein in lymphoblastoid cell lines
(ranging from 10% to 35% of normal). Rousseau et al. (1994) have shown that 12%
of males with a premutation were mentally retarded (5% with borderline MR, 5%
with mild MR, and 2% with moderate MR). In premutation carrying females, the
total was 5% (3.4% with borderline MR, 0.8% with moderate MR, and 0.8% with
severe MR), although the authors stated that these figures were not significantly
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elevated when compared to the control groups (4% for males and 3% for females).
The most likely explanation for these observations is tissue specific mosaicism with
unmethylated premutations being present in lymphocytes and methylated full
mutations present in neural tissue.
Allelic association with 10.
In the Quantitative Trait Loci (QTL) Project, Plomin et al. (1994) attempted to
identify allelic association (linkage disequilibrium) with IQ using DNA markers in or
near genes likely to be relevant to neural functioning. They analysed 46 diallelic
markers, 14 microsatellite repeats (2, 3 and 4 bp repeats) and one 48 bp repeat on
DNA from 278 pairs of non-identical twins in the top and bottom 5% of the
intelligence distribution (the extremes of the IQ distribution were used so that more
markers could be analysed on smaller numbers of individuals). In the first report of
this ongoing study, associations were found with 5 out of 46 diallelic markers and
with 3 of the trinucleotide markers, one of which was the FMR1 CGG repeat. For
each marker, the frequency of the most common allele was compared to the
combined frequency of all the other alleles, then the next most common allele was
compared to all other alleles, and so on until a frequency of 0.20 was reached. For
the FMR1 CGG repeat, the frequency of the most common allele (30 repeats) was
0.59 in the low IQ group, and 0.32 in the high IQ group. However, when they
repeated the experiments on another group of twins in the top and bottom 1 % of the
population, some of the results were not reproducible. The authors admitted that
statistical analysis of multiallelic markers is problematic because of the polymorphic
nature of these repeats. One interesting observation from their study is a difference
between IQ and allelic frequency with the marker CTGB33 (although it was not a
statistically significant difference); this is a triplet repeat which was found by
screening a human DNA library and which is expressed in brain (Li et al., 1993).
One of the most notable (and reproducible) examples of this phenomenon of allelic
association is that of the apolipoprotein E4 allele and late onset Alzheimer's disease
(Corder et al., 1993).
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Comparison of three 10 populations.
Although there was no convincing pre-existing evidence of a correlation between IQ
and polymorphic variation of CGG repeat numbers within the normal range (less
than 52 repeats), we decided to analyse our samples received for fragile X testing and
to compare this low IQ population (lower 3% of the intelligence distribution) with a
high IQ population (members of British Mensa Ltd.). The requirement for
membership of Mensa is an IQ of 132 or more (Wechsler scale) which places this
group in the top 2% of the IQ distribution. The Mensa samples were obtained by
requesting a 10 ml mouthwash from members in the Edinburgh area (of which there
are approximately 480). To ensure anonymity, only the sex and the Mensa number
of each individual was requested and the IQ corresponding to each membership
number was obtained from Mensa headquarters. A control population of presumed
average IQ consisted of mouthwash samples which were received in the laboratory as
part of the cystic fibrosis prenatal screening trial and which were tested anonymously
(though the sex of each was noted). The ages of the control population and the
Mensa population were not requested. Out of approximately 480 Mensa members
who were asked to participate in this study, 339 people responded (>70%); this is a
very high response level for a research project and is similar to take-up rates for
prenatal screening for CF in Edinburgh (Brock, 1996). This eagerness to participate
may be a reflection of the nature of the study and the cohort being studied. Figure 6
shows the approximate distribution of the three IQ populations studied.
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Figure 6. The three intellectually different populations which were analysed by PCR of the
FMR1 CGG repeat. (Not to scale).
A total of 1501 samples comprising leucocyte DNA from 781 mentally retarded
patients, buccal cell DNA from 381 controls and buccal cell DNA from 339 Mensa
members were analysed by PCR across the FMR1 CGG repeat. PCRs were carried
out using the radioactive method as described in 6.1.4.1 and PCR products analysed
as in 6.1.4a, Results were obtained for 1377 of the samples (2.3.2). The size of the
alleles in each case were compared to a female control known to consist of 20 and 30
repeats as compared to a size marker (Mspl digested pBR322). An allele of 29
repeats was reported by Fu et al. (1991) to have an amplified length of 308 bp and an
allele frequency histogram showed the mode to be 29 repeats. Later, Brown et al.
(1993) determined by sequencing that the most common allele actually consists of 30
repeats. Although I did not sequence the CGG repeat in my control samples, I have
assumed that the mode in the populations I have analysed is the same as the mode
found by other groups, i.e. 30 repeats (the mode is universally 30 repeats although
there are minor ethnic variations in allele distributions, see 2.3.2.2),
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2.2.4 Prenatal diagnosis of fragile X syndrome from 1991-1995
During the five year period when I was collecting data on fragile X cases, a total of
nine prenatal diagnoses were carried out in the laboratory. Our first prenatal
diagnosis was carried out very soon after FMR1 had been identified, in fact, the
chorionic villus sampling was delayed so that the DNA probes (Oxl.9 and StB12.3)
could be tested on the affected proband and other control samples (known affected
male and female fragile X patients). This prenatal diagnosis (a twin pregnancy in
which both male fetuses were predicted to be affected) was interesting in other
respects and is described in detail in 2.3.3.1. Later, other reports appeared in the
literature from laboratories who had also carried out DNA based prenatal diagnoses
(Hirst et al., 1991b; Dobkin et al., 1991). The fifth prenatal diagnosis carried out in
our laboratory occurred in a pregnancy in which the fetus was predicted to be a
normal transmitting male. Fetal blood sampling was necessary to guarantee that the
premutation predicted in the CVS was truly a premutation (and not a compound
premutation/full mutation) in the fetus itself (Strain et al., 1994a). This pregnancy is
described in detail in 2.3.3.3, The eighth prenatal diagnosis, although
straightforward and predicted a normal male fetus, showed that there had been a
cross-over between DXS548 and FRAXA in a previous meiosis. This is described in
more detail in 2.3.3.2, The other pregnancies were predicted to be normal (3 female
and 3 male fetuses) and proceeded to term. The detailed study of these unusual
prenatal diagnoses have contributed both to our practical experience and to our
understanding of the nature and timing of repeat expansion.
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2.3 RESULTS
2.3.1 Fragile X testing for developmental delay or mental retardation
After 4 years and 3 months a total of 781 blood samples had been received in the
laboratory for fragile X testing (Figure 7). Of these, 58 were eliminated from testing,
either because they were duplicate samples or because they failed to produce DNA.
22 DNA extractions failed because, a) the sample was too small (less than 1 ml) or b)
too old (the sample had been received in the cytogenetics laboratory and not directly
from the clinician). When this occurred a repeat sample was requested, although, out
of 22 repeats requested, fresh blood samples were obtained from only 11 patients.
Following the exclusion of duplicates and DNA extraction failures, 723 DNA
samples were subsequently analysed by Southern blotting and PCR (Figure 8).
Typical autoradiographs of a Southern blot and PCR products obtained in fragile X
testing are shown in Figures 9 and 10 (pages 73 and 74).
The majority of samples were received from the Lothian area (71%) with the Borders
region contributing 17%, and Fife 11%. The remainder of the samples (-1%) were
from other Scottish regions; these were received before fragile X testing was
available in all the Scottish Consortium centres.
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Figure 7. Synopsis of blood samples received for fragile X testing from 10/10/91 to
26/1/96.
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Figure 8. Summary of processing of DNA samples received for fragile X testing. The two
females with a full mutation are sisters. After exclusion of samples marked *, 700 DNA
samples were left for numerical analysis of the CGG repeat.
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Figure 9. Typical autoradiograph of a Southern blot of DNA from ten mentally retarded
individuals referred for fragile X testing. Lanes 1, 2, 4, 6, 8, 10, 11, 12, 14 and 15 contain
DNA from males digested with Hindlll. Lane 3 contains DNA from a male digested with
HindlW and Eagl (the double digest was performed on this male sample because the sex of
the patient was unknown at the time of the analysis, but was later confirmed to be male by
PCR at the PAB locus). Lanes 5, 7, 9, and 13 contain DNA from females digested with
HindlW and Eagl. Lane 16 contains DNA from a full mutation carrier female control
digested with Hindlll/Eagl. The marker in lane 17 is HindlW digested X DNA; the bands
shown here are 9kb, 6.6kb, 4.4kb, 2.2kb and 2.0kb. The bands at 2.5kb correspond to the
unmethylated X chromosome in females or the male X (lane 3) and the bands at 5.0kb are
either the X chromosome in males {Hindlll digest) or the methylated X in females
{HindWHEagl digest). The faintness of the band at 2.5kb in lane 16 may be due to either to
incomplete Eagl digestion or to non-random X-inactivation (or a combination). This blot
was hybridized with StB12.3.
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Figure 10. Typical autoradiograph of PCR products (amplified using primers c and f)
showing the polymorphic nature of the FMR1 CGG repeat. These are from a group of
mentally retarded patients referred for fragile X testing. Lanes 1 and 36, and lanes 2 and 37
contain amplified DNA from a male control (CI) with a 32 repeat allele and a female
control (C2) with 30 and 20 repeats, respectively. The arrows indicate the positions and
sizes of the marker (Msp\ digested pBR322 DNA). The CGG repeat numbers in this group
range from 13 repeats to 49 repeats. The three lanes in which there is no product consist of
two PCR failures (lanes 23 and 27) and one male with a full mutation which was
subsequently detected by Southern blotting (lane 35).
74
2.3.1.1 Clinical presentation of patients referred for fragile X testing.
For the 723 samples which were analysed by Southern blotting and PCR, clinical
information about the patient was obtained from the form accompanying the blood
sample, although for approximately 20% of samples, no information was available.
The ages of the patients referred for fragile X testing varied from only a few weeks to
78 years with a mode of 4 years (Figure 11).
Number of samples
Age at referral (years)
Figure 11. Histogram showing variation in age of patients referred for fragile X testing.
The initial strategy was to identify children with fragile X syndrome presenting as
developmental delay in the pre-school years (554 years or under); these made up
49.5% of the total referrals. However, early in the study, it was apparent that fragile
X testing was required for a large number and variety of patients in all age groups.
The remainder, therefore, consisted of school age children with learning difficulties,
adolescents with mental retardation, and a small proportion (3.6%) who were resident
in mental institutions in Lothian and Fife. As expected, the single most common
clinical feature in both age groups was developmental delay or mental retardation
(Figure 12), with the next most common feature being specific speech problems in
the pre-school children and behavioural disorders in the older age groups.
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Approximately 9% of the younger group (32 of 358) were referred because of autistic
features or Asperger syndrome, but only 3% of the older group were reported to be
autistic. None of these patients had an FMR1 expansion. None of the patients in the







A = autistic features
AT = ataxia or co-ordination problems
B = behavioural problems or hyperactivity
D = developmental delay or mental retardation
DE = deafness
DY = dysmorphic features
E = epilepsy or seizures
F = family history of mental retardation
M = motor delay
S = speech delay or language disorder
U = unspecified
A AT B D
Figure 12. Histogram showing clinical features of patients referred for fragile X testing.
Light shaded bars represent children aged 5/4 years or younger; darker bars represent
patients over 5/4 years. As many of these features are not mutually exclusive, the sum of
the figures is not 100%.
In constructing the histogram in Figure 12,1 used all the information provided by the
clinician who referred the sample. Obviously, some of the features listed above
would not be considered diagnostic of fragile X syndrome if they occurred alone, for
example, the two individuals who presented with deafness as part of the phenotype
(one in each age group) had other features which may be relevant to fragile X
syndrome; these were autism in one case and a family history of XLMR in the other.
Likewise, a presenting feature of epilepsy or seizures would not be indicative of
fragile X syndrome but may occur with other characteristics such as developmental
delay.
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2.3.1.2 Identification of eight new cases of fragile X syndrome
This programme of testing developmentally delayed children in S.E. Scotland
resulted in the identification of eight new cases (six males) of fragile X syndrome.
The two females were sisters who had been shown to demonstrate the cytogenetic
fragile site and were received for confirmation by molecular methods. Table 8
summarizes the clinical features recorded for each of these fragile X cases, and Table
9 shows the cytogenetic findings in each case. When a child was found to have a full
mutation, a report was sent to the clinician on the basis of the results obtained from
the initial sample; a repeat blood sample was not requested. For each positive
identification, members of the immediate family of the proband were analysed, and
in every case, the mother was a carrier of either a premutation or a full mutation
(Figures 13 and 14, pages 82 and 83).
Of the eight new cases identified, the following observations were made about the
full mutations seen on Southern blotting: cases 3 and 4 had condensed smears with
the lower limit at approximately 9kb. Case 6 had a band which may have been at the
upper end of the premutation range in addition to a full mutation smear above 6kb
(the resolution of the gel did not allow accurate determination of the lower limit of
the expansion). Methylation analysis, which would have differentiated between a
large unmethylated premutation and a small methylated full mutation, was not
carried out on this sample. Thus, it is unknown if this male is a methylation mosaic
or a mosaic for small and large full mutations. The other cases had varying degrees
of heterogeneity and smears above approximately 7kb, but were otherwise
unremarkable. PCR analysis of each of the samples showed absence of product for
each of the males and a single allele for the two females. There was no detectable




Age Sex Clinical features
1 (Family A/III: 1) 17 months M Motor and cognitive developmental delay.
Large ears, coarse facies.
2 (Family B/III:2) 49 months M Delayed language development. Single
palmar crease, mild clinodactyly (left
hand). Large ears.
3 (Family C/III:2) 12 years F Specific learning difficulties especially with
maths. Severe visual spatial problems.
Long facies with slanting eyes.
4 (Family C/II1:1) 14 years F Specific learning difficulties especially with
maths. Relationship difficulties with peers
and teachers. Long facies with slanting
eyes.
5 (Family D/III:3) 23 months M Slow speech and slow in motor milestones.
Mother's sister has two mentally retarded
children. Prominent ears, triangular face.
6 (Family F/II:1) 35 months M Mild to moderate developmental delay.
Large ears, thin face.
7 (Family E/IV:6) 27 months M Developmental delay.
8 (Family G/III:2) 22 months M Developmental delay
Table 8. Clinical features of the newly identified fragile X cases as detailed on the form
accompanying the blood sample. Cases 3 and 4 are sisters who were first diagnosed by
demonstration of the cytogenetic fragile site and were received in the laboratory for
confirmation of diagnosis. The family/individual references in the first column denote the




Sex % of Fra(X) positive cells




5 M No record
6 M 0%
7 M 12%
8 M 1 cell was found which may be Fra(X)
+ve. 2 other cells were found with
aberrant banding/morphology at distal
Xq in 72 cells scored.
Table 9. Cytogenetic findings of the eight cases detected in this study. 100 cells were
assessed in each case, apart from case 8 which was not referred as possible fragile X and
therefore cells were not cultured in low folate medium. All cytogenetic testing was carried
out at the Lothian Area Cytogenetics Laboratory, Royal Hospital for Sick Children,
Edinburgh.
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Case 6 is a false negative because this patient was not identified as having the
cytogenetic fragile site but was shown to have a full mutation by DNA testing. The
cytogenetic and DNA results of the other cases are in accordance where those
samples were sent to cytogenetics specifically for fragile X testing and were therefore
treated as such i.e. cultures were set up in low folate medium.
Following diagnosis of fragile X syndrome in these eight children, further DNA
analysis was carried out on other family members. In every case the mother was
tested and in some cases, the grandparents were also analysed. Knowing which
grandparent had transmitted the mutation meant that siblings of the spouse of that
grandparent could be excluded from further testing. The eight children belong to
seven families (A-G) which are illustrated in Figures 13 and 14 (pages 82 and 83).
In family D, the mother of the affected boy was reported to have two cousins who are
mentally retarded, but we cannot confirm whether this is due to fragile X syndrome
because blood samples were not received from these children or their mother.
Although individual IV:6 in Family E (Figure 14) was originally identified as having
fragile X syndrome through the screening programme, we discovered a few years
later that this boy is actually a nephew of the mother (111:1) in whom a prenatal
diagnosis was carried out (described in 2.3.3.1), The sisters 111:1 and 111:3 in Family
E had lost contact with each other. For this reason, the affected boy IV:6 was treated
as a newly identified case.
How does our detection rate compare with other centres?
Out of the 723 samples which were analysed, 358 (49.5%) were below the age of 5Vi.
The six males who were identified as having a full mutation (Table 8) were very
young (average age 2Vi years) when they were first diagnosed which indicates that
they are quite severely retarded. The two girls however, are much less severely
affected and are attending a normal school. Of the 358 pre-school children, 280 were
boys. Thus, the overall frequency of fragile X syndrome in this cohort is 2.2%, 2.1%
for males only, and 2.6% for females only. Since the two girls who were identified
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are sisters, they should ideally be treated as one positive identification. This reduces
the overall frequency to 1.9%, and the frequency in females to 1.3%. The figures
obtained in this study are comparable with those obtained by Slaney et al. (1995)
who found four males with a full FMR1 mutation out of 154 children (2.6%)
attending special schools in Oxfordshire. In an earlier DNA based screening survey
of mentally retarded children carried in southern England, Jacobs et al. (1993) found
four males out of 254 children tested, giving an overall frequency of 1.6%. Hence,
the frequencies of fragile X cases amongst children presenting with developmental
delay, in the U.K., as detected by molecular methods, appear to be in the region of
1-2%. However, if the seven new cases identified in this study are taken as a
proportion of all samples referrred for fragile X testing (723), this figure becomes
0.97%. Therefore, the figures vary depending upon which subgroup of the
population is used as the denominator. In a recent informal poll carried out by the
British Society of Human Genetics (BSHG), the number of new cases of fragile X
syndrome detected by DNA testing was 0.5% in most centres in the U.K., but it was
felt that this could be increased with more discriminatory referral of patients. In
order to produce a more efficient system the BSHG is in the process of collecting
clinical data on each patient referred. The plan is to correlate those clinical features
which are most often associated with a positive test result and to develop a scoring
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Figure 13. Pedigrees of families A, B, C and D. Individuals whose status was determined
by DNA testing are indicated with a cross. Premutation carriers are represented by symbols
with a dot, affected individuals are shown as filled black symbols and full mutation female
carriers are represented by filled grey symbols. The individuals with a cross-hatched
symbol are carriers of either a premutation or full mutation; they were not tested and their
status cannot be inferred from the pedigree structure. The proband in each family (indicated
by an arrow) was a mentally retarded individual who was first identified through DNA
























Figure 14. Pedigrees of families E, F and G. Symbol designations are as for Figure 13.
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2.3.2 Analysis of the FMR1 CGG repeat in three intellectually different
populations
In order to compare the allele frequencies of the FMR1 CGG repeat in the low,
average, and high IQ populations, a total of 1501 samples were analysed by PCR.
These comprised 781 samples from mentally retarded individuals, 381 from normal
controls (from the CF screening trial) and 339 from Mensa members. Results were
obtained for 1377 of the 1501 samples and represented a total of 1741 alleles from
1014 males and 363 females. Table 10 summarizes these data.
2.3.3 Comparisons of CGG repeat distributioins
The allele distributions for each IQ subgroup of the population are illustrated in
Figure 15. As shown in these histograms, the most common allele in each group
consists of 30 repeats with two other major peaks at 20 and 23 repeats, and a minor
peak at 38-40 repeats. These allele frequency distributions are similar to those
obtained by other groups (Fu et al., 1991; Eichler et al., 1995). Eichler et al. (1995)
however, reported that the frequency distribution was trimodal with peaks at 20, 30
and 40 repeats, yet it is clear from their data that the distribution in the 406 normal X
chromosomes they analysed, is similar to that obtained in this study i.e. peaks at 20,
23, and 30 repeats. Arinami et al. (1993) analysed the CGG repeat in 824 X
chromosomes in a Japanese population and found the distribution to be slightly
different; the mode was 29 repeats, the next most common allele consisted of 36
repeats and a smaller peak was present at 23 repeats. Eichler et al. (1995) found that
although there is considerable variability in the distribution of the interspersed AGG
repeats among different ethnic groups, the mode is universally 29 or 30 repeats.
In the CGG repeat analysis study described in this chapter, two alleles were found in
two DNA samples which were in the borderline normal/premutation range, one in the
low IQ group and one in the high IQ group. The presence of this large allele in the
low IQ group is probably not related to the mental retardation in this patient who
was an eleven year old girl with alleles estimated to consist of 30 and 55 repeats.
The Mensa member was a female with alleles consisting of 40 and 56 repeats.
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However, as none of the CGG repeats were sequenced, we do not know whether
these large alleles were interspersed with AGG repeats and therefore at higher risk of











Number of samples received 781 381 339
Type of sample blood blood/MW MW
Number of results obtained after exclusion
for DNA/PCR failure, duplicates etc.
700 353 324
PCR failure rate (%) 2.1 7.3 4.4
Male to female ratio 537:163 292:61 185:139
Total number of alleles0 864 414 463
Percentage of heterozygous females'3 63.8(74.2)* 63.9 61.9
Predicted heterozygosity0 81.8(81.6)* 79.8 82.0
Predicted heterozygosity using male data
onlyd
82.0 81.4 83.7
Predicted heterozygosity using female data
only0
81.4 74.8 81.1
Table 10. Comparison of data on the FMR1 CGG repeat in three intellectually different
populations. The mentally retarded population included one 46,XX male. The observed
heterozygosityb was calculated for alleles which differed by 1 or more repeats. The
predicted heterozygosity0 was calculated from the allele frequencies (Table 12) using the
Hardy-Weinberg equation. Since initial results suggested a discrepancy between observed
and expected heterozygosities, the predicted heterozygosity1* was calculated using data from
males only to obtain the "true" heterozygosity rate. Figures using female data only0 are
given for comparison. MW=mouthwash sample. The figures in brackets marked* are the
heterozygosities calculated after re-analysis of the data (see text).
The allele frequencies for each population are shown as histograms in Figure 15 and
in table form in Table 11 (page 87). The frequencies of the three populations
combined are shown as a histogram in Figure 16 (page 88).
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Figure 15. Histograms showing the allele distributions of the FMR1 CGG repeat in the





Number of Number of % of total Number of % of total Number of % of total
repeats alleles alleles alleles
7 1 0.12 0 0.00 0 0.00
10 1 0.12 0 0.00 1 0.22
11 0 0.00 0 0.00 1 0.22
12 0 0.00 1 0.24 0 0.00
13 1 0.12 0 0.00 0 0.00
14 1 0.12 0 0.00 1 0.22
15 1 0.12 0 0.00 1 0.22
16 1 0.12 0 0.00 0 0.00
17 2 0.23 1 0.24 0 0.00
18 0 0.00 2 0.48 1 0.22
19 3 0.35 1 0.24 0 0.00
20 86 9.95 41 9.90 54 11.66
21 5 0.58 1 0.24 1 0.22
22 9 1.04 6 1.45 4 0.86
23 66 7.64 30 7.25 30 6.48
24 10 1.16 8 1.93 5 1.08
25 6 0.69 2 0.48 4 0.86
26 6 0.69 4 0.97 3 0.65
27 3 0.35 0 0.00 3 0.65
28 3 0.35 2 0.48 0 0.00
29 118 13.66 60 14.49 68 14.69
30 317 36.69 162 39.13 166 35.85
31 72 8.33 34 8.21 42 9.07
32 53 6.13 26 6.28 20 4.32
33 21 2.43 10 2.42 9 1.94
34 12 1.39 5 1.21 2 0.43
35 5 0.58 0 0.00 2 0.43
36 8 0.93 3 0.72 3 0.65
37 9 1.04 2 0.48 6 1.30
38 3 0.35 5 1.21 3 0.65
39 15 1.74 2 0.48 8 1.73
40 6 0.69 0 0.00 7 1.51
41 7 0.81 3 0.72 4 0.86
42 1 0.12 0 0.00 3 0.65
43 0 0.00 1 0.24 1 0.22
44 3 0.35 0 0.00 1 0.22
45 0 0.00 0 0.00 5 1.08
46 1 0.12 1 0.24 1 0.22
47 3 0.35 1 0.24 1 0.22
49 1 0.12 0 0.00 1 0.22
50 1 0.12 0 0.00 0 0.00
51 2 0.23 0 0.00 0 0.00
55 1 0.12 0 0.00 0 0.00
56 0 0.00 0 0.00 1 0.22
I 864 414 463
Table 11. Numbers of CGG alleles and their frequencies as a percentage of the total.
Alleles consisting of 6, 8, 9, 48, 52, 53, and 54 repeats were not represented in this study.
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Figure 16. Histogram showing combined frequencies of all three IQ populations.
2.3.3.1 Calculation of heterozygote frequencies
Using the repeat number data obtained for each of the three IQ population subgroups,
as tabulated in Table 12, the following were calculated: firstly, the number of females
in each cohort with two alleles which differed by one or more repeats (observed
heterozygosity), and second, the predicted heterozygote frequencies for each set
using the Hardy-Weinberg equation. It was clear from these results (Table 10, page
85) that there was a large discrepancy between the observed and predicted
heterozygote frequencies (an average of 18% for the three groups), so the predicted
heterozygosities were then calculated using data from the males only in each group.
Finally, for comparison, the frequencies were calculated using data from the females
only.
Why is there a discrepancy?
The observed heterozygosity in the low IQ group was 63.8%, i.e. 104 females were
heterozygous. The number of females expected to have two distinguishable alleles,
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according to the Hardy-Weinberg equation is 134. The most likely explanation for
the discrepancy is that females who were heterozygous for two closely spaced alleles
were actually scored as homozygotes. Other explanations are either that the
population has not yet reached Hardy-Weinberg equilibrium, or that there is a
preponderance of a particular ethnic group among the three populations analysed.
Both of these latter alternatives are extremely unlikely. Although Fu et al. (1991)
found no significant differences between Caucasian, Black, Hispanic and Asian races
in the 492 X chromosomes they analysed by PCR, more recent data (Arinami et al.,
1993; Eichler et al., 1995) shows that while the overall distributions of CGG repeats
among different races are similar, there are ethnic differences in the percentage
heterozygosities. For example, African-Americans and Caucasians show the greatest
variation with 87.3% and 88% (Eichler et al., 1995) while the Hispanic and Asian
groups show predicted heterozygosities of 73.1% and 67.5% respectively. The high
level of heterozygosity in the Caucasian group is due to the prevalence of the 20
CGG repeat allele (10.A.9) which is rare or absent in other populations. Other causes
of deviation from Hardy-Weinberg equilibrium, related to ethnic differences, could
be caused by consanguineous marriages which would result in an increase in the
number of homozygotes. However, the majority of individuals in the three
populations analysed here are likely to be of Caucasian descent, although it is
probable that approximately 2% of the low IQ cohort may be of non-Caucasian
extraction judging by the surname of the patient. Even if the surname of a child
could be used as an indicator of race, the small number involved in this cohort is
unlikely to have any effect on the heterozygote frequencies.
The differences may be a PCR related phenomenon
The discrepancies between observed and predicted heterozygosities were evident in
all three subgroups and were presumed to be due to incorrect scoring of the alleles on
the autoradiograph. In order to determine whether the problem was specific to the
method I was using, I re-analysed the females (low IQ cohort only) who had been
scored as homozygous with the radioactive method, by using a fluorescent PCR
method (6.1.5). The rationale for this was that as only one of the primers is labelled
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and therefore only one DNA strand of the PCR product will be fluorescent this
should theoretically make scoring of closely spaced alleles easier. Figure 17 (page
92) shows examples of A.L.F. traces of FMR1 CGG PCR products from females who
were originally scored as homozygous by the radioactive method. When the
homozygous females were re-analysed by fluorescent PCR in this way, seventeen
females were subsequently additionally scored as heterozygous. This increased the
observed heterozygosity to 74.2% and reduced the difference between observed and
predicted heterozygosities in this group to 7%. The seventeen "new" heterozygotes
had little effect on the total predicted heterozygosity (81.6% compared to 81.8%
previously). This re-analysis was only carried out on the low IQ group.
Implications for fragile X testing using PCR alone
If PCR was the only method being used to determine the presence of an FMR1 CGG
repeat expansion, it would be necessary to exclude normal females by the detection
of two distinguishable normal alleles. The number of shadow bands seen on
denaturing polyacrylamide gels may be related to the nature of the CGG repeat with
pure repeats (no AGG interruptions) giving a wider spread (Snow et al., 1994). It is
possible, however, that in a female this could be misinterpreted as two alleles which
differed by only one repeat. For this reason, the females in the low IQ group were
further classified according to differences in size between alleles: Table 12 compares
the results obtained with the radioactive PCR and the corrected results after re-
analysis of the homozygous females by fluorescent PCR.
Number of females with: Radioactive PCR Fluorescent PCR
Alleles of the same repeat number 59 42
Alleles which differ by 1 repeat 14 30
Alleles which differ by 2 repeats 8 8
Alleles which differ by >2 repeats 82* 83*
Total 163 163
Table 12. Comparison of results obtained using radioactive PCR (internal labelling with a-
32P-dCTP) and a fluorescent PCR (one primer end labelled with fluorescein).
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Which PCR method is more discriminatory?
As shown in Table 12, the number of females with alleles differing by 2 or more
repeats is 55% and 56% for the radioactive and fluorescent methods respectively, and
therefore if this criterion was used in any form of screening for fragile X
heterozygotes (for example, in an antenatal setting), it would imply that the
remaining 45% of female samples would have to proceed to expensive, labour
intensive and lengthy Southern blotting. The fluorescent PCR appears to be better at
distinguishing closely spaced alleles (3bp different) but allele differences greater than
this are detected equally by both labelling methods. The female DNA sample
(marked with a * in Table 12) which moved from the homozygous category to the >2
repeat category was an example of preferential amplification but was unusual in that
the larger allele was hardly noticeable on the autoradiograph, yet quite easily
discernible on the A.L.F. trace. This sample was recorded as 22, 22 by the
radioactive method but as 22, 38 by the fluorescent method.
Other methods of detection
Only two different methods of detection of PCR products have been presented here.
Various laboratories have had success with other non-radioactive detection methods
such as silver staining of PCR products in denaturing polyacrylamide gels, ethidium
bromide staining of products in agarose gels (Wang et al., 1995), and a
chemiluminescent detection method using blotted PCR products and an alkaline
phosphatase labelled (CGG)5 probe (Brown et al., 1993). However, all methods have
one thing in common; they rely on a good yield of PCR product which is dependent
upon the length of the repeat. I think the most promising PCR method (which does
not use primers flanking the CGG repeat) is the MVR-PCR related technique which
requires that primers anneal at every triplet within the repeat and therefore the
number of CGGs in an expanded repeat is irrelevant.
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Figure 17. Examples of A.L.F. traces of the FMR1 CGG PCR in DNA from females who
were originally scored as homozygous by the radioactive PCR method. Numbers on the left
of the traces are the numbers of repeats estimated to be in each allele using the radioactive
PCR, numbers on the right are the corrected numbers from the fluorescent PCR results. The
sample which was homozygous by both methods was analysed by PCR using a y-32P-ATP
labelled primer.
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2.3.3.2 Are FMR1 CGG repeat number and IQ correlated?
For this part of the study, 339 mouthwash samples were received from Mensa
members in the Edinburgh area. DNA was extracted from each one and PCR across
the FMR1 CGG repeat was carried out as in 6.1.4.1 using the primers c and f.
Results were obtained from 324 of the samples; if a PCR failed it was repeated only
once more. The allele distribution is shown in Figure 15 (page 86, bottom graph)
and appears to be the same basic shape as the distribution derived from DNA from
people with average IQs (Figure 15, middle graph). Figure 18 illustrates the range of
IQs in the Mensa members where this information was available.
Number of samples
117 126 128 132 134 136 138 140 142 144 146 148 150 152 154 156 158 160 162 165 169 173 175 177
121 127 129 133 135 137 139 141 143 145 147 149 151 153 155 157 159 161 163 166 171 174 176 178
IQ
Figure 18. Flistogram showing the distribution of IQ in the Mensa samples (where IQ is
known). These scores were obtained using the Cattell iii B Verbal IQ test (information
provided by British Mensa Ltd.).
In order to assess whether there is a correlation between an individual's IQ and CGG
repeat number, a scatter diagram was constructed using the Mensa data only and is
shown in Figure 19. A scatter diagram could not be constructed for the mentally
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retarded individuals or the controls because the absolute IQ values of these
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Figure 19. Scatter diagram showing the relationship between IQ in the Mensa members and
FMR1 CGG repeat number. Some individuals are not represented on this diagram, either
because a PCR result was not obtained or because the IQ score of that individual was not
available. 451 alleles out of a total of 463 are represented in this diagram.
No correlation between 10 and CGG repeat number
As shown in Figure 19, there is no correlation between IQ and number of CGG
repeats (correlation coefficient = 0.018724). In view of this, there seemed to be little
point in pursuing this investigation. Since the allele frequencies of each cohort are
almost identical, the three populations can be combined and used as a "control"





















2.3.3 Prenatal diagnosis of fragile X syndrome
In the five year period since the identification of FMR1, a total of nine prenatal
diagnoses have been carried out in this laboratory. As described previously (2.2.4),
six of these posed no technical or clinical problems; normal fetuses were predicted
and the pregnancies proceeded to term. Two of the remaining pregnancies did not
cause any technical difficulties as such, but interesting observations were made in
both cases. The third was of special interest because it occurred at a time when new
evidence was emerging about the timing of FMR1 CGG repeat expansion. The first
prenatal diagnosis occurred in a family in which a woman presented in her second
pregnancy, a short time after the FMR1 gene had been identified.
2.3.3.1 Prenatal diagnosis of affected fetuses in a twin pregnancy.
Case report





■ * 1 o
11:1 11:2 11:3 11:4
58% 24% 20%
Figure 20. Pedigree of family E. The female carrier of a full mutation is shaded grey,
affected males are shown as filled black symbols. The percentage of cells shown to have
the cytogenetic fragile site are shown below the symbols.
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The proband in this family had been demonstrated to have the cytogenetic fragile site
in 58% of cells and his mother (1:1) who had phenotypic features of fragile X
syndrome demonstrated the site in 46% of her cells. Early in her second pregnancy,
the mother was found to be carrying twins and ultrasound scanning indicated that the
fetuses were in separate amniotic sacs. CV biopsies were taken (one trans-
abdominally and the other trans-cervically) from each placenta at 11 Vi weeks and
DNA analyses were carried out as described previously (2.1.3.19 and 6.1). The
fetuses were shown to be male by PCR at the PAB locus (Ellis et al., 1990) and also
demonstrated to be monozygotic twins by multilocus fingerprinting using the probe
33.15 (Jeffreys et al., 1985 and see 6.1.6), Southern blot analysis using StB12.3
demonstrated that both fetuses had a full mutation of approximately 6kb (Figure 21,
lanes 3 and 4), which appeared slightly smaller and much less heterogeneous than the
full mutation in both the proband and the mother.
1 2 3 4 5 6
Figure 21. DNA analysis of family E by Southern blotting on EcoK\ digested DNA. Lane 1
(mother), lane 2 (affected proband), lanes 3 and 4 (CVS DNA from twin fetuses), lane 5
(normal male). The marker (lane 6) is Hindlll digested A. DNA; the bands shown here are
23kb, 9kb, 6.6kb and 4.4kb. This blot was hybridized with StB12.3.
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Analysis of the microsatellite repeat, DXS548, also confirmed that both fetuses had
inherited the same haplotype as the affected boy from their heterozygous mother.
On the basis of these collective data, the pregnancy was terminated at 18 weeks
gestation. For each aborted fetus, DNA was extracted from heart, skull, cord,
placenta, skeletal muscle, and gut. From one or other fetus, DNA was also extracted
from brain, skin, testis, eye, tongue, adrenal, kidney, and cartilage. Southern blotting
showed that the size and appearance of the band was identical in all tissues
examined, including the CVS tissue (Figure 22). The full mutation in the mother
appeared as a heterogeneous smear in the region of 6-8kb (Figure 22, lane 1); when
compared to the CVS from one twin (lane 2) and fetal tissues from both twins (lanes
3 to 14), all showed discrete bands of approximately 6kb. The methylation status at
the FMR1 CpG island was not assessed in these cases.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Figure 22. DNA analysis of CVS and fetal tissues from prenatal diagnosis of family E.
Amounts of DNA vary between each lane because of the presence of RNA (samples were
not RNAse treated). DNAs were digested with HinAlW and the blot was hybridised with
StB12.3. Lane 1: full mutation carrier mother; lane 2: CVS DNA from one fetus; lanes 3-
14: DNA from termination tissue from one or other twin (brain, heart, placenta, skull, eye,
lung, gut, muscle, kidney, adrenal, tongue, testis); lane 15: normal male control; lane 16:
Marker is HinAWl digested A. DNA. Bands shown here are 9kb, 6.6kb and 4.4kb.
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The appearance and size of the full mutation in the CV and fetal tissues compared to
that in the mother suggests that the mutation transmitted by the mother, was
substantially smaller (and perhaps a premutation) than the majority of alleles present
in her blood. Another interesting observation from this case is that both twins have
identical patterns, which suggests that the events leading to somatic mosaicism were
completed before the time of division of the zygote into two embryos. It is unknown
whether the twins were monochorionic or dichorionic although they were known to
be diamniotic (monoamniotic twins result from a later form of twinning and often do
not survive). In about 25% of cases, twinning occurs before the third day of
development, but for the majority of monozygotic twins, twinning occurs between
the third and eighth day, by which time the differentiation of the blastocyst has
proceeded too far to allow duplication of the chorion. If expansion only occurs
mitotically, then it must occur sometime after day 5 when the separation of the
gametic and somatic cell lineages occur. Therefore, if the twins in family E are
monochorionic then the expansion and subsequent stabilization of somatic
mosaicism can be confined to between day 5 and 8, but if they are dichorionic, then
the expansion may have occurred around day 5.
Nine months after the twin pregnancy was terminated, the mother (1:1) presented for
prenatal diagnosis in her third pregnancy. A CV biopsy was taken and the fetus was
shown to be female by the PAB PCR (Ellis et al., 1990). DNA analysis by Southern
blotting and PCR revealed that the fetus had inherited the mother's normal X
chromosome and the presence of a paternal X was shown by PCR across the CGG
repeat. The pregnancy continued to term.
2.3.3,2 Recombination between DXS548 and FRAXA in a prenatal diagnosis
This prenatal diagnosis occurred in a family in which the proband was identified
through the programme of fragile X testing for mental retardation. He was also the
first positive identification as a result of DNA testing for fragile X in this laboratory.
The pedigree is shown in Figure 13 (page 82, Family A). Following the
identification of the affected male in this family, other family members were tested,
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including the mother, both grandparents, and three uncles of the affected boy. All
individuals were tested by Southern blotting, PCR across the FMR1 CGG repeat, and
by PCR of the microsatellite DXS548. The DXS548 and FMR1 CGG results are






















Figure 23. Pedigree of Family A showing results of DXS548 and FMR1 CGG repeat
analysis. DXS548 alleles are numbered arbitrarily with allele 1 being the largest of the two
alleles seen in this family; the FMR1 CGG repeat alleles are denoted as numbers of repeats
except for the pre- and full mutations which are denoted as pre or full respectively. Symbol
designations are as described previously.
As shown in Figure 23, a cross-over has occurred between DXS548 and the fragile X
locus in the meiosis which resulted in individual 111:2. This child was predicted to be
unaffected on the basis of a normal sized band on Southern blot analyis and a PCR
allele in the normal range, but has inherited the DXS548 allele which is associated
with the fragile X mutation in this family. As the grandmother of the affected boy is
homozygous for DXS548, phase for this marker is established from the grandfather of
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the affected boy (1:1). Following identification of the full mutation in individual
III: 1, the mother 11:4 opted for prenatal diagnosis in her subsequent pregnancies. In
the first of these, a normal PCR allele of 35 repeats and normal sized fragments on
Southern blotting were seen in the CVS DNA. However, the fetus had the same
DXS548 haplotype as the affected boy III: 1. In the second of the prenatal diagnoses,
the fetus was shown to have inherited the normal grandpaternal haplotype. Both
pregnancies proceeded to term.
The physical distance between DXS548 and FRAXA is reported to be 150kb (Riggins
et ah, 1992) and therefore the probability of a cross-over occurring in this interval is
1.5 x 1 0~3 (assuming that 150kb is approximately equivalent to a recombination
frequency of 0.15%). Dreesen et al. (1994), however, have suggested that the genetic
distance between these loci may be 0-6cM based on the data of Riggins et al. (1992)
and they reported two recombinations in two fragile X families. On the basis of the
DXS548 results shown in Family A, individual 111:2 would have been predicted to be
affected in a prenatal diagnosis, although obviously this system would not be used
alone. If Southern blot results were unobtainable and the laboratory had to rely on
PCR methods alone, then the four systems (FMR1 CGG, DXS548, FRAXAC1 and
FRAXAC2) should ideally be used together. The disadvantages of using the linked
PCR systems is that an affected individual is required to obtain phase and in rare
cases, CA repeats can "mutate" to larger alleles by the addition of one dinucleotide
repeat.
Using linked markers for prenatal diagnosis of fragile X syndrome has one very
serious drawback, however, which is that linkage cannot distinguish a premutation
and a full mutation. The final prenatal diagnosis presented here describes a situation
in which linked markers would have indicated an affected fetus.
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2.3.3.3 Prenatal diagnosis of a premutation carrier male
Case report
The pedigree of the family (Family H) is shown in Figure 24. Individual 11.12 was
referred early in her first pregnancy, because of a history of fragile X syndrome. The
family had been investigated cytogenetically in 1989, prior to the identification of the
FMR1 gene and as the fragile site had only been demonstrated in the affected male
(III. 1), individual 11.12 and her three sisters were given low risks of being carriers.
The affected girl III.3 was not tested at that time. The family was reanalysed by
a) PCR across the repeat using primers c and f as described in 6.1.4.1, and
b) Southern blotting using StB12.3 with Hindlll digested DNA (2.1.3.19 and 6.1.2,
6.1.3).
The PCR and Southern blot results (Figures 25 and 26, pages 103 and 104) indicated
that the dead father (1.1) must have been a normal transmitting male who had passed
a premutation to each of his four daughters. The mother (1:2) had two normal CGG
alleles, both of which had been passed to normal sons (Figures 24 and 25), providing
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Figure 25. Results of PCR analysis on Family FI showing premutation sized alleles in the
four daughters of 1:1:11:3,11:5,11:10 and 11:12 (lanes 1, 3, 8 and 10). Lanes 2, 4, 5, 6, 7 and
9 contain PCR products from individuals 111:2,111:3,111:4,11:7,11:9 and 11:11. 111:3 (lane 4)
is an female with one allele of 44 repeats and a full mutation which does not PCR amplify.
Lane 11 contains PCR product from fetal blood DNA (discussed later in this chapter).
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A CV biopsy was carried out at 10 weeks gestation and DNA extracted as described
in 6.1.1.2, The fetus was shown to be male by PCR at the PAB locus. Southern
blotting of HindlW digested CV DNA showed an apparently homogeneous





Figure 26. Southern blot analysis of family H showing premutations in all daughters of 1:1
(lanes 3, 4, 7 and 9) and the male fetus of II: 12 (lane 10), and normal sized fragments in all
male offspring of 1:1 (lanes 1, 2, 5, 6 and 8). HinAWl digested DNA was probed with
StB12.3. The arrows indicate the size marker (Hin&lW digested X DNA): 9kb (top), 6.6kb
(middle) and 4.4kb (bottom). Individuals are numbered as in Figure 24.
7 8 10
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The PCR allele in the CV DNA was estimated to consist of 107 repeats which had
increased slightly from the mother's premutation allele of an estimated 75 repeats
(Figure 27).
Figure 27. PCR analysis of CVS DNA showing slight increase in size from mother to fetus.
Lane 1: individual 11:10 (premutation carrier); lane 2:11:11 (normal male); lane3:II:12
(mother of fetus 111:5); lane 4:111:5 (CVS DNA); lane 5: (male control).
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Cultured CV tissue showed a normal 46, XY karyotype with no evidence of fragile
sites (cytogenetic analysis was carried out by Professor Christine Gosden, formerly
of MRC Human Genetics Unit, Edinburgh).
The presence of a homogeneous premutation in CV DNA and a normal karyotype
predicted that the fetus was a normal transmitting male and the pregnancy continued.
However, at the time that this CVS was carried out (1993) evidence was
accumulating which suggested that care was needed in the interpretation of results
obtained on CVS tissue. Firstly, finding an apparently homogeneous premutation
does not rule out the possibility of mosaicism for a premutation and a full mutation
(which makes up only a small proportion of the somatic cell population and is
therefore not detected by current methods). Mosaic males are generally not more
mildly affected than males with only full mutations (Rousseau et ah, 1994). Second,
although evidence tends now to indicate that expansion from premutation to full
mutation is a post-zygotic event and that mosaicism is established before chorionic
villus sampling (usually around 10 weeks gestation), this information was not
available at the time of the prenatal diagnosis carried out in family H. Third, the
situation in extraembryonic tissues may be different to that in fetal tissues; this is
certainly true for methylation of FMR1. All these factors were considered, and the
patient was advised to have fetal blood sampling which was carried out at 18-19
weeks gestation.
Approximately 2 mis of fetal blood was obtained and was confirmed to be purely
fetal by Kleihauer testing (carried out by Professor Christine Gosden). One ml was
used for cytogenetic testing of the fragile site; 170 lymphocytes cultured under
thymidylate stress failed to show any evidence of fragile sites and DNA was
extracted from the other half as in 6.1.1.3. Southern blotting and PCR again showed
a homogeneous premutation (Figures 28 and 29).
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Figure 28. Southern blot analysis of fetal blood DNA. DNAs were digested with Hind\\\
(top) or BgR\ (bottom) and probed with StB12.3. Lanes 1 and 2: full mutation carrier
female controls; lane 3: mother of fetus; lane 4: fetal blood; lane 5: mosaic male control;
lanes 6 and 7: full mutation male controls; lane 8 : NTM control; lanes 9 and 11:
premutation carrying female controls; lane 12: full mutation carrying female; lanes 13-17:
normal female and male controls. Marker (lane 18) is Hindlll digested X DNA. Bands
shown here are 23kb (top), 9kb, 6.6kb, 4.4kb.
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Figure 29. PCR analysis of fetal blood DNA. Lane 1: Mother of fetus (11:12); lane 2: fetal
blood DNA. This PCR product is seen more clearly in Figure 25.
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Methylation analysis of the FMR1 CpG island was carried out by Southern blotting
of fetal blood DNA digested with fscoRI and BstZX. Normal methylation patterns
consistent with a premutation were seen (not shown). From these data the patient was
reassured that her fetus was normal.
At term, DNA was prepared from cord blood. A premutation was again seen on
Southern blotting (Figure 30 and 31) and PCR analysis (Figure 32). When PCR
products from amplification of CVS DNA and cord blood DNA were run side by
side on the same gel, they were identical in size (not shown). The PCR product from
cord blood DNA contains an allele which is the same size as the mother's normal
allele. This may be due to transplacental bleeding during labour.
Cytogenetic analysis of the cord blood failed to show fragile sites in 100 cells
analysed.
DNA analysis using linked markers could not be carried out in family H for two
reasons. The affected boy (III: 1) was not available, and in this case linkage results
would have shown that the fetus had inherited the mutation carrying X chromosome
from his mother. If this prentatal diagnosis had occurred prior to the identification of
FMR1 this fetus might have been terminated on the basis of linkage results alone.
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Figure 30. Southern blot of cord blood DNA digested with Hin&lW and probed with
StB12.3. Lane 1: normal male control; lane 2: normal female control: lane 3: mother of
baby; lane 4: cord blood DNA; lane 5: full mutation male control; lane 6: full mutation
female control; lane 7: size marker {Hin&\\\ digested X DNA: bands shown here are 23kb
(top), 9kb, 6.6kb, 4.4kb).
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Figure 31. Southern blot of cord blood DNA digested with Hin&Ul and Eagl and probed
with StB12.3. Lane 1: mother of baby; lane 2: cord blood DNA; lane 3: normal male
control: lane 4: full mutation male control; lane 5: size marker (//zndlll digested X DNA,
9kb, 6.6kb, 4.4kb and 2.2kb).
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Figure 32. PCR analysis of DNA from cord blood. Lanes 1-3: normal controls; lane 4:
mother of baby; lane 5: cord blood DNA. Although the premutations are very faint, there
appears to be no further increase in size between mother's and baby's alleles.
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Experience gained from these prenatal diagnoses
The three cases described above have illustrated the variability which can occur in
prenatal diagnostic situations. With experience of nine prenatal diagnoses for fragile
X syndrome, I have learned that it is important to plan from the beginning how to
handle each case so that the maximum information can be gained from the limited
CV tissue. It would have been interesting, for example, (although not essential to the
outcome), to have carried out methylation analysis in the twin pregnancy (2.3.3.1)
and on the aborted material to determine if the twins had discordant methylation
patterns. It may be interesting to analyse cell lines which were set up from the
termination tissues to see if there are any differences in full mutation size and/or
methylation after cell culture. Kruyer et al. (1994) described a pair of monozygotic
female twins who had similar sized full mutations but the proportion of active and
inactive X chromosomes carrying the mutation were very different in each twin and
the phenotypes were correspondingly different.
The results of the prenatal diagnosis described in 2.3.3.1 were very informative in
that the timing of expansion could be confined, in this case, to a very narrow interval
during embryonic development i.e around day 5. A similar case was described by
Antinolo et al. (1996) who analysed monozygotic male twins who were concordant
mosaics for a full mutation and an unmethylated premutation. The twins were
monochorionic and monoamniotic which indicates a later form of twinning occurring
between day 10 and 20 after fertilization. Since the separation of the gametic and
somatic cell lineages occurs at approximately day 5, the timing of expansion in the
twins described by Antinolo et al. (1996) can be confined to between day 5 and day
20. The analysis of monozygotic twin pregnancies in fragile X syndrome is
important for establishing the time at which a particular event occurs; twin studies
have also shown that while expansion from premutation to full mutation occurs
before twinning, methylation occurs much later (and probably in terms of weeks
rather than days).
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For the prenatal diagnosis discussed in 2.3.3.3 in which a male fetus with a
premutation was predicted, the fetal blood sample was divided so that cytogenetic
analysis could also be carried out. Although, at the time, it was reassuring to have a
backup system, the blood sample was very small (<2ml) and half of it was clotted.
The blood was collected into lithium heparin which in my experience does not give
as high a yield of DNA as from EDTA anticoagulated blood and heparin (which
binds to DNA) is thought to retard DNA during electrophoresis. In future prenatal
diagnoses for fragile X syndrome, we would probably not use cytogenetic testing for
the fragile site as a backup.
Fortunately, none of the prenatal diagnoses carried out in this laboratory predicted a
full mutation carrying female which could potentially be clinically more problematic.
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2.4 DISCUSSION
Although information on fragile X syndrome is continually emerging and evolving, it
is now reasonably established that: a) expansion from premutation to a full mutation
occurs post-zygotically and only after female meiosis, b) the stability of a CGG
repeat is related not only to its length but to its composition, c) the presence of a full
mutation in a female does not imply that she will be mentally retarded, nor is the
length of full mutation repeat correlated with the degree of mental impairment and d)
there are differences in the degree of somatic mosaicism and methylation between
embryonic and extra-embryonic tissues. However, the following questions remain
partly or fully unresolved:
Do the small changes in size of premutation from normal transmitting male to
premutation carrying offspring occur meiotically or mitotically (post-zygotically)?
Does repeat expansion cause methylation at the FMR1 CpG island?
Is there tissue specific variation in the size and/or methylation status of full
mutations?
Are premutations in males associated with mental retardation?
Is it time for for prenatal screening for fragile X syndrome?
The idiosyncratic nature of the FMR1 mutation and its behaviour upon transmission
are probably mostly responsible for the fact that five years after the FMR1 gene was
identified, routine antenatal screening is not yet established in a U.K. genetic centre.
As mentioned earlier, fragile X syndrome is an ideal candidate for prenatal screening
because the sensitivity and specificity of the DNA test approaches 100%. Since all
mothers of children with a full mutation have either a premutation or a full mutation,
prenatal screening would detect all those mothers at risk of having a child with
fragile X. However, there is not yet a reliable PCR method of detecting all carrier
females and as described previously, if the criterion of two alleles differing by two or
more repeats is used, then approximately 45% of women will require further testing
by Southern blotting. Furthermore, Southern blotting cannot be carried out on a
mouthwash sample so for this 45%, a blood sample would be required. There are
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two routes by which DNA testing could be carried out in an antenatal setting. Either,
a small blood sample could be collected at the first clinic appointment, DNA
extracted by a boiled lysis method and PCR carried out across the CGG repeat. If the
sample did not show two distinguishable alleles in the normal range, DNA would be
extracted from the remainder of the blood sample for Southern blotting. The
alternative approach would be to extract good quality DNA from the blood sample,
carry out the FMR1 PCR and, if necessary, Southern blotting. The first approach
would probably be less time consuming and would also be cheaper (money would be
saved on Proteinase K). For screening large numbers of samples, a non-radioactive
method of detection would have to be used, either fluorescent PCR and
electrophoresis on A.L.F. sequencing gels or silver staining of unlabelled PCR
products. It is difficult to predict, without a pilot study, which method would be the
most efficient and the most practical. However, funding for such a prenatal
screening programme is not presently available.
The future for fragile X testing in Edinburgh
After an initial slow uptake by clinicians for the fragile X DNA test, the average rate
of sample receipt has been 180 samples per annum, which is a considerable number
for a test with a low detection rate (approximately 1 %). This is very low for a
procedure which is labour intensive and costly (each DNA test starting from blood is
estimated to cost between £5.50 and £6.00 for reagents alone). Each sample received
in this laboratory is analysed by Southern blotting as well as PCR and in order to
improve efficiency, samples are batched into multiples of sixteen (the capacity of an
agarose gel). The ratio of males to females referred for testing is approximately 3.3:1
and therefore, on average, each gel includes DNA from three females (taking up two
lanes for a single and double digest) and DNA from ten males (one digest only).
Depending upon the rate at which samples are received and the proportion of females
referred for testing, the time from sample receipt to final result ranges from 1 -2
weeks to 8 weeks (obviously, a sample arriving at the end of a batch will have a
shorter reporting time). In practice, more than 70% of fragile X results were reported
within six weeks.
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It may be an appropriate time to review DNA testing for fragile X syndrome and
assess whether we should continue as previously or progress to more economical and
more efficient methods of testing. There are two areas in which improvements could
be made:
1) If samples were tested by PCR and then Southern blotting carried out only if
necessary i.e. if a female sample was homozygous or a male sample gave no
result. Using the data presented in this chapter, 11% of all the samples received
failed to give a satisfactory diagnostic result by PCR analysis.
2) If there was more discriminatory referral of patients for testing the proportion of
negative test results could be reduced from the present figure of 98-99%. A
prospective survey, organised by the BSHG, is currently underway to establish
which clinical critera have been associated with a positive DNA test result. A
simple scoring system will be developed and DNA testing only carried out on
patients with an appropriate score. It is important that patients with mental
retardation are still referred for cytogenetic testing for other chromosomal
abnormalities, however. Preliminary data from the United States suggests that it
may be possible to reduce the number of fragile X tests by over 50% without
missing any true affected cases.
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3. Mapping of a non-specific mental retardation gene to Xql2-
Xq21.
3.1 INTRODUCTION
When a child presents with developmental delay without any obvious clinical
features, the paediatrician will generally want to exclude the most common causes of
mental retardation by a series of tests. These may include cytogenetic analysis to
rule out chromosomal abnormalities, biochemical tests to exclude metabolic
disorders and DNA tests to rule out genetic diseases. As the prevalence of fragile X
syndrome is approximately 1 in 1500 with a variable phenotype, many clinicians will
refer a child for DNA testing for this disorder on the basis of mental retardation
alone. However, as described earlier, only 1-2% of children with developmental
delay will subsequently be shown to have a full FMR1 mutation. For the majority of
cases of childhood mental retardation, a specific defect will never be found.
Nevertheless, fragile X syndrome is one of the most common disorders for which a
simple diagnostic test is widely available.
A family (Family I) is presented in this chapter, in which a boy was first investigated
for fragile X syndrome because of developmental delay and also because of
behavioural problems which were considered to be typical of fragile X syndrome.
DNA testing specific for fragile X syndrome showed that the boy had a PCR CGG
repeat allele in the normal range and a normal fragment on Southern blotting. In
spite of this, it was still thought to be highly probable that the behavioural phenotype
represented fragile X syndrome. Since it was possible that another form of FMR1
mutation other than the CGG repeat expansion was responsible for the phenotype,
linkage analysis using the polymorphic CGG repeat as a marker was carried out on
the proband and other family members (including the proband's cousin and two
maternal uncles who were also mentally retarded). LOD scores were negative with
FMR1. The inheritance of the mental retardation in the family was presumed to be
X-linked because only males were affected and there was no male to male
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transmission. As a result of obtaining a negative LOD score with FMR1, further
linkage analysis in this family, using highly polymorphic microsatellite markers
covering all of the long arm of the X chromosome, and a small region in proximal
Xp, was carried out. Positive LOD scores above +2 were found with markers in the
proximal long arm (Xql3-Xq21) within a lOcM interval. At least eight other non¬
specific mental retardation conditions map within this interval.
3.2 FAMILY STUDIES
The family (Family I) described in this chapter is shown in Figure 33.
+
111:1 111:2 111:3 111:4 111:5
Figure 33. Pedigree of family I. Obligate carrier females are represented by symbols with a
dot, males with mental retardation are represented by filled black symbols. Blood was
obtained from those individuals marked with a cross.
3.2.1 Case reports
The proband The proband in family I (111:5), originally presented as a mildly
dysmorphic boy with developmental delay and aggressive behaviour. He was born in
1982 after a normal pregnancy and delivery, although he was of relatively low birth
weight (2.8kg) and had a small head (OFC well below the 10th centile) in the early
neonatal period. His motor development was slightly delayed; he did not walk until
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19 months of age. He was described as having an unusual facies but "within normal
limits" and he had marked epicanthic folds and full lips. He had a slight systolic
murmur (also present in his mother) which was initially thought to be a ventricular
septal defect (VSD) but later investigations when he was 11 years of age showed that
his heart anatomy was normal (the VSD was presumed to be closing). There was no
family history of congenital heart disease. A CT scan was performed at the age of
four because of a single epileptic fit; the scan was reported as normal with "«o cause
for this patient's focalfit identified'' and also demonstrated that there was no
definitive lesion within the CNS to account for his mental retardation. An EEG
showed a "probable excess ofslow wave activity but no focal or paroxysmal activity"
which was thought to be consistent with the boy's overall developmental delay. At
the age of six, he was described as hyperactive with autistic features, atrocious
language skills and unintelligible speech.
Other affected family members A cousin of the proband is also mentally retarded
(111:3) and was reported to "look the same and behave the same" as the proband. He
also attends a special school, has delayed speech and is unable to read or write.
Two maternal uncles of the proband (11:1 and 11:9) are also mentally retarded with
delayed speech; both attended special schools. The uncle (11:9) had a significantly
small head as a child with prominent epicanthic folds but no other significant
physical abnormalities. A third maternal uncle (11:8) may have been slightly dull
intellectually although he attended normal schools and has four children.
Both obligate carrier females (11:4 and 11:7) are of normal intelligence.
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3.3 METHODS
3.3.1 DNA and cytogenetic analysis
Blood was obtained from family members marked on the pedigree (Figure 33) with a
cross and DNA was extracted as in 6.1.1.1. In order to exclude fragile X syndrome
as the cause of the mental retardation in the family, DNA analysis was carried out on
the proband (111:5) and his mother (11:7) by PCR across the FMR1 CGG repeat.
Alleles in the normal range were seen in both cases. Cytogenetic analysis on the
proband (carried out by the Lothian Area Cytogenetic Service at the Royal Hopital
for Sick Children) showed a normal karyotype with no evidence for FRAXA or other
fragile sites.
The easiest way of finding if an FMR1 mutation other than the CGG repeat
expansion was present in the proband was to use the polymorphic repeat as a marker
for linkage analysis of the whole family. If linkage could be excluded then it would
not be necessary to search the FMR1 gene for a mutation. The results are shown in
Figure 34 (page 125). Even without formal linkage analysis, it was obvious from
inspection of the pedigree that there was no linkage between the FMR1 locus and the
MR locus in family I. For this reason, I undertook a search for linkage to other
regions of the X chromosome using polymorphic microsatellite and VNTR markers
(heterozygosities generally above 0.7). The details of each marker are shown in
Table 13. A total of 31 markers were analysed, although only 23 of these were
informative in the family (these are shown on the pedigree in Figure 35, page 126).
PCR markers were analysed covering all of Xq and the proximal region of Xp.
All the markers shown in Table 13 (page 124), apart from the FMR1 CGG repeat,
were analysed by PCR with one fluorescent primer using conditions as described in
6.1.4 and annealing temperatures as shown in Table 13. The FMR1 CGG repeat was
analysed as in 6.1.4.1 using primers c and f, and PCR products were electrophoresed
in a 5% denaturing sequencing gel. The non-radioactive PCR products were
analysed on the automated laser fluorescent sequencer (A.L.F., Pharmacia) in 6%
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denaturing polyacrylamide gels. A typical result of a marker analysed in this way
(.HPRT) is shown in Figure 36 (page 127). For each marker analysed the largest
allele in the family was denoted as allele 1 and the smallest as 3.
The following markers were also analysed in this family but were uninformative:
DXS178, DXS237, COL4A5, DXS1231, DXYS1, DXS135 and CHM(CA repeat
within the choroideremia gene).
3.3.2 Linkage analysis
Two-point linkage analysis was carried out using the MLINK component of the
LINKAGE program package version 5.2 (Lathrop and Lalouel 1984). An arbitrary
mutation rate of 1 x 1 (f5 was chosen. If male and female mutation rates are equal and
the XLMR condition segregating in this family is reproductively lethal, this
corresponds (in a population at equilibrium) to a gene frequency of 3 x 1 (f5 (Ott
1991). These figures were used for the MLINK calculation. Complete penetrance
for the disease was assumed. The results of the pairwise analysis are shown in Table
14 (page 131).
Multipoint analysis was also carried out using the LINKMAP component of
FASTLINK using genetic distances as shown in Figure 37 (page 130). If the genetic
distance between two markers was zero, only one of the markers was included in the
multipoint analysis. Sixteen of the 23 informative markers were subsequently used
for the LINKMAP analysis. As the relationship between genetic distance and
recombination fraction is only linear below ~10cM, genetic distances greater than
this were converted into recombination fractions using the Kosambi mapping
function. According to Ott (1991), this map function is preferable to the Haldane
map function because it takes into account the effect of interference and therefore
produces more realistic map distances.
Because of the computer memory limitations on the number of haplotypes (a
maximum of 64 haplotypes, including the disease locus) which can be analysed at
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one time on a stand-alone PC, the LINKMAP analysis was carried out, via Telnet, on
a mainframe computer at the Human Genome Mapping Project Resource Centre.
The method used was that recommended by Terwilliger and Ott (1994) which
involves "sliding" groups of four loci and the disease locus down the map and
analysing the disease only in the middle interval (i.e. with two flanking markers on
each side). This was repeated until all the markers had been analysed. Five
evaluations were computed within each test interval unless the interval was greater
than lOcM when ten were calculated. For the purposes of the multipoint analysis
(and because of HGMP restrictions in the LINKAGE programs), the mutation rates
were set at zero. The linkage report program (LRP) was then used to obtain
multipoint LOD scores which were plotted against genetic distance (using the marker
DXS1204 as a starting point) and the resulting graph is shown in Figure 38 (page
132).
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Location Locus Reference Primer sequences (5'-3')
Anneal
temp.



















































































































Table 13. DNA markers analysed by PCR in Family I. Chromosome locations were
obtained from Willard et al. (1994) and annealing temperatures for each primer pair were
either as published or calculated from the sequence. Primer sequences for the RGCP CA




Preliminary results using PCR across the FMR1 CGG repeat
The results of this analysis are shown in Figure 34.
111:1 111:2 111:3 111:4 111:5
31 31 23 31 23
Figure 34. Results of FMR1 CGG PCR analysis in family 1. The CGG repeat number is
shown below each symbol (the haplotype for individual 1:2 is inferred from her offspring).
The affected and unaffected brothers in generation II have inherited the same
maternal allele, and the two affected boys in generation III have both inherited the
normal grandpaternal allele. The two-point LOD score for FMR1 and the MR locus
was -oo at 0 = 0 (see Table 14, page 131).
The 23 markers which were subsequently found to be informative in this family i.e.
for which individuals 11:4 and 11:7 were heterozygous, are shown on the pedigree in
Figure 35. When linkage to the proximal long arm was found, the density of markers
analysed in that region was increased in order to define the interval more specifically,
although the coverage depended upon the availability and informativeness of the



























1 r i. J A 1-y J V m J
11:1 11:2 11:3 11:4 11:5 11:6 11:7 11:8 11:9
DXS1204 Ka 2 I g 2 1 2 1 2 R8 2 2
DXS991 Pa 2 i s 2 1 3 1 3 2 3
AR ga 1 3 X 1 3 2 3 2 1 2
DX.S339 l 3 § 2 3 1 3 1 2 1
DXS106 2 1 8 2 1 2 1 2 2 2
DXS453 l 2 g 1 2 1 2 1 : l 1
DXS566 2 1 g 2 1 2 1 2 2 2
PGK1 2 1 X 3 1 2 1 2 3 2
DXS986 1 2 X 1 2 1 2 1 1 1
DXS1197 1 3 g 2 3 1 3 1 2 1
DXS995 3 1 g 2 1 3 1 3 2 3
DXS3 2 1 g 1 1 2 1 2 1 2
DXS1203 2 1 g 3 1 2 1 2 3 2
DXS990 1 2 X 2 2 1 2 1 2 1
DXS1106 1 2 8 2 2 1 2 1 2 1
DXS1105 2 1 8 3 1 2 1 2 3 2
DXS1059 2 3 g 1 3 2 3 2 1 2
DXS1212 1 2 5 1 2 1 2 1 1 1
HPRT 3 1 X 2 1 3 1 3 2 3
DXS1062 2 3 8 1 3 2 3 2 1 2
FMR1 1 3 8 2 3 1 3 1 | 1 1 1
RGCP 2 1 8 2 1 2 1 2 1 2 2










DXS1204 r 1 1 2 11 2 2
DXS991 1 1 3 3 3
AR 3 3 2 2 2
DXS339 3 3 1 1 1
DXS106 1 1 2 2 2
DXS453 2 2 1 1 1
DXS566 1 1 2 1 2
PGK1 1 1 2 1 2
DXS986 2 2 1 2 1
DXS1197 3 3 1 3 1
DXS995 1 1 3 1 3
DXS3 1 1 2 1 2
DXS1203 1 1 2 1 2
DXS990 2 2 1 1 1
DXS1106 2 2 2 1 1
DXS1105 1 1 1 2 2
DXS1059 3 3 3 2 2
DXS1212 2 1 1 2 1 2
HPRT 1 3 1 3 1
DXS1062 3 2 3 2 3
FMR1 I 1 1 3 1 3
RGCP ■ 2 2 1 2 1
DXS1108 | 1 1 2 1 2
Figure 35. Pedigree of Family I showing results of DNA analysis. Markers are shown in















Figure 36. Results of analysis of the VNTR marker HPRT on the A.L.F. sequencer. The
largest allele is arbitrarily denoted as 1 and the smallest allele as 3. The marker (described
in 6.1.4c) shown in the first and last lanes consists of peaks at 250bp (left) and 300bp. The
numbers on the left of each lane indicate the individual's identifier as shown in Figure 35.
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In Figure 35, the three different shaded bars represent the three grandparental X
chromosomes (black represents the affected haplotype). Alleles are numbered as 1
being the largest allele and 3 being the smallest allele seen in the family. As the
haplotype for 1:2 is unknown, the pedigree is drawn as if the individuals in
generation II (apart from 11:8) have inherited a non-recombinant X chromosome from
their mother. The pedigree could equally have been drawn with only 11:8 being non-
recombinant and his siblings as recombinants for the markers in Xq27.3-Xqter
(FMR1 to DXS1108).
The bars in Figure 35 indicate that if the clinical status for each individual is as
shown, then the only region shared by affected males but not shared with unaffected
males is the region between the markers DXS453 and DXS990. Linkage analysis was
carried out to confirm this observation.
3.4.2 Linkage analysis
The linkage report program (LRP) was used to produce a two-point LOD score table
from the two-point analysis and this is shown in Table 14. Positive LOD scores were
obtained with the markers extending from DXS566 to DXS1203. The maximum
LOD score of 2.71 at a recombination fraction of zero was obtained with several
markers (PGK1, DXS1197, DXS995, DXS3 and DXS1203) producing a plateau of
scores at 2.71. Two other positive LOD scores of 1.49 were obtained with DXS566
and DXS986, the latter of which lies between two markers which gave scores of 2.71.
Although this could be due to polymorphic differences in these markers, inspection
of the pedigree shows that one of the key individuals (obligate carrier 1:2) is
homozygous for these markers (albeit inferred) and therefore this would be expected
to reduce the LOD score. Two-point linkage analysis suggests, therefore, that the
MR gene in Family I, is situated between DXS566 to DXS1203 (a distance of 6.8cM)
although the precise limits may extend on either side to the markers DXS453 and
DXS990 (lO.lcM). In order to define the interval more specifically, multipoint
linkage analysis was carried out using the genetic distances shown in Figure 37 (page
130) and the results of this analysis are shown graphically in Figure 38 (page 132).
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Although the output of the LRP program from LINKMAP results in location scores,
Terwilliger and Ott (1994) recommend converting these to multipoint LOD scores
(by dividing each location score by 21n(10)) to provide a more meaningful

















































Figure 37. Genetic distances between
informative markers analysed in Family I.
Figures on the left are in cM and were taken
from Fain et al. (1995). For the LINKMAP
analysis these genetic distances were converted
from cM to recombination fractions (shown on
the right) using the Kosambi mapping function
[0 = Vz tanh(2x)] where x is the distance in
Morgans.
The marker RGCP is not listed by Fain et al.
(1995) but is known to lie between DXS15 and
F8C (Willard et al., 1994), both of which are on
the Fain map at the same genetic location.
Markers in brackets were excluded from the
LINKMAP calculation either because the genetic




LOD score at recombination fraction (0) of:
Locus 0.0 0.01 0.05 0.1 0.2 0.3 0.4 7'-max Qmax
DXS1204 -oo -0.52 0.11 0.32 0.42 0.37 0.22 0.42 0.19
DXS991 -oo -1.33 -0.07 0.34 0.54 0.46 0.25 0.54 0.19
AR -oo -1.33 -0.07 0.34 0.54 0.46 0.25 0.54 0.19
DXS339 -oo 0.67 1.21 1.30 1.14 0.80 0.37 1.30 0.10
DXS106 -oo -0.52 0.11 0.32 0.42 0.37 0.22 0.42 0.19
DXS453 -oo -0.52 0.11 0.32 0.42 0.37 0.22 0.42 0.19
DXS566 1.49 1.47 1.39 1.28 1.02 0.73 0.40 1.49 0.0
PGK1 2.71 2.67 2.49 2.25 1.74 1.17 0.54 2.71 0.0
DXS986 1.49 1.47 1.39 1.28 1.02 0.73 0.40 1.49 0.0
DXS1197 2.71 2.67 2.49 2.25 1.74 1.17 0.54 2.71 0.0
DXS995 2.71 2.67 2.49 2.25 1.74 1.17 0.54 2.71 0.0
DXS3 2.71 2.67 2.49 2.25 1.74 1.17 0.54 2.71 0.0
DXS1203 2.71 2.67 2.49 2.25 1.74 1.17 0.54 2.71 0.0
DXS990 -oo 0.67 1.21 1.30 1.14 0.80 0.37 1.30 0.10
DXS1106 -oo -1.33 -0.07 0.34 0.54 0.43 0.19 0.54 0.19
DXS1105 -oo -1.33 -0.07 0.34 0.54 0.43 0.19 0.54 0.19
DXS1059 -oo -1.33 -0.07 0.34 0.54 0.43 0.19 0.54 0.19
DXS1212 -oo -6.39 -3.72 -2.54 -1.38 -0.74 -0.31 0.0 0.5
HPRT -oo -5.31 -2.63 -1.57 -0.67 -0.31 -0.16 0.0 0.5
DXS1062 -00 -5.31 -2.63 -1.57 -0.67 -0.31 -0.16 0.0 0.5
FMR1 -00 -9.21 -5.18 -3.47 -1.87 -1.01 -0.45 0.0 0.5
RGCP -oo -7.11 -4.94 -3.49 -1.98 -1.11 -0.48 0.0 0.5
DXS1108 -00 -7.11 -4.94 -3.49 -1.98 -1.11 -0.48 0.0 0.5
Table 14. Results of two-point LOD scores. Zmax is the maximum LOD score and 0max is




Figure 38. Results of the LINKMAP analysis in Family I. The marker DXS1204 (not
shown) was used as the starting point (OcM). Markers in brackets were not included in the
LINKMAP analysis because the genetic distances between that marker and the adjacent
marker was zero. The location scores produced by LRP were converted to multipoint LOD
scores by dividing by 21n(10) as described in Terwilliger and Ott (1994). LOD scores
produced by this "sliding" method are not strictly comparable to a complete 16-point
multipoint analysis. Furthermore, the odd shape of the curve in the region of the maximum
LOD scores may be a consequence of carrying out this type of analysis. Alternatively, it
may represent the overlap of two curves (one each for DXS566 and DXS3) which show no
recombination with the disease. The maximum multipoint LOD score obtained was 2.71
with the marker pair DXS3/DXS1203. Mutation rates were set at zero for this analysis and
an arbitrary cut-off point of -6 was used for the y axis.
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3.5 DISCUSSION
The mental retardation condition segregating in this family is thought to be a non¬
specific form of XLMR with global developmental delay. The only obvious clinical
features observed in two out of four affected males were low birth weight,
microcephaly in the neonatal period, and prominent epicanthic folds. The two boys
in generation III are slightly dysmorphic. Although these males do not appear
normal, the clinical features are so bland that the mental retardation condition
affecting the males in this family is presumed to be non-specific (MRX) rather than
syndromic (MRXS). Two-point linkage analysis using highly polymorphic X
chromosome markers has placed the locus for this MRX condition to a 1 OcM region
in Xql3-Xq21 (between DXS453 and DXS990). Multipoint linkage analysis in this
family, however, has not narrowed the region further than lOcM.
This region of the X chromosome contains a cluster of MRX loci which are shown in
Table 15 (extracted from Table 5, Chapter 1).
Name Locus Description Reference
MRX1 Xpl 1,4-q21.31 Mental retardation only Suthers et al., (1988)
MRX4 Xpl 1.22-q21.31 Speech delay, learning
disability
Arveiler et al., (1988a)
MRX5 Xp21.1-q21.3 Hyperactive behaviour,
speech delay
Samanns et al., (1991)
MRX7 Xpl 1.4-q21.3 Mental retardation only Jedele et al., (1992)
MRX8 Xpl 1.3-q21.22 Mental retardation only Schwartz et al., (1992)
MRX 12 Xp21.3-q21.1 Hypotelorism, large ears Kerr et al., (1992)
MRX 13 Xp22.3-q21.22 Large ears Kerr et al., (1992)
MRX 17 Xpl l-q21.3 Mental retardation only Gedeon et al., (1994)
Table 15. Non-specific XLMR conditions which map in the same region as the XLMR
condition in Family I.
Linkage analysis in families with non-syndromal forms of XLMR is hampered by the
fact that the families are usually small and the phenotype of affected males is either
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very subtle or absent. For this reason, families cannot usually be combined to
increase LOD scores, and many localisations are based on LOD scores barely
reaching +2. The linkage based localisations of the MRX conditions listed in Table
15 cover large parts of the X chromosome (in some cases as much as 50%,
corresponding to genetic distances of 80-90cM) and therefore comparison of these
loci and the MR condition in Family I is probably not very helpful in determining
whether this is the same condition as a previously described condition. Furthermore,
the unaffected males in Family I were not examined and therefore we cannot tell
whether the subtle dysmorphic facial features seen in the two males in generation III
are peculiar to these individuals or whether other family members have similar
characteristics.
The eight non-specific mental retardation conditions listed in Table 15 have
localizations which appear to overlap the interval containing the MR locus in Family
I. In five of the families in which MRX numbers have been assigned (MRX4,
MRX5, MRX 12, MRX 13 and MRX 17) hyperactivity and speech delay were part of
the phenotype of the affected males in addition to mild to moderate mental
retardation. In two of the families (assigned to loci MRX4 and MRX7), the affected
males had delayed motor milestones as well as behavioural problems. Most of the
affected males in these families were non-dysmorphic although some individuals
were described as having an unusual facies. In the family assigned to MRX8
(Schwartz et al., 1992), the affected males were microcephalic. They also have a
sloping forehead and upslanted palpebral fissures although the unaffected males also
have these features (except with normal head circumferences). In the family reported
by Schwartz et al. (1991) the mental retardation ranged from mild to severe, but in
the other families listed in Table 15, the mental retardation was generally mild to
moderate (as in Family I). The two-point linkage analyses in these reports usually
resulted in LOD scores of just over +2 and in some cases the linkage analysis was
carried out with penetrance set at 0.8 (in the linkage analysis carried out in Family I
full penetrance was assumed).
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The LOD scores obtained in Family I were well above +2 and the localisation of the
disorder was narrowed to an interval of lOcM. A distance of lOcM would be of
practical use if there were any females who required prenatal diagnosis or carrier
detection but localisations spanning distances greater than this would probably be of
little use in a diagnostic situation. It is not known whether any of the relatives of
individual 1:2 in Figure 35 are affected with the same condition. A female cousin of
11:5 is a resident of a mental institution but this is obviously a different condition to
the one segregating in the part of the family shown in Figure 35, otherwise it would
imply that male to male transmission had occurred. Although the individual 11:8 was
reported to be "slightly dull intellectually" this was not felt on clinical grounds to be
the same condition. This is supported by the observation that 11:8 has inherited the
opposite haplotype, for the candidate region, to the other affected males. In spite of
this, I felt it necessary to see what effect recoding him as affected would have on the
two-point linkage analysis. This resulted in negative LOD scores with markers
which had previously given positive scores (Table 14), apart from DXS566 and
DXS986 which both still gave positive LOD scores (of 1.67). Oddly, after this
recoding, a negative LOD score of -2.91 was obtained with the PGK1 locus which is
located between these two loci. Inspection of the haplotypes in generation II showed
that this is presumably due to the fact that the mother 11:8 (1:2) is heterozygous at
PGK1 but homozygous at the flanking markers DXS566 and DXS986. Therefore,
changing the affection status of 11:8 has a large effect on the family's two-point LOD
score with PGK1, but little effect on the score with DXS566 and DXS986.
The DNA studies in this family illustrate two important points concerning a linkage
analysis of this type. First, it is crucial to have the correct clinical information for
each individual because, as shown above, if this is not available or is ambiguous, it
can have a dramatic effect on the outcome of the analysis. Secondly, it shows how
the variability in polymorphism can make substantial differences to the LOD scores.
The former may be a general problem with the MRX disorders. In some cases this
may be due to a very mild phenotype, or it could be due to insufficient phenotype
analysis. As pointed out by Schwartz (1993), the original Martin-Bell (fragile X
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syndrome) family was originally reported as a family with a non-specific form of
mental retardation. Conversely, the family described by Proops et al. (1983) which
was reported as a Martin-Bell family, was later shown to be fragile X negative, with
the MRX gene located in distal Xp (Arveiler et al., 1988a).
On the other hand, that linkage analysis results may dictate re-assessment of a
clinical diagnosis is illustrated in the next chapter. A family with XLMR is
described in which the mental retardation and associated spastic diplegia were
originally thought to be due to X-linked hydrocephalus and MASA syndrome. Re-
analysis of the pedigree using polymorphic DNA markers and re-evaluation of the
clinical features of the affected males indicates that a new XLMR syndrome has been
identified.
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4. Localization of an X-linked mental retardation gene in Xp22.
4.1 INTRODUCTION
Unlike the non-specific X-linked mental retardation conditions (MRX), the XLMR
syndromes (MRXS) usually have characteristic and well defined, though highly
variable, phenotypes. Moderate to severe mental retardation is usually the only
common feature. It is the presence of these distinctive phenotypes which facilitates
mapping of XLMR syndromes; if the clinical features of several families are thought
to represent the same syndrome, linkage data from more than one family can be
combined (as has been possible in mapping of the Coffin-Lowry syndrome locus).
Higher LOD scores are often obtained as a result. However, as described below, the
presence of such a distinctive phenotype actually led to erroneous assumptions about
the nature and location of an XLMR gene, in spite of early linkage data which
suggested a gene location elsewhere on the X chromosome.
The family described in this chapter (Family J) was first reported more than 20 years
ago (Fried, 1972) and at that time consisted of five mentally retarded males in one
generation and a sixth affected male (deceased) in a previous generation. The degree
of mental retardation varied from moderate to severe within the family and there
were also two cases of hydrocephalus, one of which was reputedly due to aqueductal
stenosis (this is described more fully in Chapter 5). All the affected males had
delayed motor development and difficulty in walking as adults. At the time of this
initial investigation DNA analysis was not possible, but a biochemical study by Fried
and Sanger in 1973 using the polymorphic properties of the Xg blood group in
Xp22.33 suggested possible linkage between this locus and the mental retardation
gene segregating in the family. The gene which encodes the Xg blood group antigen
has recently been identified as PBDX (pseudoautosomal boundary divided on the X
chromosome; Ellis et al., 1994). Four out of five affected males who were analysed
in Family J were Xg(a+) and five out of seven unaffected males were Xg(a-). These
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results produced a maximum likelihood of linkage, between the XLMR gene and Xg,
of 20.2 at 9 = 0.11. The family was not investigated again until 1989.
At this time, the clinical presentation of the affected males, of mental retardation,
hydrocephalus and spastic diplegia was very suggestive of MASA syndrome which
was first documented in 1974 (Bianchine and Lewis), later localized to Xq28 (Winter
et ah, 1989), and subsequently found to result from mutations in LICAM {Jouet et al.,
1994). For these reasons, in spite of the initial suggestion by Fried that the gene
responsible for the mental retardation and hydrocephalus in this family was probably
linked to Xg, family J has been assumed by others (including Willems et al. (1990)
and the London Dysmorphology Database) to be an example of the allelic
MASA/HSAS syndromes (see Table 4) and by OMIM (Online Mendelian
Inheritance in Man) to be a non-specific mental retardation syndrome (MRX1). It
was important, therefore, to establish whether the gene responsible for this family's
disorder was situated in Xp near the Xg locus, or in Xq28. Linkage to another region
of the X chromosome was also possible.
Because of the similarities of the phenotype to the MASA syndrome phenotype, an
extensive linkage analysis using DNA markers in Xq28, in the region of the LICAM
locus was undertaken. When linkage to this region was excluded, other regions of
the X chromosome were screened using markers at widely spaced intervals until
there was evidence of linkage to a particular region, when the concentration of
markers was increased. Most of the X chromosome was covered, extending from
close to the pseudoautosomal boundary in Xp22.33 to distal Xq28, with variable
coverage of markers across the chromosome.
4.2 FAMILY STUDIES
The pedigree of Family J is shown in Figure 39 (page 141). Each of the five affected
males in generation III are sons of five sisters; the sixth affected male was their uncle
(11:5). Three of the affected males are still alive in three different mental institutions
in Scotland. In order to update the clinical information it was felt necessary to re-
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examine the affected males in the family, although this was only possible on one
individual (111:26) who was examined by Drs. David Bonthron and Alan Wright
(University of Edinburgh, Human Genetics Unit and MRC Human Genetics Unit,
respectively). New information was also obtained about the other two living affected
males (111:35 and 111:41) from the mental institutions in which they were resident.
4.2.1 Case reports
Case 1 (111:26) was born in 1947 after a normal delivery although his mother had
been admitted to hospital with oedema one week prior to delivery. He weighed 81bs
at birth. He developed normally at first, but at 9 months suddenly regressed and
developed loss of muscle tone with associated muscle wastage. Thereafter his
development was slow; he walked at 3 years of age and talked at 4 years. He
attended special schools from the age of 6 until he was 16 but was irritable and very
difficult to manage at home. He was eventually admitted to a mental institution
when he was 22 years old. His IQ was 39 (Binet). He had kyphosis with mild
scoliosis and mild pes planus. His facial appearance was normal although at the time
of his most recent examination in 1995, he was described as having coarse features
(Figure 40, page 142). When he was 31 he was referred to a neurologist because he
was unsteady on his feet and had difficulty walking; he was found to have weakness,
sensory loss and impaired coordination in both legs with an extensor plantar reflex
on the right side. He was diagnosed as having a progressive neurological disorder of
unknown cause. One year later he was confined to a wheelchair. A skull X-ray
carried out two years later showed bilateral symmetrical intracranial calcification
affecting the basal ganglia. When he was examined again in 1995, he was noted to
have increased tone in his arms and legs, lower limb weakness, bilateral extensor
plantar reflexes and bilateral ankle clonus. A CT scan performed at this time showed
extensive calcification of the basal ganglia and enlarged lateral ventricles (Figure 41,
page 143).
Case 2 1111:351 was born in 1936 after a normal pregnancy and delivery. He had
delayed developmental milestones and did not walk until 2 years of age or talk until
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he was 2Vi years old. He attended a special school from the age of eight and was
admitted to a mental hospital when he was 45 with an IQ of approximately 45. His
facial appearance was normal but he had mildly dysplastic ears. At the age of 47 he
was referred to a neurologist because of weakness and confusional episodes. He was
found to have bilaterally increased limb reflexes and some thinning of the
interosseous muscles in the hands.
Case 3 (111:41) was born in 1951. Neurological examination at the age of 20 years
showed an abnormal gait and spastic diplegia with exaggerated limb reflexes.
Further examination at the age of 40 showed that he had kyphosis, mild choreic
involuntary movements, a wide-based flat footed gait, and wasting of the small
muscles of the hands. The plantar reflexes were extensor and abdominal reflexes
were present. He had poor speech and an IQ of approximately 40. A skull X-ray in
1995 showed calcification of the basal ganglia (Figure 42, page 146).
The three cases described above all had a normal 46,XY karyotype and were negative
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Figure 41. CT scan of individual 111:26 showing bilateral calcification of the basal ganglia
and lateral ventricular dilatation. Portions A to D are transverse sections of the skull at 1 cm
intervals moving upwards.
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There are also five deceased affected males in this family:
1) Individual 11:5 was described as a severely handicapped male who never attended
school and who had difficulty in walking. He was also described as having an
unsteady gait, scoliosis and poor muscularity. He died in a mental hospital at age
40 from pulmonary tuberculosis. No post-mortem was carried out.
2) Individual 111:1 was a severely handicapped male who was noted to have
macrocephaly in infancy and never walked. He died at age 15 from meningitis
although his death certificate stated "congenital hydrocephalus".
3) Individual 111:20 was a mentally handicapped male with dorsolumbar scoliosis
and wasting of calf muscles. Neurological examination in 1972 revealed
cerebellar ataxia and spastic diplegia with exaggerated reflexes (plantar reflexes
extensor and abdominal reflexes absent). He died when he was 33 years old
from a suspected heart attack.
4) Individual 111:30 was born in 1938 after a normal pregnancy although labour was
prolonged and he was delivered by forceps. His milestones were delayed; he was
unable to sit up until 8-9 months and did not walk unaided until he was 2Vi years
old. Although he attended school he was described as ineducable and never
learned to read or write. He was admitted to a mental hospital on a permanent
basis at age 16; at this time his IQ was 25. His legs were reported to be thin and
he had bilateral genu valgum, pes planus and walked with a clumsy gait. He was
also noted to have a posterior curvature of the upper third of his spine. No
information is available about the cause of death.
5) Individual 111:39 was born in 1955 with probable hydrocephalus. His head was
noted to be large at the age of six weeks and at 6 months his OFC was 53 cm
(>97th percentile). Ventriculography showed gross symmetrical hydrocephalus
with a small 4th ventricle and a suspected block in the aqueduct of Sylvius. He
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underwent a ventriculo-peritoneal drainage operation at 6 months of age. He
only spoke a few words, was able to stand with support, but could not walk
unaided. He died when he was 4 years old.
The phenotype of the affected males in this family, therefore, is moderate to severe
mental retardation in association with a progressive neurological disorder and spastic
diplegia (which is, in fact, similar to the MASA phenotype). Wasting of the small
muscles of the hand was also apparent in two of the three living affected males. The
facial dysmorphism is very subtle; individual 111:26 (Figure 40) has a long face with
long ears and has coarse facial features; he has been described as having a facial
appearance similar to males with fragile X syndrome. Although macrocephaly was
present in infancy in the two males who were reported to have had hydrocephalus,
the other mentally retarded males had normal head circumferences. Of the two males
who had recent skull investigations (CT scan and X-ray) both had marked
intracranial calcification of the basal ganglia, and one had enlarged lateral ventricles
(it is unknown if 111:41 also had enlarged ventricles because this could not be
detected on an X-ray).
None of the obligate carrier females (11:8,11:10,11:14,11:16 and 11:18) were known to
have any manifestations of the disorder and all were of normal intelligence.
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Blood or lymphoblastoid cell lines had been obtained from some family members in
the 1980's and were stored in the MRC Human Genetics Unit, Edinburgh. DNA
samples were transferred to our laboratory in 1989 and fresh blood samples were
obtained from some family members. DNA was extracted from these new samples
as described in 6.1.1.1. DNA was available on individuals marked on the pedigree
(Figure 39, page 141) with a cross. As it was presumed that the syndrome involved
in family J was MASA, the initial analysis concentrated on markers in distal Xq (the
gene responsible for MASA had been localised to Xq28 in 1989; Winter et al.) and
was carried out by Southern blotting and hybridization with radioactive probes, and
also by PCR analysis. The details of these markers are shown in Tables 16 and 17.
Location Locus Probe Enzyme Alleles (kb) Reference
Xq27.1 DXS98 4D-8 Mspl 25,7.8 Boggs and Nussbaum (1984)
Xq27.3 DXS297 VK23B Xmn\ 10.3, 6.6 Suthers et al., (1991b)
Xq28 DXS296 VK21A Taql 10.9,9.9 Suthers et al., (1989)
Xq28 DXS305 St35-691 Pstl 5.1,2.9/2.2 Vincent et al., (1989)
Xq28 F8C F814 Bell 1.2, 0.9 Heilig et al., (1988)
Table 16. DNA markers in distal Xq analysed by Southern blotting and hybridization with
radioactive probes.
Location Locus Reference Primers (5'-3') Anneal
temp.



















Table 17. Distal Xq markers which were analysed by PCR.
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When linkage to Xq28 was excluded (see LOD score results in Table 19, page 153)
an extensive search for linkage to other regions was undertaken. Only DNA markers
which could be analysed by PCR and detected using the A.L.F. sequencer were used,
partly for ease of analysis, and also because DNA was limited on some family
members. The details of the other markers which were analysed are shown in Table
18.
4.3.2 Linkage analysis
Two-point linkage analysis was carried out using MLINK. An arbitrary mutation
rate of 1 x 10"5 and a corresponding gene frequency of 3 x 10° were used for the
MLINK calculation. Deceased individuals 11:5,111:20 and 111:30 were coded as
affected and complete penetrance for the disease was assumed. The alleles of each of
the microsatellites were assumed to occur at equal frequencies and for the dimorphic
markers, the published frequencies were used. The results of the pairwise analysis
are shown in Table 19 (page 153).
Multipoint analysis was also carried out using the LINKMAP component of
FASTLINK using genetic distances as shown in Figure 44 (page 152) by carrying
out 15 overlapping five-point analyses (four marker loci and the disease locus). For
the purposes of the LINKMAP analysis the mutation rates were set at zero. Genetic
distances were converted into recombination fractions using the Kosambi mapping
function prior to the calculation and reconverted to cM afterwards. Multipoint LOD
scores were calculated from location scores which were obtained from the linkage
report programme (LRP). These were plotted against genetic distance (using the
marker DXS996 as the starting point) and the final graph is shown in Figure 45 (page
154).
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Location Locus Reference Primers (5'- 3') Anneal
temp.


























































































Table 18. DNA microsatellites covering the X chromosome (apart from Xq27 and q28)
which were analysed by PCR. The marker KAL is a CA repeat at the Kallmann syndrome
locus, 5'DYS-II is one of two CA repeats at the 5' end of the dystrophin gene and AR is a




A total of 33 X chromosome markers were analysed in family J and of these, 26 were
informative, i.e. either the possible carrier 11:3 or the obligate carriers 11:10 and 11:16
were heterozygous. The results of markers which gave positive LOD scores (Table
19) are shown on the pedigree in Figure 43. In the construction of this pedigree, the
haplotypes were arbitrarily drawn as if individual 11:3 had inherited a recombinant X
chromosome from her mother and the other females in generation II are non-
recombinants. The black bars represent the affected haplotype which was derived
from the carrier 1:2; she is assumed to be an obligate carrier because of the presence
of 11:5. If 11:5 had not been affected it could have been possible that the father of the
six carrier females in generation II was a gonadal mosaic for normal and mutant
alleles and had transmitted the mutation to five out of six daughters. We can only
assume that 11:5 was affected with the same condition as the living affected males,
from evidence in the report by Fried (1972).
Other markers which were analysed in family J but were not informative were:
DXS52 (Stl4), DXS15 (DX13), DXS105 (55.E), DXS523 (pDK9.5), DXS443,
DXS365, DXS228 and DXS1226.
4.4.2 Linkage analysis
The LRP program was used to produce a table of two-point LOD scores (Table 19).
Positive scores from DXS1224 (Xp22.31) to DXS1052 (Xp22.13) were obtained with
a maximum LOD score of 4.22 at the DXS418 locus (Xp22.1). However, two-point
linkage analysis cannot define precisely the region of localization of the MR locus in
this family which may be anywhere between KAL (Xp22.31) and DXS989 (Xp22.12)
and therefore LINKMAP analysis was carried out. The maximum multipoint LOD
score obtained using markers from Xp22.3 to Xq28 (175cM) was 4.26 with the
marker DXS207 and the adjacent marker DXS999 (Figure 45).
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Figure 44. Genetic distances between
informative markers analysed in Family J.
Figures on the left are in cM and were
taken from Fain et al., (1995). For the
LINKMAP analysis these genetic
distances were converted from cM to
recombination fractions (shown on the
right) using the Kosambi mapping
function. Markers in brackets were
excluded from the LINKMAP analysis
because, either the genetic distances
involving these markers were
unobtainable, or the distances between two
adjacent markers was zero. Of the three
markers at the F8C locus, the CA repeat in
intron 13 was used in the LINKMAP
analysis (because it is more polymorphic).
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LOD scores at 0 of:
Locus 0.0 0.01 0.05 0.1 0.2 0.3 0.4 7'-'max 0wmax
DXS996 -00 1.85 2.29 2.25 1.83 1.24 0.57 2.30 0.06
DXS237 -00 1.85 2.29 2.25 1.83 1.24 0.57 2.30 0.06
KAL -00 1.97 2.39 2.33 1.88 1.25 0.54 2.40 0.06
DXS1224 2.31 2.28 2.16 1.99 1.62 1.17 0.63 2.31 0.00
DXS987 4.04 3.99 3.76 3.46 2.75 1.91 0.95 4.04 0.00
DXS207 3.26 3.21 3.00 2.71 2.10 1.42 0.68 3.26 0.00
DXS1053 1.69 1.66 1.53 1.36 1.00 0.62 0.23 1.69 0.00
DXS418 4.22 4.15 3.89 3.54 2.78 1.91 0.93 4.22 0.00
DXS999 1.83 1.80 1.67 1.50 1.12 0.71 0.28 1.83 0.00
DXS1229 1.77 1.73 1.59 1.41 1.04 0.65 0.25 1.77 0.00
DXS1683 2.36 2.33 2.21 2.05 1.67 1.21 0.66 2.36 0.00
DXS1052 3.56 3.51 3.27 2.97 2.30 1.56 0.75 3.56 0.00
DXS989 -oo 2.45 2.89 2.84 2.38 1.69 0.83 2.90 0.06
DXS1234 -oo 0.46 1.60 1.88 1.76 1.31 0.67 1.90 0.12
5' DYS -oo -3.83 -1.21 -0.25 0.41 0.50 0.32 0.50 0.27
DXS426 -00 -4.98 -2.40 -1.47 -0.80 -0.51 -0.24 0.00 0.50
AR -00 -4.65 -2.00 -0.99 -0.19 0.07 0.11 0.11 0.37
DXS3 -oo -5.19 -2.51 -1.45 -0.55 -0.18 -0.03 0.00 0.50
DXS98 -oo -6.71 -3.32 -1.95 -0.79 -0.31 -0.11 0.00 0.50
DXS297 -00 -3.03 -1.61 -1.02 -0.52 -0.29 -0.13 0.00 0.50
FMR1 -oo -10.70 -5.87 -3.85 -1.96 -0.99 -0.40 0.00 0.50
DXS296 -00 -3.57 -1.71 -1.10 -0.78 -0.64 -0.31 0.00 0.50
DXS305 -00 -2.89 -1.54 -1.04 -0.73 -0.59 -0.32 0.00 0.50
F8C (F814) -oo -3.30 -1.42 -0.79 -0.43 -0.42 -0.32 0.00 0.50
F8C (int. 13) -00 -13.46 -7.30 -4.75 -2.39 -1.17 -0.44 0.00 0.50
F8C (int. 19
Hindm RFLP)
-oo -3.30 -1.42 -0.79 -0.43 -0.42 -0.31 0.00 0.50




Figure 45. Results of LINKMAP analysis on microsatellite data on Family J using genetic
distances as shown in Figure 44. The marker DXS996 (not shown) was used as the starting
point (OcM). The location scores produced by LRP were converted to multipoint LOD
scores by dividing by 21n(10) as described in Terwilliger and Ott (1994). A negative LOD
score cut-off point of -6 was arbitrarily chosen. The method used in this LINKMAP
analysis is that recommended by Terwilliger and Ott (1994) although LOD scores produced
by this "sliding" method are not strictly comparable to a complete 18-point multipoint
analysis. The maximum multipoint LOD score obtained in this analysis was 4.26 with the
marker DXS207. Markers shown in brackets were excluded from the LINKMAP analysis
for the reasons described in Figure 44. The shoulder between the markers DXS999 and
DXS1229 may be a consequence of combining information from two 5-point analyses.
Alternatively, it may reflect differences in informativeness of markers in this region.
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4.5 DISCUSSION
Family J originally presented with moderate to severe mental retardation and spastic
diplegia in 1972. However, more than 20 years later, the cause of their mental
retardation has not been determined. Although Fried (1972) suggested that the MR
locus in this family lay in the distal short arm of the X chromosome, and data
presented here confirm this, the striking phenotype in this family led to the belief that
the affected males had MASA syndrome. In addition, the presence of two males who
were suspected of having hydrocephalus, and the recent discovery that one form of
X-linked spastic paraplegia (SPG1) is also caused by L1CAM mutations (Jouet et al.,
1994), added weight to the assumption that the MASA/HSAS/SPG1 syndromes were
involved. Therefore, early DNA analysis in family J (both by myself and by Dr Alan
Wright, MRC Human Genetics Unit) concentrated on markers in distal Xq.
Linkage analysis
When linkage to distal Xq was excluded, markers spanning the whole of the X
chromosome were then analysed. The two-point linkage analysis resulted in a
maximum LOD score at 4.22 with the marker DXS418. Positive LOD scores were
also obtained with the markers surrounding DXS418 although the absolute values
vary as a reflection of the differences in informativeness of the markers. The
important observation is the presence of several adjacent strongly positive LOD
scores in one region and negative LOD scores elsewhere on the X chromosome.
Two-point linkage analysis indicated, therefore, that the locus for the mental
retardation gene segregating in Family J lies in Xp22.1-Xp22.3 between DXS989
proximally and KAL distally; a distance of 26.7 cM (see Figure 43). Multipoint
linkage analysis gave a maximum LOD score of 4.26 with the marker cluster
DXS207/DXS1053/DXS987 and the neighbouring cluster, DXS999/DXS418. If a
confidence level of 2 units of LOD score is used (likelihood ratio of 100:1), the
region containing markers with LOD scores above 2.26 are encompassed within the
interval KAL-DXS989. Using a less stringent 1 LOD unit of support, the interval can
be confined to that between the markers DXS1224 and DXS1229 which is a distance
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of 17.2cM. Therefore, depending upon the level of confidence used, the interval
containing the MR locus in Family J is either 17.2cM or 26.7cM.
Two lines of evidence, therefore, excluded MASA/HSAS as being implicated in the
condition affecting Family J:
a) Negative LOD scores were obtained with Xq28 markers and positive LOD
scores obtained with distal Xp markers.
b) Further evaluation of the phenotype showed several features which are absent
in MASA but present in this family and vice versa.
Recent skull examinations in two of the affected males showed that they both had
marked intracranial calcification of the basal ganglia (it is presumed to be calcium
because of the density of the substance on X-ray). This is a feature which has not
been seen in the MASA/HSAS syndromes although enlarged ventricles (as seen in
individual 111:26) have been observed in some MASA families (Boyd et al., 1993).
Other features seen in this family include exaggerated limb reflexes, kyphosis,
scoliosis, and wasting of the small muscles in the hands; the first two features have
been seen in MASA patients, the latter have not. In addition, the males in family J
did not have aphasia, although their speech was poor. None of the affected males
had adducted thumbs.
Linkage data and new clinical evidence, therefore, have shown that the disorder
segregating in family J is not one of the allelic MASA/HSAS/SPG 1 syndromes, but a
mental retardation/spastic diplegia syndrome with a gene localization in distal Xp.
We can speculate whether this is the same as, or allelic to, other mental retardation
syndromes in this region or whether the condition in family J represents a new
XLMR syndrome.
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Other syndromes associated with mental retardation in Xp22.1-Xp22.3
1) Coffin-Lowrv syndrome. This was first described Coffin et al. (1966), later by
Lowry et al., (1971) and finally demonstrated to be a single entity by Temtamy et
al. (1975). It is an X-linked semi-dominant condition characterized by severe
mental retardation, speech delay, coarse facies with epicanthic folds,
hypertelorism, thick lips and anteverted nostrils, large soft hands with puffy
tapering fingers, hypotonia with hyperlaxity ofjoints, and various progressive
skeletal abnormalities including pectus carinatum (pigeon chest), kyphosis (hump¬
back) and scoliosis (lateral curvature of the spine). Arrested hydrocephalus may
also be a feature. Miyazaki et al., (1990) described a 22 year old man with Coffin-
Lowry syndrome (CLS) whose cervical spinal canal was compressed by calcified
ligamenta flava (fibrous ligaments between the vertebrae). He had a spastic gait
and exaggerated reflexes in his legs. Biochemical analysis suggested that an
alteration in glycosaminoglycan metabolism was a pathogenetic factor in
calcification of ligamenta flava. Ishida et al., (1992) described 3 males with CLS
who had calcification of the ligamenta flava as a result of calcium pyrophosphate
dihydrate deposition disease which was interpreted as further evidence that a
metabolic abnormality in collagen and proteoglycans is present in CLS. Linkage
data presented by Biancalana et al., (1992) on 16 families using 7 RFLP markers
spanning the Xp22.2-p22.1 region, placed the CLS locus, with a maximum
multipoint LOD score of 7.3, within a 7cM interval defined by the DXS207-
DXS43-DXS197 cluster distally and DXS274 proximally. Biancalana (1994), later
refined the genetic localisation of the CLS gene to a 5 cM interval between
DXS7161 and DXS1052 (the proximal limit is now defined by the marker
DXS1683 (Willard et al., 1994) by construction of a high-resolution linkage map.
To date, no linkage heterogeneity has been detected.
2) Snvder-Robinson syndrome. In 1969 Snyder and Robinson described a family
with nine males with mental retardation over three generations. The males had
hypotonia and dysequilibrium but no specific facial characteristics and the authors
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concluded that their family had a non-specific form of XLMR. This family was
restudied by Arena et ah, (1994). DNA studies were conducted on 17 family
members: 6 affected males, 3 carrier females, and 8 normal males and produced a
maximum LOD score with DXS41 in Xp22.13. The clinical features were: mild to
moderate mental retardation, large head, asthenic body build (marfanoid habitus),
diminished muscle bulk, nasal voice, high, narrow or cleft palate, long,thin
asymmetrical face, mild joint hypermobility, long, thin fingers and great toes and
mild to severe scoliosis. The phenotype suggests that the condition affecting this
family is a syndromic disorder and not a non-specific XLMR.
3) Partington X-linked mental retardation syndrome tMRXSIL In 1988, Partington
et al. described a family in which 10 males had mild to moderate mental
retardation, recurrent dystonic spasms of the hands, and dysarthria. DNA linkage
analysis gave a maximum LOD score with the marker DXS41 (Xp22.2-Xp22.1)
and analysis with flanking markers placed the locus for the MRXS1 syndrome in
Xpter - Xp21.
Of the three syndromes described above, the one which most closely resembles the
disorder in Family J is Coffin-Lowry syndrome, but only in terms of the mental
retardation, ventricular dilatation and skeletal abnormalities. The other features of
CLS are not consistent with those seen if Family J and the affected males have none
of the facial features which are so characteristic of CLS. The most interesting
observation is the deposition of calcium in the spinal canal although there is no
evidence of intracranial calcification in CLS patients. It is conceivable that the
disorder in Family J and CLS are allelic variants although this cannot be determined
until the CLS gene has been identified.
Further investigations in this family?
DNA analysis in this family has confined the region of localization to between 17cM
and 27cM (depending upon the level of confidence). This is a large distance in
genetic terms (-9-14% of the X chromosome). This interval could probably be
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narrowed considerably if microsatellites between KAL and DXS1224 (7.6cM) and
DXS989 and DXS1052 (0-8cM) were analysed; the actual interval of localization
could be then anywhere from 11 .lcM to 26.7cM.
According to the haplotypes shown on the pedigree in Figure 44, there are no women
in generation III who have the affected haplotype and therefore no-one in generation
IV is likely to require carrier testing or prenatal diagnosis in the future. Individuals
111:21 and 111:31 have recently enquired about their carrier status on behalf of their
daughters (IV: 19, IV:20 and IV:23) and both women were reassured that, as they did
not have the same Xp22 haplotypes as the affected males, they were unlikely to be
carriers of the disorder affecting their brothers. However, there is a remote
possibility that a double recombination event has occurred in this region; two of the
intervals between markers analysed in Family J are about 8cM which means that the
chance of a double cross-over occurring but not being detected is 6.4 x 10" .
In this chapter, the distinctive phenotype of the affected males in Family J, that of
mental retardation and spastic diplegia, misled others into believing that the
condition was MASA/HSAS. The following chapter describes a family which
presented with the classical HSAS phenotype (which was confirmed pathologically)
and which was also found not to be linked to Xq28 markers.
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5. Gonadal and somatic mosaicism mimicking genetic heterogeneity
in X-linked hydrocephalus (HSAS).
5.1 INTRODUCTION
As illustrated in the previous chapter, linkage analysis was invaluable in
demonstrating that the syndrome affecting Family J was not MASA/HSAS but an
XLMR syndrome in the distal short arm of the X chromosome. Exclusion of
MASA/HSAS was also verified by new clinical evidence. Two males in Family J
died in childhood as a result of congenital hydrocephalus and in one of the males,
this was reported to be due to aqueductal stenosis, which, in an X-linked pedigree is
usually indicative of HSAS.
In this chapter, Family K is presented in which four males were unambiguously
affected with aqueductal stenosis (HSAS) and in one case this was verified by
neuropathological investigation. In contrast to the linkage studies carried out in the
previous two chapters, linkage analysis in Family K confounded investigations by
giving an impression of genetic heterogeneity in HSAS with a second locus near
FMR1. This suggestion had to be reconsidered later, when the proband was shown to
have an L1CAMmutation which segregated with the disease in the family. The most
likely explanation for the discordant linkage data is that the maternal grandmother of
the affected males is a gonadal and somatic mosaic for the LICAM mutation.
5.1.1 Congenital hydrocephalus
Hydrocephalus is defined as an increase of free cerebrospinal fluid (CSF) in the
ventricular system of the brain. Fluid formed in the lateral ventricles flows through
the foramina of Monro into the third ventricle and from there through the Sylvian
aqueduct into the fourth ventricle. CSF leaves the fourth ventricle and moves into
the subarachnoid space at the back of the brain, from where it is gradually reabsorbed
into veins or through the capillaries of the subarachnoid spaces.
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Congenital hydrocephalus is a symptom of heterogeneous disorders rather than a
specific diagnosis and is often associated with other central nervous system
abnormalities. The majority of cases of have no clear-cut etiology and could be due
to a combination of genetic and environmental factors (Stoll et al., 1992). Most
cases of congenital hydrocephalus are sporadic but a minority are inherited as either
autosomal recessive (McKusick 236670 and 220200) or X-linked traits (McKusick
307000). The overall incidence of obstructive hydrocephalus is between 0.4 and 0.8
per 1000 live and stillbirths (Halliday et al., 1986).
5.1.2 X-linked hydrocephalus (HSAS)
Sixty percent of cases of congenital hydrocephalus are male. This excess is due to
the existence of the well defined X-linked recessive form (HSAS; hydrocephalus due
to stenosis of the aqueduct of Sylvius). HSAS accounts for 7-15% of congenital
hydrocephalus in males with a birth prevalence estimated at 1 in 30,000 (Halliday et
al., 1986). The true prevalence may be higher than this because HSAS can present
with atypical features and even without hydrocephalus [Willems et al., (1987);
Serville et al., (1992)].
Background
Hereditary aqueductal stenosis was first reported by Bickers and Adams in 1949 and
since then more than 40 families have been reported with the condition [Edwards
(1961); Shannon and Nadler (1968); Holmes et al., (1973); Faivre et al., (1976);
Cassie and Boon (1977); Sovik et al., (1977); Habib (1979); Landrieu et al., (1979);
Renier et al., (1982); Van Egmond-Linden et al., (1983); Holden et al., (1990); Orth
et al., (1991); Willems et al., (1987,1990,1992); Lyonnet et al., (1992); Serville et al.,
(1992); Jouet et al., (1993a,b, 1995); Ruiz et al., (1995)].
Pathogenesis
In HSAS, the hydrocephalus is due to narrowing or occlusion of the Sylvian
aqueduct connecting the third and fourth ventricles which prevents fluid draining into
the subarachnoid space from where it can be re-absorbed. This may be the result of
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stenosis of the lumen, forking of the aqueduct, or complete or partial occlusion by a
septum. As CSF formation is relatively constant, it is the change in resistance to
absorption that determines whether the hydrocephalus is progressive. A normal
aqueduct can permit moderate variations in the rate of production of CSF without an
increase in third ventricular pressure but a stenotic aqueduct cannot. The increase in
CSF volume leads to a rise in intracranial pressure; occasionally, the fetal head is so
distended that perforation of the skull is necessary during delivery (Cassie and Boon,
1977).
Clinical features of F1SAS
HSAS is characterised by hydrocephalus, macrocephaly, flexion-adduction
deformities of the thumbs (which are usually adducted) and forefingers, neurological
abnormalities, such as spasticity of the lower limbs secondary to hypoplasia or
absence of pyramidal tracts, enlarged ventricles and varying degrees of mental and
physical handicap. Other cerebral malformations including agenesis of the corpus
callosum and septum pellucidum have also been reported but all features are highly
variable. Landrieu et al., (1979) postulated that aqueductal stenosis develops
secondary to communicating hydrocephalus and may even be absent (Van Egmond-
Linden, 1983). It has also been postulated that adducted thumbs are not secondary to
a neurological defect but are defects in the development of the abductor and extensor
muscles (Holtzman et al., 1976). The diagnosis of F1SAS is not always easy; in the
absence of a conclusive family history the arguments in favour are: the detection of
hydrocephalus with aqueductal stenosis, one or both thumbs adducted, or the
congenital absence of pyramids in sections of the medulla. Congenital absence of
pyramids is observed in almost all cases of HSAS but is not pathognomonic.
Prognosis and Treatment
The prognosis for males with HSAS is poor; the most severe cases die prenatally or
shortly after birth with gross hydrocephalus and associated severe abnormalities.
Attempts to arrest the hydrocephalus usually involve CSF shunting, via a ventriculo-
peritoneal shunt. The poor developmental outcome in surgically treated patients
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suggests, however, that the mental retardation is not secondary to the hydrocephalus
but caused by associated brain abnormalities.
5.1.3 Localisation of HSAS to Xq28
In 1989, the HSAS gene was assigned to distal Xq28 close to Factor VIII (.F8C) and
DXS52 by two-point linkage analysis in a family with 5 affected males (Willems et
ah). Extensive linkage analysis of this family plus an additional three HSAS families
was later carried out using 10 DNA markers spanning Xq26-Xq28 (Willems et al.,
1990). A total of 6 affected males, 16 obligate heterozygotes and 14 unaffected
males were analysed in this study. No recombinants between HSAS and F8C or
DXS15 were found in 20 and 15 informative meioses respectively; however, one
recombinant between HSAS and DXS52 in 30 informative meioses, placed HSAS
and DXS15 on the same side of DXS52. The relative order of the DXS52, DXS15,
F8C cluster at this time was unknown but is now established as:
(.DXS52, DXS15, HSAS, F8C -> Xqter).
In 1992, Willems et al. extended their linkage study to analyse 21 probes from 18
Xq27-Xq28 loci in 13 HSAS families, including the four families from their previous
study. Multipoint linkage analysis and key recombination events in these families
indicated that the putative HSAS gene was situated between DXS52 and F8C, a
distance of 1-2 Mb by physical mapping data (Poustka et al., 1991). This
localization was subsequently confirmed in additional families (Holden et al., 1990,
Orth et al., 1991; Serville et al., 1992; Lyonnet at al., 1992) to be a 1.5 Mb region
between DXS52 and DXS605 (Jouet et al., 1993a), by further linkage analysis. With
the exception of one family (family 12) studied by Willems et al. (1992) there is
currently no evidence for linkage heterogeneity although the authors pointed out that
the clinical diagnosis in an unaffected individual in this family, who carried the
affected haplotype, may have been incorrect.
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5.1.4 The L1CAM gene and the LI cell adhesion molecule
The only known gene in Xq28 in the 1.5Mb interval between DXS605 and DXS52
which had a function in neurological tissue was L/CTM (Djabali et al., 1990). This
encodes a neural cell adhesion molecule and was therefore considered as a candidate
gene for HSAS [Willems et al., (1992); Rosenthal et al., (1992)]. The LI molecule is
a member of the immunoglobulin superfamily of neural adhesion molecules and is a
highly conserved integral membrane glycoprotein involved in neuron-neuron
adhesion, neurite fasciculation, outgrowth of neurites, cerebellar granule cell
migration and interactions between epithelial cells of intestinal crypts (Moos et al.,
2+
1988). The Ca independent neural adhesion molecules are important in the
specification of cell interactions during development, maintenance and regeneration
of the nervous system. Hlavin and Lemmon (1991) cloned and sequenced cDNA
from human brain LI and demonstrated that LI supports neurite growth in vitro. The
protein has a multidomain structure comprising six extracellular immunoglobulin
domains of type C2 and five fibronectin type III domains. In human L1CAM, the
second Ig domain C2 (Ig2) and the second fibronectin type III (Fn2) show a high
degree of conservation with the mouse (LIcam), rat (NILE) and chicken (Ng-CAM)
homologues and are therefore likely to be functionally important (Hlavin and
Lemmon, 1991). In addition, the cytoplasmic domain shows interspecies
conservation indicating that this portion of the molecule may also be involved in
regulating cell adhesion.
5.1.5 HSAS is caused by mutations in the L1CAM gene.
In 1992, Rosenthal et al. found a point mutation at a potential branch point signal in
intron 18 of the LI CAM gene which segregated with hydrocephalus in an HSAS
family. Translation of the aberrantly spliced mRNA resulted in a protein with
significant changes in the cytoplasmic domain. This was the first definite indication
that LI was the gene involved in HSAS. Van Camp et al., (1993) subsequently
screened 25 HSAS families for this point mutation but found it to be absent, although
they did identify a 1.3 kb duplication which cosegregated with HSAS in one family.
164
To date, 20 mutations in the LICAM gene have been reported in HSAS families.
These are listed in Table 20.




Rosenthal etal., 1992 A/C substitution intron 18 Insertion/deletion
Van Camp et al., 1993 1,3kb duplication exon 28
Jouet et al., 1993b G/A substitution exon 7 Cys264Tyr
Coucke et al., 1994 5' splice site mutation intron 4
Jouet et al., 1994 G/A substitution exon 6 Argl84Gln*
Jouet et al., 1994 G/A substitution exon 11 Gly452Arg
Jouet et al., 1994 C/T substitution exon 12 Arg485STOP
Jouet and Kenwrick
1995
G/T substitution intron 1 donor
splice site
Jouet et al., 1995 G/C substitution exon 1 Trp9Ser
Jouet et al., 1995 G/A substitution exon 4 Glyl21Ser
Jouet et al., 1995 A/T substitution intron 10 splice
junction
skipping of exon 10:
deletion of 48 a.a.
Jouet et al., 1995 C/T substitution exon 14 Gln586STOP
Jouet et al., 1995 G/T substitution exon 18 Val768Phe
Jouet et al., 1995 G/T substitution exon 21 Pro941 Leu
Jouet et al., 1995 A/T substitution exon 24 Tyrl070Cys
Gu et al., 1996 1 bp insertion (C) exon 1 Frameshift/9 novel
a.a./STOP
Gu et al., 1996 A/G substitution exon 6 Tyrl94Cys
Gu et al., 1996 C/T substitution exon 7 Pro240Leu
Gu et al., 1996 G/A substitution exon 8 Trp276STOP
Gu et al., 1996 1 bp deletion (G) exon 8 Frameshift/70 novel
a.a./STOP
Table 20. Mutations found in L1CAMin HSAS families. The Argl84Gln* is the mutation
found in the original HSAS family described by Bickers and Adams in 1949 and further
characterized by Edwards et al. in 1961.
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The LICAM gene consists of 28 exons spanning 15 kb. Nearly every form of
mutation has been described so far (with the exception of whole gene deletions) with
missense mutations being the most common, comprising more than 50% of all
mutations. The mutations are distributed across the LICAM gene. It appears that the
mutations which would predict truncation of the protein before the transmembrane
domain and hence result in absence ofLICAM function are associated with severe
congenital hydrocephalus and early mortality (Kenwrick et al., 1996). Conversely,
the mutations which appear in MASA patients result in a protein which is truncated
in the cytoplasmic portion and presumably is expressed on the cell surface.
5.1.6 MASA and SPG1 are also caused by mutations in the LICAM gene
Two other related neurological disorders, MASA syndrome (mental retardation,
aphasia, shuffling gait and adducted thumbs) and spastic paraplegia type 1 (SPG1)
have also been shown to be caused by heterogeneous mutations in LICAM
[Rosenthal et al., (1992); Jouet et al., (1993a, 1994); Jouet and Kenwrick, 1995)].
MASA syndrome was first reported in 1974 (Bianchine and Lewis) in a large
Mexican/American family and since then at least 13 other families with more than 50
patients have been documented [Gareis and Mason,(1984); Yeatman,(1984); Winter
et al., (1989); Schrander-Stumpel et al., (1990); Rietschel et al., (1991); Straussberg
et al., (1991); Macias et al., (1992); Legius et al., (1994)]. The main clinical features
are summarised by the acronym, although there is considerable intrafamilial and
interfamilial variability with mental retardation being the only consistent feature.
Other findings include strabismus, ptosis, and musculoskeletal abnormalities
including kyphoscoliosis, lordosis and torticollis (Boyd et al., 1993). Some of the
features of MASA syndrome (which has also been referred to as clasped thumb
mental retardation by some authors) are shared with X-linked spastic paraplegia type
1 (SPG1). In addition, although MASA and SPG1 patients do not generally present
with hydrocephalus, enlarged lateral ventricles and agenesis of the corpus callosum
have been reported in some MASA patients [Schrander-Stumpel et al. (1992); Boyd
et al. (1993)].
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To date, more than 30 LICAM mutations have been reported in the MASA, HSAS
and SPG1 conditions and it is apparent that each family has a different mutation and
that the mutations are distributed across the gene i.e. there are no common mutations
or a common type of mutation. An additional mutation (marked as * in Table 21)
found in a sporadic case of HSAS first reported by Jouet et al., in 1994, is now
presumed to be the result of gonadal mosaicism in the mother of the affected boy
(Jouet and Kenwrick, 1995). The mutations which have been found in families
presenting with combinations of MASA, SPG1 and HSAS are listed in Table 21.






C/T substitution exon 28 Serl 194Leu HSAS/MASA
Jouet et ah, 1994 C/G substitution exon 6 His210Gln MASA
Jouet et ah, 1994 2 bp deletion (TG) exon 26 Frameshift/STOP SPG1
Jouet et ah, 1994 1 bp deletion (G) exon 22 Frameshift/STOP sporadic HSAS*
Vits et ah, 1994 C/G substitution exon 6 His210Gln MASA
Vits et ah, 1994 G/A substitution exon 14 Asp598Asn MASA
Vits et ah, 1994 ORF deletion exon 28 MASA
Jouet et ah, 1995 G/A substitution exon 8 Glu309Lys MASA
Jouet et ah, 1995 C/T substitution exon 21 Pro941 Leu HSAS/MASA
Ruiz et ah, 1995* T/G substitution exon 6 Ilel79Ser HSAS/MASA/SPG1
Ruiz et ah,
1995**
G/A substitution exon 9 Gly370Arg HSAS/MASA
Table 21. Mutations which have been found in families presenting with MASA, SPG1 and
HSAS or a combination of the three. This family was previously reported by Fryns et ah,
(1991). **This family was previously reported by Kaepernick et ah, (1994).
5.1.7 Carrier detection and prenatal diagnosis of HSAS
Since heterozygote carriers of HSAS are asymptomatic, carrier detection is usually
not possible before the birth of an affected son. In families where there is a
conclusive family history, HSAS can, in principle, be diagnosed prenatally by
ultrasound during the second and third trimesters (Brocard et ah, 1993). However,
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this is unreliable because ventricular dilatation may occur late in pregnancy (Rogers
and Danks, 1983) or even postnatally (Jansen, 1975), and adducted thumbs are
observed in only 44 per cent of affected males (Halliday et al., 1986). In some
families the age of onset of HSAS varies from one child to another (Holmes et ah,
1973). Sonographic monitoring must be meticulous, repetitive and prolonged in
order to diagnose HSAS prenatally.
Although prenatal diagnosis is possible by direct mutation analysis of LICAM, for
most diagnostic laboratories this is not practical, unless a particular mutation has
previously been identified in the family.
Family K was diagnosed with typical X-linked aqueductal stenosis before mutations
in LICAM were identified as being the cause of the disease. DNA analysis was
conducted using Xq28 markers which were known to be closely linked to the HSAS
locus but the disease in this family appeared not to be linked to these markers.
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5.2 FAMILY STUDIES
The X-linked hydrocephalus family (Family K) studied here is shown in Figure 46.
The carrier female (111:3) had three affected boys who died perinatally with
hydrocephalus and her sister (111:8) gave birth to a hydrocephalic boy (IV:7) who is
still alive.
Figure 46. Pedigree of family K. Affected individuals are shown as filled black symbols
and obligate carriers as symbols with a dot.
5.2.1 Case reports
Case 1 (TV.31 - 1973
The pregnancy progressed normally until 32 weeks' gestation, when the uterus was
felt to be enlarged on examination. Abdominal X-ray at 34 weeks showed the fetal
head to be grossly enlarged. Spontaneous labour occurred at 36 weeks and CSF was
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drained by puncture at the time of delivery. Gross hydrocephalus was confirmed
after delivery and the baby survived for about two hours. No further details were
available.
Case 2 (TV.4) - 1974
The post-mortem examination of this baby was carried out by Dr J. Begg at Forth
Park Maternity Hospital, Kirkcaldy.
At the end of this pregnancy Caesarean section was performed on account of massive
hydrocephalus. The heart was beating at delivery but the child did not breathe and
no resuscitation was attempted. At post mortem it was reported that "there were
abnormalities ofthe hands and fingers. There was massive dilatation ofboth lateral
ventricles. The cortex overlying both was paper-thin. There was obviously some
degree ofobstructive hydrocephalus. The other major abnormalities in the head
were the absence ofolfactory nerves and the posterior fossae on each side ofthe
base ofthe skull were poorlyformedThe brain was not fixed.
Case 3 (TV.5) - 1980
The post-mortem examination of this baby was carried out by Dr A.D. Bain at the
Royal Hospital for Sick Children, Edinburgh. The neuropathological study was
carried out by Dr A. Gordon, Department of Neuropathology, Western General
Hospital, Edinburgh.
Late in the pregnancy ultrasound scanning suggested hydrocephalus and labour was
induced at 38 weeks. Caesarean section was performed after failure of the fetus to
progress. The baby weighed 3.8 kg, OFC was 42.5 cm. He gasped at birth and
Apgar scores were 3 at 1 minute and 3 at 5 minutes - no active resuscitation was
given and regular respirations developed at 10 minutes. Examination showed a
grossly hydrocephalic infant with generalised hypotonia and a single right palmar
crease. The head transilluminated. The baby died 8 days later.
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At post mortem, the brain was removed intact and fixed. "There was marked
symmetrical enlargement ofboth cerebral hemispheres which felt grossly cystic. The
major gyral markings appeared to be present except in the parietal and occipital
regions where the gyri were extremely broad. There was ballooning ofthe floor of
the third ventricle. The section showed a very severe hydrocephalus which involved
symmetrically all compartments ofthe lateral ventricles. There was gross bilateral
ventricular dilatation, with only a few mm thickness ofwhite matter overlying the
convexities. There was no septum pellucidum and the corpus callosum was absent;
being represented only by a thin membrane forming a ridge between the lateral
ventricles. The temporal horns were less dilated than the remainder ofthe lateral
ventricles. The anterior part ofthe third ventricle and the foramina ofMonro were
dilated. The basal ganglia were present but were slightly rotated outwards from the
midline. The fourth ventricle, brain stem and cerebellum were normal, but the
aqueduct was completely occluded. Histologically, the aqueduct was represented by
an anterioposterior cleft with closely apposed walls, rather than the usual triangular
shape, the resultant appearance resembling a zip-fastener, the cilia on opposite sides
interlocking with one another. The section through the ventricular wall showed a
reasonably normal cortex, a narrow sheet ofwhite matter and a sub-ependymal layer
ofsmall round cells, with no visible lining epithelium. "
Case 4 - 1990
The only surviving affected individual in this family was born in 1990 (Figure 47).
Ultrasound scanning at 19 weeks gestation had shown no abnormality and elective
Caesarean section was performed at term. The baby had obvious gross
hydrocephalus. The birth weight was 4.7 kg, and apart from a brief apnoea lasting
two minutes his breathing became well established and Apgar scores of 6 at one
minute, 10 at five minutes and 10 at ten minutes were awarded. His OFC was 49 cm
and he had a very large fontanelle and splayed sutures with prominent veins. At
birth, cranial ultrasound showed enormous dilatation of the lateral ventricles, mild
dilatation of the third ventricle and a normal fourth ventricle. The cerebellar vermis
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was normal, and the cerebral cortex only 8 mm thick. His thumbs were noted to be
adducted at birth but this was less apparent later in infancy and he had a normal
pattern of palmar dermatoglyphics. He underwent an immediate ventricular tap from
which pink CSF was obtained and at five days of age a ventriculo-peritoneal shunt
with a right frontal Rickham reservoir was inserted. Cranial ultrasound at 9 weeks
revealed absence of septum pellucidum and corpus callosum and CT scanning at age
8 months confirmed these anatomical abnormalities, with "a complicated midline
dysraphic problem with probable partial agenesis ofthe corpus callosum". At the
age of 10 months there was evidence of premature fusion of the sagittal and coronal
sutures. Morcellation of the skull was performed in which bone was removed from
the perisaggital suture and the coronal area. Formal psychological assessment at the
age of 2 years placed the boy's performance in various areas in the 6-10 months
range.
Therefore, the clinical and pathological investigations of affected males in Family K
established an unequivocal diagnosis of X-linked aqueductal stenosis. Linkage
analysis was carried out so that carrier females in this family could be offered future
prenatal diagnosis. Unexpectedly, this resulted in negative LOD scores with markers
which were previously shown to be linked to HSAS. For this reason, many other
markers were analysed in distal Xq until positive linkage was eventually obtained





DNA was extracted from blood from all family members (except 1:2,111:1 and the
deceased individuals IV:3, 4, and 5) as described in 6.1.1.1, Paraffin embedded
sections of brain were available from individual IV:5 but although I was able to
extract DNA (6.1.1.5) from this tissue (it could be seen on an EtBr stained agarose
gel), I could not PCR amplify the DNA with any CA repeat primers. The twins 111:2
and 111:3 were shown to be monozygotic by multilocus DNA "fingerprinting" using
the hypervariable probe 33.15 (as described in 6.1.6).
Initially, markers in Xq28 (DXS52, DXS15 and F8C) were analysed because these
had previously been shown to be very closely linked to HSAS. Later, other markers
within Xq28 and Xq27.3 were analysed. The markers which were analysed by
blotting and hybridization (6.1.2 and 6.1.3) are shown in Table 22 and markers
analysed by PCR are shown in Table 23. PCR reactions were carried out as
described in (6.1.4) using either a radioactive method (6.1.4.a and 6.1.4.b) or a
fluorescent method (6.1.4.c). Two exceptions were the FMR1 CGG repeat which
was carried out as in 6.1.4.1 and the DXS52 VNTR which was carried out non-
radioactively. In the latter system the repeat unit is approximately 60bp long and
therefore alleles which differ by only one repeat can be distinguished on a 1%
agarose gel stained with EtBr (Richards et al., 1991).
The initial results obtained in Family K with Xq28 markers (DXS52, DXS1177,
DXS15, F8C and DXS1108) are shown in Figure 48 (page 177).
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Locus Probe Enzyme Alleles (kb) Reference
DXS152 cX33.2 ApaLl 12,8.3 Arveiler et al., (1988b)
DXS105 55.E Pstl 16,10 Mandel et al., (1986)
DXS477 2-34 Taql 2.8,2.0 Rousseau et al., (1991)
DXS465 Do33 BgR 23,16 Rousseau et al., (1991)
DXS296 VK21A Taql 10.9,9.9 Suthers et al., (1989)
DXS304 U6.2 Taql 7,3.3 Dahl et al., (1989c)
DXS15 DX13 Bgia 5.8,2.8 Drayna et al., (1984)
Table 22. DNA probes analysed by radioactive hybridization. F814* is a 'hybrid' probe
which detects a F8C Bell diallelic polymorphism in addition to the VNTR at DXS52.
Location Locus Reference Primers (5'-3') Anneal
temp.















































Table 23. Microsatellites analysed by PCR. The marker DXS1177 was originally named
p26 (Wehnert et al., 1993).
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Other markers which were typed in Family K but which were uninformative (i.e.
individual 11:2 in Figure 48 was homozygous) were:
CDR1, DXS98, DXS369, DXS297, DXS463, DXS305, F8C (IJindUl and Bell
polymorphisms), and DXS115.
5.3.2 Linkage analysis
Two-point linkage analysis was carried out using MLINK. As in the previous two
chapters, the disease segregating in this family is also reproductively lethal. An
arbitrary mutation rate of 1 x 10"5 and a corresponding gene frequency of
3 x 1CT5 were again chosen (assuming that male and female mutation rates are equal
and the population is at equilibrium). Complete penetrance for the disease was
assumed. The deceased individuals IV:3, IV:4 and IV:5 were coded as affected and
the monozygotic twins (111:2 and 111:3) were coded as one individual with two
partners (because coding them as two individuals would artificially increase the LOD
score by adding another informative meiosis). The alleles of each of the
microsatellites were assumed to occur at equal frequencies and for the dimorphic
markers, the published frequencies were used.
The results of the pairwise linkage analysis are shown in Table 24 (page 182).
Multipoint analysis was also carried out as described previously (Chapters 3 and 4)
before using the LINKMAP component of FASTLINK and genetic distances as
shown in Figure 50. Fifteen overlapping five-point analyses (four marker loci and
the disease locus) were carried out in this family. For the purposes of the LINKMAP
analysis the mutation rates were set at zero. Genetic distances were converted into
recombination fractions using the Kosambi mapping function prior to the calculation
and reconverted to cM afterwards. Multipoint LOD scores were calculated from
location scores and plotted against genetic distance (using the marker DXS984 as the




The initial results obtained with Xq28 markers (DXS52, DXS1177, DXS15, F8C and
DXS1108) in Family K are shown in Figure 48.
Figure 48. Pedigree of Family K showing haplotypes for Xq28 markers which had been
shown to be linked to HSAS. Symbol designations are the same as in Figure 46. The
markers are shown on the pedigree in chromosome order i.e. —> Xter. Black bars have been
arbitrarily assigned as the affected haplotype from individual IV:7.
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It was apparent from the preliminary results (Figure 48) that the disease (which was
undoubtedly X-linked aqueductal stenosis) in this family did not segregate with
Xq28 markers. Two normal males in generation III have inherited the same Xq28
haplotype as the affected boy. To exclude the possibility of a sample mix-up, a fresh
blood sample was obtained from each member of the family and the DNA analyses
repeated, confirming the original results. The pedigree structure was also verified by
by multilocus fingerprinting using the probe 33.15, on both sets of samples.
Furthermore, the affected boy has inherited the great-grandpaternal haplotype. Since
linkage appeared to be excluded from this region, a search for linkage to other
regions of the X chromosome was initiated. Twenty five markers were subsequently
analysed in Xq28 and Xq27 and the 16 which were informative are shown on the
pedigree in Figure 49.
In the construction of this pedigree, individual 11:2 was taken as the starting point and
the haplotypes of her offspring drawn as if 11:2 had inherited a non-recombinant X
chromosome from her mother (1:1). Haplotypes are drawn with markers in
chromosome order (Xq27.1 to Xq28). For markers analysed by alkali blotting and
radioactive hybridization, the actual sizes of alleles in kb are indicated on the
pedigree; for CA repeats, alleles are denoted as numbers, beginning with 1 for the
largest allele in the family; and for the FMR1 CGG repeat, alleles are marked as
repeat number. Inferred results are in brackets; if a result is unknown or cannot be
inferred this is indicated by a "?". Six individuals in the pedigree are marked with a
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Figure 49. Results of DNA analysis in Family K. The structure of the pedigree, symbol
designations and bar codes are the same as in Figure 48. See text for further explanation.
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5.4.2 Linkage analysis
The results of the two point linkage analysis are shown as a LOD score table (Table
24) with maximum LOD scores (Zmax) at recombination fractions (0). Only
informative markers were used in the two-point linkage analysis. The result of the

































Figure 50. Genetic distances between
informative markers analysed in Family K.
The order of markers was taken from
Willard et a!., (1994) and Fain et al.,
(1995). Figures on the left are genetic
distances (cM) and were taken from a
number of sources. Intermarker distances
involving markers in bold were taken from
Fain et al., (1995). Distances involving
underlined markers were taken from the
following: DXS1113 (Weber et al., 1993);
DXS1177 (Wehnert et al, 1993). These
were reported as physical distances and
converted to cM on the assumption that
1Mb approximately corresponds to lcM
(Ott et al, 1991).
For the LINKMAP analysis these genetic
distances were converted from cM to
recombination fractions (shown on the
right) using the Kosambi mapping
function. Markers in brackets were
excluded from the LINKMAP analysis
because, either the genetic distances
involving these markers were
unobtainable, or the distances between two
adjacent markers was zero.
There is some uncertainty about the exact location of the marker DXS152. According
to the HGMP RC Genome Database it lies distal to DXS105 but according to Willard et
al. (1994) and Nelson et al. (1995b) it is as shown here. However, in this family this
discrepancy is irrelevant because there are no recombinations between DXS152 and the
adjacent loci.
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LOD scores at 9 of:
Locus 0.0 0.01 0.05 0.1 0.2 0.3 0.4 ^max ©max
DXS984 -2.54 -0.14 0.52 0.73 0.78 0.61 0.32 0.79 0.15
DXS152 -2.54 -1.43 -0.19 0.24 0.49 0.43 0.24 0.49 0.20
DXS105 -2.54 -1.43 -0.19 0.24 0.49 0.43 0.24 0.49 0.20
DXS691 -2.54 -1.77 -0.53 -0.05 0.26 0.25 0.11 0.28 0.25
DXS548 2.16 2.15 2.07 1.94 1.58 1.12 0.57 2.16 0.0
DXS477 2.16 2.13 1.97 1.77 1.32 0.81 0.27 2.16 0.0
FMR1 2.16 2.15 2.07 1.94 1.58 1.12 0.57 2.16 0.0
DXS465 1.56 1.55 1.48 1.38 1.11 0.75 0.33 1.56 0.0
DXS296 -2.54 0.15 0.78 0.97 0.95 0.73 0.37 0.97 0.10
DXS11J3 -2.54 -2.19 -1.08 -0.56 -0.14 -0.01 0.01 0.01 0.35
DXS304 -2.54 -1.94 -0.75 -0.27 0.08 0.15 0.10 0.15 0.30
DXS52 -2.54 -2.51 -1.72 -0.96 -0.27 0.00 0.07 0.07 0.40
DXS1177 -2.54 -1.77 -0.53 -0.05 0.27 0.28 0.17 0.30 0.25
DXSJ5 -2.54 -1.77 -0.54 -0.07 0.23 0.25 0.14 0.26 0.25
F8C -2.54 -1.78 -0.59 -0.15 0.11 0.11 0.06 0.12 0.25
DXS1108 -2.54 -1.77 -0.53 -0.05 0.27 0.28 0.17 0.30 0.25
Table 24. Results of two-point analysis in Family K for all informative markers (as shown
on the pedigree in Figure 49).
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Distance (cM)
Figure 51. Results of the LINKMAP analysis in Family K using genetic distances as shown
in Figure 50. The marker DXS984 (not shown) was used as the starting point (OcM). As
before, the location scores produced by LRP were converted to multipoint LOD scores and a
negative LOD score cut-off point of -6 was chosen. The maximum multipoint LOD score
obtained in this analysis was 2.71 with the microsatellite DXS548 and the FMR1 CGG
repeat. Markers shown in brackets were excluded from the LINKMAP analysis for the
reasons described in Figure 50. The two markers in boxes were also excluded from the
analysis because their chromosomal locations are unknown. Ten evaluations were carried
out in the interval between DXS105 and DXS548.
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Conclusions so far
The clinical and neuropathological studies on the four males in this family have
established an unequivocal diagnosis of "classical" X-linked hydrocephalus.
However, linkage analysis using markers which are known to be closely linked to the
LICAM locus gave negative LOD scores. Positive LOD scores were obtained with
markers at, and close to, the FMR1 locus. In addition, multipoint analysis also
showed that the most likely location for the disease locus in Family K was at the
FMR1/DXS548 locus pair. These data led to the assumption that there must be a
second gene for HSAS which is located in Xq27.3 and this was reported as such
(Strain et al., 1994b). The putative second locus was named HSAS2. As expected,
the possibility of genetic heterogeneity in HSAS caused some alarm among the
genetics community because of the implications for prenatal diagnosis of the disease
with linked markers (Serville et al., 1993). For this reason, we advocated that
prenatal diagnosis of HSAS using linked markers should only be carried out in
families which were large enough for linkage to HSAS1 to be demonstrated (Strain et
al., 1994c).
Identification of an LICAM mutation in Family K
Several months after the linkage analysis in Family K had been carried out, DNA
from the living affected male (IV :7) was screened for a mutation in the LICAM gene
by SSCP analysis (this was carried out by Monique Jouet and Susan Kenwrick,
Addenbrooke's Hospital, Cambridge). A single mobility shift for exon 23 of the
LICAM gene was detected (Jouet et al., 1996). Sequencing of PCR product of this
exon revealed a single adenosine deletion at position 3088 within the LI coding
sequence. The effect of this would be the insertion of 72 novel amino acids and a
premature stop codon (UGA) after amino acid 1029 of the mature protein.
Heteroduplex analysis was carried out on all family members and six individuals
were found to carry the mutation (marked with a cross on the pedigree in Figure 49).
The heteroduplex analysis showed complete segregation of the mutation with the




The possibility of genetic heterogeneity in HSAS could therefore eventually be
refuted but explanations for the discordance between the mutation analysis and the
linkage data in this family were sought. Three hypotheses are proposed:
1. Somatic and gonadal mosaicism tgermline or germinal mosaicism) in 11:2
The most probable (because it's the most parsimonious) explanation for the
discrepancy in this family is that of somatic and gonadal mosaicism in 11:2.
Examination of the pedigree (Figure 49) shows that the affected Xq28 haplotype in
11:2 (shown in black) has been derived from her father (1:2) As HSAS is
reproductively lethal and the disease is fully penetrant, 1:2 must be normal. This
implies, therefore, that a de novo mutation has occurred in 11:2 (on her paternally
derived X chromosome). 11:2 has passed on the same haplotype, with a mutation to
the twins (111:2 and 111:3) and to 111:8, and without a mutation to her normal sons
(111:6 and III: 11). This suggests that she has two populations of gametes:- XX and
XX+, where X+ is the chromosome carrying the LICAM mutation. Furthermore, as
the mutation was found in DNA from two separate samples of her peripheral blood
(Jouet et ah, 1996), 11:2 must be a somatic as well as a gonadal mosaic, which
indicates that the mutation occurred early in embryogenesis, before the partition of
the gonadal and somatic cell lines (day 5-6 post conception).
Combined gonadal and somatic mosaicism has been reported elsewhere for a number
of X-linked and autosomal diseases: haemophilia A (Brocker-Vriends et al., 1990);
haemophilia B (Sommer et al., 1995); Duchenne muscular dystrophy (Bunyan et al.,
1994); Ehlers-Danlos syndrome (Kontusaari et al., 1992); retinoblastoma (Kato et al.,
1994) and osteogenesis imperfecta (Bonaventure et al., 1992).
A similar situation to that which has occurred in Family K was reported by Arveiler
et al. (1990) in a family with Wiskott-Aldrich syndrome. Linkage analysis using the
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hypervariable marker DXS255 (which is known to be closely linked to the WAS
locus) gave negative LOD scores. This prompted a search for linkage to other
regions of the X chromosome but when this proved fruitless, they considered the
possibility of gonadal mosaicism in the grandfather of the affected boys. If this was
the case, the WAS mutation would then be expected to be carried on the
grandpaternal haplotype, although they could not prove this directly since the
affected boys were dead. They were able to show, however, that the grandmother
was not a WAS carrier by X-inactivation studies (WAS carriers have skewed X-
inactivation).
In Family K, the possibility of gonadal mosaicism for the LICAM mutation in the
maternal grandfather of the affected boy had been considered as an explanation for
the negative LOD scores. However, this was ruled out because his Xq28 haplotype
(.DXS52, DXS1177, DXS15, F8C, DXS1108: 2, 3, 5.8, 1, 3) has been passed through
the obligate carrier (111:2) to her normal son (IV: 1). In addition, the Xq28 haplotype
inherited by the affected boy (IV: 7) is grandmaternal.
2. Two double crossovers
Apart from the discordant linkage data, one very unusual feature of the DNA analysis
in Family K is obvious from examination of the haplotypes in Figure 49, and that is,
there is an unexpectedly high frequency of recombination in this family irrespective
of the segregation of the disease. In particular, there is 1 recombinant (111:5) between
DXS296 and DXS1113 (0 = 0.007), 1 (111:6) between DXS691 and DXS548 (0 <
0.182), 1 (111:7) between DXS465 and DXS296 (0 « 0.006), 1 (111:8) between DXS52
and DXS1177 (0 = 0.09), and 2 recombinants (III. 10, III. 12) between DXS304 and
DXS52 (0 = 0.084). A crossover has also occurred in IV:6 somewhere between
DXS296 and DXS52 (her mother is homozygous at these loci so the exact region is
unknown).
LI CAM is situtated between DXS15 and F8C. A double recombination event in
meiosis in 11:2, within this interval, could move L1CAM to the opposite chromosome
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while maintaining phase between the flanking markers DXS15 and F8C although
such a recombination would have gone unnoticed. However, two such double
recombination events would have to have occurred (giving rise to 111:6 and 111:11) in
order to explain the pedigee data. However, no recombinations have been reported
between these loci (and therefore the genetic distance is reported to be OcM; Fain et
al., 1995) which makes the probability of a double crossover within this interval
infinitesimally small. Also, this possibility would still require the occurrence of a
new mutation in spermatogenesis in 1:2, since the affected haplotype for the
DXS1177-DXS1108 region is 1, 2.8, 3, 1, that carried on II:2's paternally derived X
chromosome.
3. Chromosomal rearrangement
It is theoretically possible that a cytogenetic rearrangement in Xq28 has occurred in
this family. Because of this, detailed cytogenetic analysis of the carrier female III.8
was carried out by Professor Christine Gosden (MRC Human Genetics Unit,
Edinburgh). Fresh blood samples were subjected to high resolution banding which
failed to reveal any abnormalities of the Xq27-q28 region (further details of the
cytogenetic analysis are reported in Strain et al. (1994b)).
Although a rearrangement on one X chromosome is feasible, such an occurrence
would be expected, if anything, to suppress local recombination, rather than to
increase it. Furthermore, there is no evidence from the pedigree in Figure 49 of any
double recombinations which one might expect if local chromosomal rearrangements
had occurred. Multicolour FISH might be able to resolve whether there are any
structural anomalies of distal Xq, although this would be extremely complex
because, in order to space markers at 1 Mb intervals, for example, 10 markers would
be needed and would have to be used in multiple combinations.
Despite these residual uncertainties, the important issue in this family is that prenatal
diagnosis can be carried out in future male pregnancies and this would simply be
done by an LICAM exon 23 mutation detection.
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One simple way of distinguishing hypothesis 1 from hypotheses 2 and 3 would be to
analyse the family with an intragenic polymorphism. Under the first hypothesis, 11:2
(if she was informative) would have passed the same allele to 111:6 and III: 11 as to
the carrier women. On the other hand, if she passed the same allele to all the
unaffected males and the opposite one to the carriers, this would support a local
rearrangement. DNA from 11:2 was analysed with the DNA probe p2HK13 (Willems
et al., 1991) but she was uninformative. There is likely to be a CA repeat within
LICAM but until recently only cDNA sequence was available. Now that the
complete gene sequence is accessible at the HGMP resource centre it will be easy to
search for a CA repeat within the gene.
The nature of the LICAM mutation found in this family is further supporting
evidence that the singe adenosine deletion is responsible for the disorder in Family
K. Three other mutations have been identified in three independent HSAS families
(also with severe phenotypes) which result in truncation of the LI protein prior to the
transmembrane domain (Jouet et ah, 1996).
It is now clear that the negative LOD scores were obtained in this family because
individuals 111:6 and 111:11 are normal males who carry the affected Xq28 haplotype.
Equally, the positive LOD scores (2.16) obtained with FMR1 and DXS548 can be
explained by the five normal sons of 11:2 having inherited the opposite Xq27.3
haplotype to the one inherited by the affected boy (IV: 7) and the obligate carrier
females. The only discordant individual in this family is the normal individual (11:3)
who has the same Xq27.3 haplotype as the affected boy (IV:7).
Finally, there were two interesting observations concerning the FMR1 CGG repeat in
this family. First, the disease appeared to segregate with a rare CGG repeat allele
which is estimated to consist of 46 repeats. This is in the intermediate range (45-60)
between normal and premutation alleles and according to our data (Chapter 2, Table
11), alleles of n=46 make up less than 0.2% of the total population. The second
observation was that, in the meiosis which resulted in the twins (111:2 and 111:3), the
188
CGG repeat has increased by one repeat to consist of 47 CGG triplets. This must
have taken place very early in embryogenesis, or more likely as a meiotic event, as
the change in size occurred in both twins (providing confirmation that they are
monozygotic). For the linkage calculations this allele was assumed to consist of 46
CGG repeats.
The faint possibility that instability of the repeat could be involved in the disease was
eliminated by Southern blotting using the probe StB12.3 on Hindlll digested DNA
(as described in 6.1.2 and 6.1.3). This showed homogeneous, normal-sized bands in





6.1.1.1 Peripheral blood and cord blood
DNA was extracted from 5-20 mis of whole blood by an adaptation of two published
methods. Initially, erythrocytes were lysed in a solution containing NH4C1
(150mM), NaHC03 (lOmM) and Na2EDTA (0.1 mM), pH7.4 (Topic and Gluhak,
1991). The leucocyte pellet obtained after centrifugation and washing in this
solution was resuspended in 3ml Tris-HCl buffer (50mM, pH7.4) containing NaCl
(lOOmM) and Na2EDTA (ImM). Proteinase K (100p.g/ml) and SDS (lOmg/ml) were
added and samples incubated at 37°C overnight. DNA was "salted-out" of this
solution by the addition of 1ml of 6M NaCl as in Miller et al. (1988). DNAs were
adjusted to a final concentration of 0.5mg/ml by the addition of TE buffer (lOmM
Tris-HCl, ImM Na2EDTA, pH8.0). DNAs prepared from peripheral blood did not
usually require further purification by phenol-chloroform extraction. For DNA
extraction from blood from young children, where the sample volume received was
often less than 1 ml, the method was scaled down accordingly.
6.1.1.2 Chorionic villi
DNA was extracted from CVS (which had been sorted to remove maternal decidua)
according to Old (1993). The villi were washed in 0.5ml of 150mM NaCl, 25mM
Na2EDTA, pH8.0, centrifuged briefly and the aqueous layer removed. The villi were
resuspended in the same buffer with the addition of 0.1% SDS and 50pg/ml
proteinase K and incubated overnight at 37°C. Two phenol/chloroform/isoamyl
alcohol (25:24:1) extractions and one chloroform/isoamyl alcohol (24:1) extraction
were carried out. 250pl of 7.5M ammonium acetate was added to the final aqueous
layer. This was mixed thoroughly and DNA precipitated by the addition of 1.5ml of
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absolute ethanol. The DNA was washed with 70% ethanol, dried and dissolved in
TE buffer.
In addition, for each CVS, three individual fronds of tissue were separated from the
bulk of the cleaned tissue and placed in individual tubes. These pieces of tissue were
washed in the above buffer and then treated exactly as for mouthwash samples
(6.1.1.4). This provides material which can only be PCR amplified but is useful for
obtaining a rapid preliminary result.
6.1.1.3 Fetal blood
DNA was extracted from fetal cord blood using a lysis buffer containing lOmM Tris-
HC1 (pH8.0), 320mM sucrose, 5mM MgCf>, and 1% Triton X-100, followed by
incubation with Proteinase K (50 pg/ml) and SDS (0.1%) overnight at 37°C. The
DNA was purified by phenol-chloroform extractions as for chorionic villi. The
sucrose/Triton based buffer was used to lyse the fetal erythrocytes because they are
resistant to lysis in the NH4C1 based buffer used on other blood samples.
6.1.1.4 Mouthwash samples
Mouthwash samples (each approximately 10ml) were centrifuged to pellet the buccal
cells which were resuspended in 0.5ml 0.05M NaOH. This was transferred to a
screw-cap 1.5ml tube and boiled for 20 minutes. 50pl of 1M Tris-HCl, pH7.7 was
added and the tube centrifuged for 5 minutes to pellet debris. 3-5 pi of the
supernatant was used for PCR.
6.1.1.5 Paraffin embedded tissue
DNA was extracted from paraffin embedded tissue from an adaptation of a method
described in Jackson et al. (1991). A 5pm tissue section was suspended in 100 pi of
digestion buffer (lOOmM NaCl, lOmM Tris-HCl pH8.0, 25mM Na2EDTA, 0.5%
SDS) and O.lmg/ml of Proteinase K was added. This was incubated at 37°C for 48
hours. Two phenol/chloroform/isoamyl alcohol (25:24:1) extractions and one
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chloroform/isoamyl alcohol (24:1) extraction were carried out. DNA was
precipitated by the addition of 10 pi of 3M sodium acetate (pH5.2) and 2 volumes of
cold ethanol and pelleted in a microcentrifuge at 13,000g. The DNA was dried and
resuspended in distilled H20. 1-5 pi aliquots were used for PCR.
6.1.2 Alkali blotting
5-10pg of DNA was digested with appropriate restriction endonucleases in a volume
of 50pl and electrophoresed in 0.8% agarose gels in 1 x TAE buffer (0.04M Tris-
acetate, 0.001M EDTA) containing 0.5pg/ml ethidium bromide. Gels were
depurinated in 0.25M HC1 and blotted on to Hybond N+ membrane (Amersham) in
0.4M NaOH. DNA probes were prepared by one of the following methods:
i) Excision of the insert from the plasmid by digestion with appropriate restriction
endonucleases. The insert and plasmid were separated by electrophoresis in 1.2%
low melting point agarose and the agarose containing insert labelled directly
without further purification.
ii) Amplification across the insert with flanking PCR primers. PCR products were
purified by adsorption onto glassmilk (Vogelstein and Gillespie, 1979).
6.1.3 Hybridization
DNA probes (30-50 ng of insert) were labelled by the random priming method
(Feinberg and Vogelstein, 1984) overnight at room temperature or for approximately
4 hours at 37°C. Hybridizations were carried out overnight at 65°C in a mix
containing 5 x SSC (0.75M NaCl, 0.075M tri-sodium citrate), 5 x Denhardt's (0.1%
PVP, 0.1% BSA, 0.1% Ficoll), 0.1% SDS, 0.1% sodium pyrophosphate, 10%
dextran sulphate, and lOOpg/ml sonicated denatured herring testes DNA. Filters
were washed at 65°C to a final stringency of 0.5 x SSC and autoradiographed with
intensifying screens for an average of 2 days.
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6.1.4 Polymerase chain reactions (PCR)
Unless otherwise stated all PCR reactions were carried out in 50 pi volumes and
contained the following ingredients:
Stock Final concentration
5 pi dNTPst 2m M 200pM of each dNTP
5 pi 10 x buffer1 10 x 1 X
1.25 pi forward primer lOpM 0.25pM
1.25 pi reverse primer lOpM 0.25pM
250 ng DNA
1U Taq polymerase 5U/pl
H20 to 50pl
+deoxy nucleotide tri phosphates - consisting of equimolar amounts of dATP, dCTP, dGTP,
dTTP. *10 x PCR buffer is lOOmM Tris-HCl (pH8.3), 500mM KC1, 15mM MgCl2.
For CA repeat polymorphisms, PCRs were carried out in one of three ways:
32
a) Incorporation of a-~P-dCTP
32
2pCi of a- P-dCTP (3000Ci/mmol) were added to the reaction mix as above prior to
cycling. 2pl of product were added to 2pl of formamide loading dye (98% deionized
formamide, 0.025% xylene cyanol FF, 0.025% bromophenol blue, lOmM EDTA
pH8.0). Samples were denatured at 98°C for 5 minutes and electrophoresed in a 6%
denaturing gel (6% acrylamide 29:1, 7M urea) at 70W in lx TBE buffer (0.089M
Tris, 0.089M boric acid, 0.002M EDTA, pH8.0). The length of the run depended on
the size of the product. The gel was dried without fixing and autoradiographed for
1-2 days.
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b) 5' end labelling of one primer with y-~P-ATP
Labelling reactions consisted of:
40 ng of primer per sample
5 jul (10 x PNK buffer1)
4 pi y-32P-ATP (40 pCi)
10U T4 polynucleotide kinase (PNK)
H20 to 50 pi
+ 10 x PNK buffer is 500mM Tris-HCl (pH7.6), lOOmM MgCl2 50mM dithiothreitol, ImM
spermidine HC1, ImM EDTA (pH8.0).
These were incubated at 37°C for 1 hour followed by 10 minutes at 65°C to
inactivate the enzyme. PCR reactions and electrophoresis were carried out as above.
c) Fluorescein tagged primer
One of the pair of PCR primers was conjugated at the 5' end with FluorePrime™
amidite (Pharmacia). This allows the addition of a linker bearing fluorescein to the
5' end of the oligonucleotide during the last step of automated synthesis on the
Pharmacia Gene Assembler. PCR products were denatured in formamide loading
dye (95% formamide, 20 mM EDTA and lOmg/ml Dextran blue 2M), and analysed
on the automated laser fluorescent sequencer (A.L.F., Pharmacia) in a 6% denaturing
acrylamide gel. Gels were run in 0.6 x TBE at 40W.
A size marker for A.L.F. was prepared by amplifying sections of the ApoB
(Apolipoprotein B) gene in a multiplex PCR reaction. Primers were designed from
published sequence so that the final product consisted of a ladder ranging from 100
to 500 bp in 50 bp increments. Two multiplex PCRs were required; one producing
100-200 bp fragments and the other producing 250-500 bp fragments. The forward
primer in each case had been 5' end labelled with fluorescein during synthesis as
described above.
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All PCR reactions were carried out in a Perkin Elmer thermal cycler usually under
the following cycling conditions:
94°C 5 mins
x°C 1 min =>
72°C 1 min
(1 cycle)





=> 72°C 10 mins
6.1.4.1 PCR of the fragile X CGG repeat
PCR amplification across the CGG repeat was carried out essentially as in Fu et ah,
(1991) with the following modifications: 100-250ng of DNA was used in a final
volume of 15pl, 10% glycerol was included, and the number of cycles increased to
35. 2pCi of a-32P-dCTP was used per reaction and 2p,l of product was
electrophoresed in 5% denaturing sequencing gels in 1 x TBE at 70W for 31/2 hours.
Gels were dried without fixing and exposed as above.
The PCR primers used were (Figure 5)
c 5' GCTCAGCTCCGTTTCGGTTTCACTTCCGGT 3'
f 5' AGCCCCGCACTTCCACCACCAGCTCCTCCA 3'
An allele containing 30 repeats corresponds to a product of 308bp. The size marker
used for the sequencing gels was pBR322 plasmid digested with Mspl and end-
labelled with y-32P-ATP or y-33P-ATP.
6.1.5 PCR of the fragile X CCG repeat using a fluorescently labelled primer.
PCR was carried out as above using the same primers c and f except that primer c
had been 5' end labelled with fluorescein during synthesis as described above.
Samples were loaded onto A.L.F. as described previously.
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6.1.6 Multilocus fingerprinting
This was carried out using the repeat unit multipriming (RUMP) method (Ferrie et al.
1991) to label the probe 33.15 (Jeffreys et al., 1985). DNA (2|ug) was digested with
Hinfi and electrophoresed in a 0.8% agarose gel in recirculated 1 x TAE for 48
hours. Alkali blotting was carried out as above. Filters were pre-hybridized in 0.5 M
sodium phosphate buffer (pH7.2), 1% SDS at 62°C for 45 mins and then hybridized
overnight at 62°C in 0.2M sodium phosphate buffer (pH7.2), 1% SDS, 1% BSA, 6%
PEG 6000 and 0.5 ng/ml labelled probe. After hybridization, filters were washed
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SUMMARY
Direct detection of the fragile X mutation by DNA analysis has greatly simplified prenatal diagnosis of this
disease. However, women carrying a fragile X premutation may pass their expanded trinucleotide repeat to sons
without expansion to a full mutation. Such sons are predicted to be intellectually normal. In this situation, the
accuracy with which the fetal status can be inferred from analysis of chorionic villus sample (CVS) DNA is unclear.
We describe such a case, in which it was felt necessary to proceed to fetal blood sampling despite technically
unambiguous DNA results from the CVS. The lack of prospective data means that this dilemma may be expected
to recur over the next few years when performing prenatal diagnosis on fragile X premutation carriers.
key words—Fragile X, unstable DNA, premutation, fetal blood sampling, PCR, Southern blotting.
INTRODUCTION
Fragile X syndrome (reviewed in Hirst et al.,
1992) is the commonest inherited cause of mental
handicap. It is transmitted in an X-linked semi-
dominant fashion, with females typically being
more mildly affected than males. Affected males
may show suggestive physical features (the Martin-
Bell phenotype), consisting of long face and ears,
rather coarse features, and post-pubertal macro-
orchidism. However, the phenotype may go un¬
noticed, and cannot be relied upon to make the
diagnosis. Laboratory tests therefore play a crucial
role in the clinical management of fragile X.
The fragile X phenotype is the consequence of
inactivation of the FMR1 gene, located at Xq27.3.
This may result from deletions (Gedeon et al.,
IPresent address: Department of Obstetrics, University of
Liverpool, P.O. Box 147, Liverpool, U.K.
Addressee for correspondence: Lisa Strain, Human Genetics
Unit, University of Edinburgh, Western General Hospital,
Crewe Road, Edinburgh, EH4 2XU, U.K.
1992; Wohrle et al., 1992) or point mutations
(De Boulle et al., 1993), but usually results from
transcriptional silencing of the gene secondary to
massive expansion of a trinucleotide repeat
(CGG)„ located within its first exon. Trinucleotide
repeat expansion is accompanied by methylation
of a CpG island around exon 1, somatic variability
of the repeat length, and expression of the cyto¬
genetic fragile site (FRAXA) from which the
syndrome derives its name (Oberle et al., 1991;
Verkerk et al. 1991; Fu et al., 1991).
Normal individuals have a CGG repeat number
n with 6<«<46 (Fu et al., 1991). Affected individ¬
uals with fragile X have heterogeneous smears seen
on Southern blots, generally reflecting /7>200.
Between these limits is the so-called 'premutation'
range (roughly 50<«<200). A premutation is not
associated with abnormal CpG methylation, and
males or females carrying premutations are pheno-
typically normal (Rousseau et al., 1991). However,
alleles in this range arc unstable when transmitted
from a carrier mother, usually undergoing a
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© 1994 by John Wiley & Sons, Ltd.
470 l. strain ET AL.
further increase in size. With females carrying large
premutations, the probability of expansion to full
mutation approaches 100 per cent, with an appar¬
ently sigmoidal curve determining the risk for
smaller premutations (Fu et al., 1991). Thus, when
the X chromosome carrying a premutation is
transmitted from a carrier mother, two general
classes of outcome are possible: (i) expansion to
full mutation or (ii) transmission of a premutation,
often with some increase in size.
In this paper we describe a prenatal diagnosis in
which a premutation was transmitted to a male
fetus with an increase in size observed in CVS
DNA, giving rise to considerable uncertainty as to
the correct course of further management for the
pregnancy. Because it was not felt possible on the
basis of available data to be confident that the
apparently homogeneous premutation reflected
accurately the situation in the fetus, further fetal
blood sampling was performed at 20 weeks' gesta¬
tion. Direct analysis of fetal blood and subse¬
quently of cord blood obtained at term failed to
show any somatic instability.
MATERIALS AND METHODS
DNA analysis
DNA was extracted from blood by the method
of Miller et al. (1988) and from cleaned CVS tissue
according to Davies (1986). HindAW digests were
performed on 5-10 /ig of DNA, electrophoresed in
0-8 per cent agarose gels, and blotted onto Hybond
N+ in 0-4 m NaOH. Hybridization to the
intragenic probe StB12.3 (Rousseau et al., 1991)
was carried out overnight at 65°C in 5 x SSC,
5 x Denhardt's, 01 per cent SDS, 01 per cent
sodium pyrophosphate, 50 per cent dextran sul¬
phate, and 100/ig/ml sonicated denatured herring
testes DNA. Filters were washed at 65°C to a final
stringency of 1 x SSC and autoradiographed with
intensifying screens for 12^48 h.
PCR amplification across the CGG repeat was
carried out as in Fu et al. (1991) using 2//Ci of
[a32P]dCTP per reaction and electrophoresis of
2 //I of product in 5 per cent denaturing sequencing
gels at 70 W (40 V/cm) for 31 h. Gels were dried
without fixing and exposed as above.
Cytogenetic analysis
Conditions for fragile X analysis of fetal blood
were as described by Gosden et al. (1992). Fragile
X analysis of the CVS was carried out as in
Rooney and Czepulkowski (1992).
RESULTS
Case report
The patient (11.12), a 23-year-old primigravida,
was referred to the genetics clinic at 8 weeks'
gestation because of a family history of fragile X
syndrome. Her family (Fig. 1) had been investi¬
gated 4 years previously, but lost to follow-up.
At that time, the patient and her three sisters had
been given low risks of carrying the fragile X
gene, on the basis of failure to demonstrate
fragile sites in all tested family members except
the proband III. 1. (III.3 had not been tested
at that time.) The family was reanalysed by
Southern blotting and PCR, with the results
shown in Fig. 1.
The presence of two normal CGG alleles in the
mother (1.2), both of which had been passed to
normal sons, confirmed that the dead father (1.1)
was a normal transmitting male who had passed a
premutation to each of his four daughters (Fig. 2,
lanes 3, 4, 7 and 9).
After discussion, 11.12 chose to undergo trans¬
abdominal CVS at 10 weeks' gestation. A male
fetus was demonstrated by PCR of the pseudo-
autosomal boundary region of the Y chromosome
(Ellis et al., 1990) and Southern blotting indicated
the presence of an apparently homogeneous pre¬
mutation (Fig. 2, lane 10). On PCR, this was found
to correspond to an allele which had increased in
size from 74 to approximately 106 repeats (Fig.
3a). Analysis of cultured chorionic villus tissue
showed a 46,XY karyotype with no evidence of
fragile sites in 100 cells cultured in folate-deficient
medium.
On the basis of these data, a low risk of mental
handicap was given, and the pregnancy continued.
It was not felt possible, however, to exclude
mosaicism completely in this pregnancy, and there¬
fore our patient elected for fetal blood sampling at
20 weeks.
Kleihauer testing indicated a sample of 100 per
cent fetal origin. Southern blotting and PCR of
fetal blood DNA (Fig. 3b) again indicated a homo¬
geneous premutation. Cytogenetic analysis of 170
lymphocytes cultured under thymidylate stress
failed to show any evidence for fragile sites.
At term, DNA was prepared from cord blood.
A premutation was again seen on PCR analysis
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Figure 1—Pedigree of family. Affected males are indicated as ■, female premutation carriers as O, female carriers of a full
mutation as ©, and male premutation carriers as U. FRAXA (CGG)„ alleles are denoted as number of repeats, and StB 12.3
alleles as sizes in kb
ck
1 234567 8 9 10
Figure 2—Southern bot of 7/indIII-digested DNA probed with StB12.3
(Fig. 3c) and Southern blotting (Fig. 4a). The
premutation size in CVS and cord blood DNA
appeared identical on PCR. Additional digests of
the cord blood DNA were performed with HindW I
and the methylation-sensitive enzyme BstZ\.
These showed only an unmethylated 3-1 kb band
(Fig. 4b), slightly larger than the corresponding
maternal fragment, confirming that the CpG
island at the 5' end of the FMR1 gene was not
hypermethylated. Culture in folate deficient
medium failed to show fragile sites in 100 cells
analysed.



























Figure 3—PCR amplification of CVS DNA, fetal blood DNA,
and cord blood DNA. Size marker is pBR322 digested with
Msp\
DISCUSSION
Molecular genetic linkage studies have been
important for the prenatal diagnosis of fragile X
for some years; analysis of the segregation of
closely linked polymorphisms (Riggins et al., 1992;
Richards et al., 1991) can still predict with a high
degree of accuracy whether the high-risk FMR1
allele in a family has been inherited by a fetus, but
when the mother is a premutation carrier, it
does not distinguish between a fetus carrying a
premutation or full mutation. Direct analysis of
the fragile X mutation (Rousseau et al., 1991; Fu
el al., 1991), in contrast, in addition to eliminating
the small possibility of error due to recombination,
permits pregnancies such as the one described here
to continue, though they might previously have
been terminated on the basis of a DNA linkage
result. This advance, though, critically assumes
that a normal outcome can be predicted from the
finding of a premutation in CVS tissue.
While there is no reason to question the under¬
lying assumption of a normal outcome for a fetus
inheriting a premutation, the scantiness of current
data does suggest caution in the interpretation of
prenatal tests on CVS material. Some males with
fragile X syndrome are so-called 'mosaics', with a
population of premutation-carrying cells in addi¬
tion to those with the full mutation (Rousseau et
al., 1991; Nakahori et al., 1991). While the
premutation-carrying cells in such males might
perhaps arise from contraction of repeats previ¬
ously in the full mutation range, the alternative
possibility must be considered, of transmission in
the zygote of a premutation, followed by a major
role of mitotic instability in generation of the
population carrying full mutations. Such post-
conceptual instability could in fact be the sole
mechanism of production of full fragile X
mutations; this instability probably only operates
during a small early window of embryonic devel¬
opment (Wohrle et al., 1993; Reyniers et al., 1993).
However, its occurrence raises the worrying possi¬
bility that the distribution of full mutation and
premutation could differ from one tissue to
another. This point is crucial for prenatal diagno¬
sis, when usually DNA from extraembryonic tissue
(chorionic villus) is analysed for the presence of the
mutation. The mechanism or timing of mitotic
instability may differ in chorionic and embryonic
tissue, and therefore it is possible that a large
premutation appearing stable in CVS DNA may
have undergone greater expansion and somatic
instability in the embryo. There is little published
data bearing on this issue, but quantitative differ¬
ences in the distribution of pre- and full mutation
between CVS and fetal DNA have been noted by
Devys et al. (1992), suggesting that there are
indeed grounds for caution.
General implications for fragile X prenatal
diagnosis and screening
A mother's CGG repeat number n determines
the risk of expansion to full mutation. Although







Figure 4—Southern blot of //wdlll-digested DNA (a) and ///ndlll/AvtZI-digested DNA (b)
probed with StB12.3
the absolute value of the risk attached to each
allele size has been questioned on the grounds of
biased ascertainment (Bundey and Norman, 1993),
it is clear that alleles of <50 repeats are very stable
and those >200 very unstable in maternal trans¬
mission. The overall sigmoidal shape of the curve
relating allele size to risk (Fu et al., 1991) is
therefore likely to hold true, and more precise
absolute risks should be obtainable by formal
segregation analysis of families to allow for
proband effects. In general, the smaller the
mother's premutation, the greater will be the
chance of the fetus inheriting a premutation rather
than a full mutation. This makes the relationship
between premutation CGG repeat number in CVS
and embryonic tissue a crucial one, which needs to
be established for a large number of sample pairs.
Additional reports of the outcome of pregnancies,
in which a premutation has been transmitted, are
therefore required. Because of present uncertainty
over the confidence with which fetal premutation
size can be inferred after the finding of a pre¬
mutation in CVS, we currently recommend fetal
blood sampling for further DNA analysis in this
situation. We have already pointed out that this
approach, if it proves not to be overcautious, has
major implications for population screening for
fragile X (Bonthron and Strain, 1993); it implies
that a substantial proportion of the mothers
detected as premutation carriers by any screening
programme may have to proceed to fetal blood
sampling.
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The cadaveric growth hormone is available on the black market
and is about half the price of recombinant growth hormone. The
source of the cadaveric growth hormone is the former Soviet Union
where pituitary-derived growth hormone is still produced. We
presume that this group of growth hormone recipients is not
adequately informed about the potential risk for Creutzfeldt-Jakob
disease and the possible risk of transmission by tissue or organ
donation.
We had the opportunity to analyse a growth hormone ampoule
from the former Soviet Union. The specific activity was low (about
2 U/mg protein) and on sodium dodecylsulphate gel-
electrophoresis was not pure monomelic, which jeopardises the
quality of this hormone. It appears unlikely that suitable
precautions were taken to eliminate slow virus contamination.3
Because this type of growth hormone is used in other countries,
(anecdotally we know of use by weight lifters and body builders in
Germany, Poland, Italy, and Austria), more information should be
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DNA single-strand conformation
polymorphism method to distinguish DR4
alleles
Sir,—Mr Young and Dr Darke (Jan 16, p 183) report that DNA
single-strand conformation polymorphisms (SSCPs) are not ideal
for predicting HLA compatibility for the DR4 group, and these
findings contradict those of Summers and colleagues.1 We have
used our established polymerase chain reaction (PCR)-SSCP
method for DRB1 alleles (unpublished) to examine DR4 alleles.
Eight different DRB1 alleles of the DR4 group from Japanese,
Korean, and Russian (DRB1*0401, 0402,0403, 0404, 0405, 0406,
0407, and 0410) individuals were identified by the PCR-SSO
(sequence-specific oligonucleotide) method2 or by direct
sequencing. SSCP banding patterns are known to vary with the
conditions of electrophoresis, especially gel concentration and
2 3 6
SSCP patterns of HLA-DRB1 alleles in DR4 group.
DRB1 gene exon 2 fragments of HLA-DR4 alleles were selectively
amplified by PCR with primer pair DRBAMP-4 and DRBAMP-B.21 pL
of amplified solution was mixed with 7 (iL of denaturing solution (95%
formamide, 20 mmol/L edetic acid [EDTA], 0 05% bromophenol blue,
and 0 05% xylene cyanol FF), heated at 95°Cfor 5 min, and applied to a
10% polyacrylamide gel (acrylamide/bisacrylamide = 49/1, 5%
glycerol). Electrophoresis was done in 45 mmol/L tris-borate (pH 8 0)
and 1 mmol/L edetic acid at 4"C, followed by silver staining. Genomic
DNAs were obtained from the following blood samples: (1):DRB1*
0407/0803; (2):0401 /1502; (3):0405/-; (4):0403/1201; (5):04
06/0901: (7):0404/0101; (8):0410/1 502; (9):0402/-; (6):mixed
sample of PCR products obtained from (4) and (5).
temperature.3 Furthermore, we found that application of a small
amount of amplified DNA to non-denaturing electrophoresis
followed by silver staining resulted in distinct banding patterns. All
examined DR4 alleles were discriminated both at 4°C (figure) and at
22°C (not shown), including DRB1 *0403 (lane 4) and 0406 (lane 5),
which were not discriminated with the conditions used by Young
and Darke. Lane 6, a mixture of DRB1*0403 and 0406,
discriminated these alleles clearly. All tested alleles of DRB1 in
addition to DR4 were discriminated in our system.
This method can be used not only to discriminate alleles but also
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Population screening for fragile-X syndrome
Sir,—Fragile-X mental retardation syndrome is in many ways,
as stated by G. E. Palomaki and Dr Haddow (Feb 6, p 373), an ideal
target for prenatal screening. Although we, like other UK genetic
units, are considering a fragile-X screening programme, we cannot
agree that "the only significant barrier, at present ... is the
variability in the severity of mental retardation in female offspring
with the full mutation". Palomaki and Haddow ignore important
aspects of fragile-X syndrome that will complicate prenatal
screening.
When a premutation is found in a mother, there are a number of
possible outcomes when the affected chromosome is transmitted.
First, expansion to full mutation may occur. This creates problems
of interpretation in a female fetus because the intellectual outcome is
so variable. While our ability to correlate intellectual outcome to the
results of methylation and other DNA studies might improve, this
may not help prenatal diagnosis. For example, if tissue-specific
variation in the pattern of X-inactivation proves an important
determinant of intellectual outcome, analysis of amniocytes, or
extra-embryonic material obtained at chorionic villus sampling
(CVS) would be unlikely to yield useful information. Those
considering prenatal screening for fragile-X may still have to
communicate a 50% risk of mild mental handicap to mothers
carrying female fetuses with a full mutation.
Second, transmission of a premutation may occur, often with
some increase in size. This should result in a normal outcome, but
caution is needed in interpreting test results, particularly on CVS
material. The existence of affected "mosaic" males, who have cells
carrying premutations and cells carrying full mutations, underlines
the need to consider somatic instability of the fragile-X repeat. The
process of instability development may not be the same in chorionic
and embryonic tissue: a large premutation which appears to be
stable on CVS analysis may have undergone greater expansion and
somatic instability in the embryo. Little has been published on this
issue. However, we have experience of one prenatal diagnosis in
which the degree of somatic instability of a full mutation seen on
chorionic villus tissue was much less than that seen in all fetal tissues
recovered after termination. We currently recommend fetal blood
sampling for further DNA analysis on male fetuses shown to be
carrying large premutations on CVS. This approach may prove to
be overcautious, but it implies that a substantial proportion of the
mothers detected as premutation carriers by a screening programme
may have to proceed to fetal blood sampling.
Third, the risk at which a prenatal test is offered needs to be
defined. A sigmoidal curve relates a mother's CGG repeat number
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n to the risk of expansion to full mutation.1 These data may become
more precise as greater numbers of families are analysed. However,
the lower the cut-off value of n, the greater will be the number of
pregnancies in which the ferns appears to have inherited a
premutation rather than a full mutation Thus, the true risks
attached to finding a premutation at prenatal diagnosis must be
defined before setting a value of n at which testing is offered.
In addition to these biological uncertainties, there are technical
problems hindering implementation of prenatal screening for
fragile-X. These have prevented us from adding fragile-X into the
framework of the Edinburgh trial of cystic fibrosis screening in
antenatal clinics.2 Rapid diagnosis by polymerase chain reaction of
premutations1 on mouthwash samples is in our experience simple
and cheap, but full mutations do not amplify, and full mutation
carriers are not distinguished from the 10-15% of women who are
homozygous for allelic (CGG)n variants within the normal size
range. These full mutation carriers are at the highest risk of having
mentally handicapped offspring, and therefore must be detected by
any programme aiming at high sensitivity. The only reliable
detection method at present involves use ofblot hybridisation. This
is labour-intensive, skilled, and expensive to perform on several
thousand samples annually.
None of these difficulties is insuperable. However, population
screening for fragile-X will undoubtedly be more complicated than
suggested by Palomaki and Haddow. There is a need for trials in
several centres, involving different protocols and analytical
methods, before a consensus can be reached over feasibility and
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Sir,—There is a major flaw in G. E. Palomaki and Dr Haddow's
argument about screening for the fragile-X premutation. They
suggest that nearly half the pregnancies of women carrying the
premutation would result in a child with the full mutation.
However, this figure is based on data obtained from families
ascertained through an affected child, and as such is inevitably
biased. The genetic risk for a woman carrying the premutation and
with no family history ofmental retardation is not known. However,
genealogical studies from Sweden, Finland, and the Netherlands1"3
show that premutation can exist in a family for many generations.
Moreover, studies of the AC repeat sequences that flank the
fragile-X gene show that certain haplotypes are associated with
increased size of the CGG repeat of the gene, even in normal
individuals, providing evidence for only a few ancestral
chromosomes." The risk for a premutation expanding to a full
mutation could be very much less than 1 in 2. More information is
needed on the definitions of the normal gene, the stable
premutation, the unstable premutation, and the genetic significance
of the last two. Until these are known, consideration of screening
healthy women in the population is unwise.
Department of Paediatrics and Child Health,
Clinical Genetics Unit,
Birmingham Maternity Hospital,
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Sir,—We agree with G. E. Palomaki and Dr Haddow that fragile
X syndrome has the high frequency and morbidity necessary to
make carrier screening cost-effective from a societal viewpoint, and
that the test for expansion of the (CGG)n repeat region near the
FMR-1 gene is highly sensitive and specific. However, we feel that
certain factual statements related to clinical and laboratory genetic
aspects ofthis condition are potentially misleading. We also disagree
with their final conclusion.
It is correct that among the unaffected population, only female
individuals need carrier testing if the intent is to discover people at
risk of having affected children. Unaffected male carriers have
premutations that will be inherited by none of their sons and all of
their daughters, who will be unaffected. (Affected males have full
mutations and, although they are usually fertile, generally do not
reproduce.) However, in females it is inaccurate to equate the terms
carrier with premutation, and affected with full mutation.
Unaffected female carriers ascertained by DNA analysis would
include women with either a full or a premutation. Full mutations
remain full if passed to the next generation, whereas premutations
have a probability ofbecoming full that depends on the actual length
ofthe DNA expansion, and can reach 100%. Males that inherit full
mutations are nearly always retarded, and about half the females
that do so are retarded.1
If the mother is identified as having a premutation or full
mutation, then fetal testing is available. Fetal cells from chorionic
villus sampling (CVS) or amniocentesis can be used but CVS offers
the advantage of earlier detection. Despite the reliability of direct
DNA analysis, simultaneous cytogenetic analysis for the presence of
the fragile X site is recommended. The combined data are
important in the final interpretation of the risk for affected versus
carrier offspring, especially in the female ferns. A range ofobserved
outcomes and probabilities would be given, allowing the parents to
make an informed decision.
DNA-based fragile X screening of pregnant women with a
suggestive family history in their extended families has been
initiated by at least two groups,2-3 who reported screening results for
103 and 40 women, respectively. 2 pregnant carrier females were
identified in the 103 family study, with no previous known history
of fragile X. This group of patients, at least, should continue to be
offered screening for fragile X. However, a positive family history is
not essential for a female to be a carrier. In the past 6 months in our
prenatal clinics, several pregnant women with a negative family
history have requested fragile X screening. We support the test
being offered to informed patients, most of whom would have
clearcut test results, and advocate fragile X testing more broadly to
members of the prenatal female population.
Genetics and IVF Institute,
Fairfax, Virginia 22031, USA;
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Simple analgesics versus NSAIDs for
osteoarthritis
Sir,—Professor Dieppe and colleagues (Feb 6, p 353) correctly
note the lack of peer-reviewed clinical trials of simple analgesic
versus non-steroidal anti-inflammatory drugs (NSAIDs) in
patients with osteoarthritis, and suggest that the absence of such
studies can be attributed to the fiduciary interests of the
pharmaceutical manufacturer.
In describing the very few studies that provide this comparison
these workers refer to our comparison ofpatients with osteoarthritis
ofthe knee treated with ibuprofen 1 -2 g or 2-4 g daily or paracetamol
4 g daily.1 Their table summarising our results indicates that
ibuprofen, in comparison with paracetamol, significantly improved
pain at rest. It is misleading, however, to summarise the results of
our study by that point alone. All 3 ofour treatment groups showed
Am. J. Hum. Genet. 54:236-243, 1994
Genetic Heterogeneity in X-linked Hydrocephalus:
Linkage to Markers within Xq27.3
L. Strain,* C. M. Gosden/ D. J. H. Brock,* and D. T. Bonthron*
•Human Genetics Unit, University of Edinburgh, and tMedical Research Council Human Genetics Unit, Western General Hospital, Edinburgh
Summary
X-linked hydrocephalus is a well-defined disorder which accounts for >7% of hydrocephalus in males.
Pathologically, the condition is characterized by stenosis or obliteration of the aqueduct of Sylvius. Previous
genetic linkage studies have suggested the likelihood of genetic homogeneity for this condition, with close
linkage to the DXS52 and F8C markers in Xq28. We have investigated a family with typical X-linked aqueductal
stenosis, in which no linkage to these markers was present. In this family, close linkage was established to the
DXS548 and FRAXA loci in Xq27.3. Our findings demonstrate that X-linked aqueductal stenosis may result
from mutations at two different loci on the X chromosome. Caution is indicated in using linkage for the prenatal
diagnosis of X-linked hydrocephalus.
Introduction
Hydrocephalus unassociated with neural tube defect is
a clinical entity of diverse etiology. It has a birth preva¬
lence of ~ 1/1,700 (Halliday et al. 1986). There is an
excess of males affected with hydrocephalus, resulting
from the existence of a well-defined X-linked recessive
form of the condition (HSAS1, X-linked aqueductal
stenosis; MIM 307000; McKusick 1992). This was first
recognized by Bickers and Adams (1949) and reinvesti¬
gated by Edwards (1961). Since HSAS1 accounts for
>7% of hydrocephalus in males (Halliday et al. 1986), it
is likely to have a birth prevalence of >1/25,000. Path-
ogenetically, HSAS1 may result from a primary CNS
malformation which includes stenosis or obliteration
of the aqueduct of Sylvius, connecting the third and
fourth ventricles. This interpretation of the pathologi¬
cal features has, however, been disputed by others, who
feel that aqueductal stenosis may be a secondary fea¬
ture (Landrieu et al. 1979). Other principal manifesta¬
tions are either hypoplasia or absence of pyramidal
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tracts, enlarged ventricles, varying degrees of mental
and physical handicap, and the presence of clasped
thumbs.
A common clinical problem is the need to decide
whether an isolated case of hydrocephalus in a male is
due to HSAS1. In this situation, there is dispute over
the significance to be attached to individual clinical
features, including presence of clasped thumbs and ra¬
diological evidence of aqueductal stenosis, which have
been claimed by some to be specific to the X-linked
disorder. HSAS1 is frequently associated with a poor
outcome because of severe hydrocephalus and asso¬
ciated CNS malformations. Perinatal death is common.
However, clinical and genetic similarities with the
MASA syndrome (mental retardation, aphasia, shuf¬
fling gait, and adducted thumbs), which appears to map
genetically to the same region of the X chromosome
(Winter et al. 1989; Macias et al. 1992), have raised the
possibility that these disorders may be allelic variants
encompassing a spectrum of severity within this condi¬
tion (Schrander-Stumpel et al. 1990; Fryns et al. 1991).
For better understanding of the basis of these clinical
features, detailed molecular genetic analysis of
HSAS1/MASA will be required. Linkage of HSAS1 to
the markers DXS52 and F8C in Xq28 was first reported
by Willems et al. (1990). Subsequent reports have con¬
firmed this linkage in additional families and refined the
localization of HSAS1 to a region of ~2 Mb between
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DXS52 and F8C (Holden et al. 1990; Orth et al. 1991;
Lyonnet et al. 1992; Serville et al. 1992; Willems et al.
1992; Jouet et al. 1993). On this basis, Willems et al.
(1990, 1992) have advocated the use of these Xq28
markers for prenatal diagnosis of X-linked hydrocepha¬
lus. Here, however, we report a family with "classical"
X-linked aqueductal stenosis, in which the disease is
not genetically linked to Xq28 markers. Linkage to the
FRAXA region of Xq27.3 was demonstrated, with a
maximum two-point LOD score of 2.23. These findings
suggest that locus heterogeneity is a potential source of
error in prenatal diagnosis of hydrocephalus by using
linked markers and that, wherever possible, linkage to a




DNA was extracted from whole blood by the
method of Miller et al. (1988). Digests were performed
on 5-10 |ig DNA, electrophoresed in 0.8% agarose
gels, and blotted onto Hybond N+ in 0.4 M NaOH.
Hybridizations were carried out overnight at 65°C in a
mix containing 5 X SSC, 5 X Denhardt's, 0.1% SDS,
0.1% sodium pyrophosphate, 50% dextran sulfate, and
100 pg sonicated denatured herring-testes DNA/ml.
Filters were washed at 65°C to a final stringency of 0.1
X SSC and autoradiographed with intensifying screens
for an average of 2 d. PCR amplifications were carried
out according to the recommendations of the authors
listed in table 1.
Cytogenetic Analysis
Detailed cytogenetic studies were carried out on
blood from III-8. Peripheral blood lymphocytes stimu¬
lated with phytohemagglutinin were cultured in two
different media (RPMI 1640 Dutch modification and
Ham's F10) supplemented with 10% fetal bovine
serum. Culture times of 48 and 72 h were used (the
former to try to detect any abnormal cell lines unable to
progress beyond the first division). Induction of rare
and common fragile sites was attempted using thymidy-
late stress (Gosden et al. 1992). High-resolution chro¬
mosomal banding was carried out by synchronizing the
cells with excess thymidine, releasing the block by three
washes of prewarmed serum-free RPMI 1640, incubat¬
ing for a further 3.75 h, and then adding rolcemid for
15 min prior to harvesting (Gosden et al. 1992). Cyto-
logical preparations and high-resolution banding using
a modified acetic saline Giemsa method were used
(Gosden et al. 1992). Identical chromosomal studies
were also performed on 12 control females of compara¬
ble age with no history of X-linked disease. Chromo¬
somal analysis was done by three methods: first, by
using direct microscopic analysis; second, by preparing
photomicrographs of X chromosomes from the pro¬
band (IV-8) and from control subjects; and finally, by
using computer-aided analysis (Piper and Granum
1989), which allows alignment of very long X chromo¬
somes from different cells, for comparison of band
sizes. The computer analysis used includes special pro¬
grams for "straightening" the high-resolution banded
chromosomes, which allows direct comparisons of the
X chromosomes from the subject and the controls, on a
flexible screen. Measurements of bands of the distal
part of the long arm of the X chromosome and detailed
examinations for rearrangements such as inversions
were undertaken. Microdensitometry of the bands of
the distal portion of the long arm of the X chromo¬
somes was carried out.
Linkage Analyses
Two-point linkage analysis was carried out using the
MLINK component of the LINKAGE program pack¬
age, version 5.2 (Lathrop and Lalouel 1984). The gene
frequency and new mutation rate for HSAS2 are un¬
known. If most X-linked hydrocephalus is due to
HSAS1 (L1CAM) mutations, with a disease frequency
of 1 /20,000 (5 X 10"5), HSAS2 must be rarer. We arbi¬
trarily chose a mutation rate of 10~J/gamete. If male
and female mutation rates are equal and the disease is
reproductively lethal, this corresponds (in a population
at equilibrium) to a gene frequency of 3 X 10~5 (Ott
1991). These figures were used for the MLINK calcula¬
tion. Complete penetrance for the disease was assumed.
Deceased individuals IV-3, IV-4, and IV-5 were coded
as affected, as the clinical information was unam¬
biguous. Since multilocus fingerprinting proved that
III-2 and III-3 were MZ twins, they were coded as a
single individual with two partners. Multipoint analyses
were also carried out using the LINKMAP component
of LINKAGE, analyzing two overlapping groups of six
loci. VNTR alleles were condensed to a maximum of
three, according to the methods of Ott (1978).
Results
The pedigree of the family is shown in figure 1. It was
verified by DNA fingerprinting (see Discussion). Four
males were unambiguously affected with aqueductal steno¬
sis, though only IV-8 could be examined in person.
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Case Reports
Case I (IV-3).—The pregnancy (in 1973) was unre¬
markable until 32 wk gestation, when the uterus was
felt to be enlarged. Gross enlargement of the fetal head
was seen on abdominal X-ray at 34 wk. Spontaneous
labor occurred at 36 wk; cerebrospinal fluid was
drained by puncture at the time of delivery. Gross hy¬
drocephalus was confirmed after delivery; the baby sur¬
vived ~2 h. No further details were available.
Case 2 (IV-4).—At the end of this pregnancy (in
1974) Cesarean section was performed on account of
massive hydrocephalus. The heart was beating at deliv¬
ery, but the child did not breathe; no resuscitation was
attempted. At autopsy it was reported that "there were
abnormalities of the hands and fingers." There was
massive dilatation of both cerebral ventricles, with
paper-thin cortex, indicative of obstructive hydroceph¬
alus. The brain was not fixed. However, the olfactory
nerves were said to be absent, and the posterior fossa
was poorly formed.
Case 3 (IV-5).—The third pregnancy occurred in
1980. Ultrasound scanning suggested hydrocephalus
late in pregnancy, and labor was induced at 38 wk.
Cesarean section was performed after failure to pro¬
gress. Birth weight was 3.8 kg, occipitofrontal circum¬
ference (OFC) 42.5 cm. Apgar scores were 3 at 1 min
and 3 at 5 min. The baby survived for 8 d. At autopsy,
the brain was removed and fixed intact. There was
gross bilateral ventricular dilatation, with only a few
millimeters thickness of brain tissue overlying the con¬
vexities. The septum pellucidum and corpus callosum
were absent; the latter was represented only by a thin
membrane between the lateral ventricles. The anterior
part of the third ventricle and the foramina of Munro
were dilated. The fourth ventricle, brain stem, and cere¬
bellum were normal, but the aqueduct was completely
occluded. On histological sections, the aqueduct was
represented by an anterioposterior cleft with closely
apposed walls, rather than the usual triangular shape.
Section through the ventricular wall showed a more or
less normal cortex, a narrow sheet of white matter, and
a subependymal layer of small round cells, with no visi¬
ble lining epithelium.
Case 4 (IV-8).—The only surviving affected individ¬
ual in this family was born in 1990. Ultrasound scan¬
ning at 19 wk gestation had shown no abnormality.
Elective Cesarean section was performed at term. Birth
weight was 4.7 kg, and Apgar scores were 6, 10, and 10
at 1, 5, and 10 min, respectively. OFC was 49 cm. Gross
hydrocephalus was present at birth; cranial ultrasound
showed enormous dilatation of the lateral ventricles,
mild dilatation of the third ventricle, and a normal
fourth ventricle. The cerebellar vermis was normal, the
cerebral cortex 8 mm thick. Thumbs were reported to
be adducted at birth, but this feature was less apparent
later in infancy. Opening pressure at ventricular tap was
15 mm Hg. A ventriculoperitoneal shunt was inserted
at age 5 d. Cranial ultrasound at age 9 wk revealed
absence of septum pellucidum and corpus callosum.
Computed tomography scanning at age 8 mo con¬
firmed these anatomical abnormalities, by detecting "a
complicated midline dysraphic problem with probable
partial agenesis of the corpus callosum." Sagittal and
coronal craniosynostosis necessitated radical craniec¬
tomy at the age of 10 mo. Formal psychological assess¬
ment at the age of 24 mo placed the boy's performance,
in various areas, in the 6-10 mo range.
Linkage Study
The clinical and pathological diagnosis of typical, se¬
vere X-linked aqueductal stenosis was therefore well
established prior to the linkage study. We initially stud¬
ied markers reported elsewhere (Willems et al. 1990,
1992) to be closely linked to HSAS1. For the purposes
of the multipoint linkage analysis, additional markers
4D-8 (DXS98), pRNl (DXS369), and VK23B (DXS297),
in the interval DXS105-DXS296, and 767 (DXS115),
distal to F8C, which were only partially informative,
were included (Boggs and Nussbaum 1984; Arveiler et
al. 1988; Oostra et al. 1990; Suthers et al. 1991).
Markers which were uninformative in this family were
VK14 (DXS292), St35-691 (DXS305), pi 14.12 (F8C),
and F8C (HmdIII RFLP). The DNA probes used in this
study are listed in table 1. As shown in table 2, the distal
Xq28 markers previously shown to be linked to HSAS1
gave negative LOD scores in our family. We therefore
began to analyze more proximal long-arm markers. The
order of the markers used is well established, and a
consensus map of the region is shown in figure 2. The
markers DXS548 and FRAXA (defined by the CGG
trinucleotide repeat number) are within 150 kb of each
other (Riggins et al. 1992). For both markers, the allele
coded "1" in figure 1 segregates with the hydrocepha¬
lus. A peak two-point LOD score of 2.23 was calcu¬
lated at a recombination fraction (0) of 0. Using the
genetic distances shown in figure 2, multipoint linkage
calculation was performed. This indicated a most-likely
location between DXS105 and DXS296, for the disease
gene (fig. 2). Although we are continuing to attempt
closer localization of the gene within this interval,
markers analyzed so far within this region (DXS98,
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DXS369, DXS297, and DXS292) have been uninforma-
tive.
Cytogenetic Studies
No abnormalities were detected in the X chromo¬
somes in the mother (II1-8) of the proband, and in par¬
ticular no abnormalities of the distal part of the long
arm. No differences could be seen between the two X
chromosomes of III-8 or between her X chromosomes
and those of control subjects (which had been cultured
under identical conditions) by using all the methods of
analysis described.
Discussion
The family described here is clinically typical of X-
linked hydrocephalus, with a perinatal death in three
cases and poor outcome in the surviving infant. In one
case, full neuropathological study proved the existence
of aqueductal stenosis; additional brain malformations
were also present. The linkage heterogeneity demon¬
strated here cannot therefore be related to a clinically
atypical picture. Negative LOD scores were obtained
with the probes DXS15, DXS52, and F8C. In previous
studies (Willems et al. 1990, 1992; Orth et al. 1991;
Serville et al. 1992), these markers have been shown to
be linked to HSAS1; recombinants between HSAS1
and DXS52 or between HSAS1 and F8C have given a
likely position in the interval DXS52-F8C, for the
HSAS1 gene. A candidate gene within this interval
(L1CAM) has been shown to be aberrantly spliced as
the result of a point mutation in one HSAS1 family
(Rosenthal et al. 1992). In addition, though, to our fam¬
ily, it should be noted that one previously reported
Table 2
Two-Point Linkage Analysis
LOD Score at 9
Locus (Probe) .0 .01 .05 .1 .2 .3 .4 °max
DXS105 (55.E) -2.47 -1.45 -.22 .21 .46 .41 .21 .46 .22
DXS548 ((CA)„) 2.23 2.21 2.11 1.95 1.57 1.10 .54 2.23 .00
FRAXA ((CGG)J 2.23 2.21 2.11 1.95 1.57 1.10 .54 2.23 .00
DXS296 (VK21A) -2.47 .21 .82 .98 .95 .71 .36 1.00 .13
DXS304 (U6.2) -2.47 -1.94 -.77 -.30 .05 .13 .09 .13 .30
DXS52 (F814) -2.47 -2.45 -1.68 -.94 -.27 .00 .07 .07 .40
DXS15 (DX13) -2.47 -1.71 -.48 -.02 .28 .29 .17 .31 .25
F8C ((CA)„) -2.47 -1.72 -.52 -.09 .17 .17 .09 .18 .24








Figure 2 Multipoint linkage analysis of X-linked hydrocephalus with Xq27-q28 markers. LINKMAP was used to calculate LOD scores
from the following 0 values and map, by analyzing two overlapping groups of six markers: DXS105-.039-DXS98-.123-DXS369-.0-DXS297-
.037-DXS548-.0-FRAXA-.012-DXS296-.012-DXS304-.12-DXS52-.005-DXS15-.015-F8C-.012-DXS115. The relative order of the loci is
taken from Feil et al. (1990), Williamson et al. (1991), and Riggins et al. (1992). The 0 values are based on data from Wehnert et al. (1990),
Richards et al. (1991), Suthers et al. (1991), and Riggins et al. (1992). The Haldane map function was used to convert 0 values to map distance.
HSASl family gave negative LOD scores for Xq28
markers (Orth et al. 1991; Willems et al. 1992).
The maximum possible two-point LOD score obtain¬
able in our family, from a fully informative marker
showing no recombination with the disease, is 2.71 (de¬
termined by use of a dummy marker in an MLINK
calculation). In the family that wc studied, the peak
two-point LOD score of 2.23 at 9 = 0 was obtained
with the DXS548 and FRAXA (FMR-1) loci. A number
of points are worth comment with regard to these data.
First, individual 11-3 is the sole discordant member of
the family, having the hydrocephalus-associated 1,1
haplotype for DXS548,FRAXA. He may demonstrate a
recombination, occurring in 1-1, between the disease
and these markers, or alternatively he may indicate that
11-2 represents a new mutation for X-linked hydroceph¬
alus. Since additional markers proximal to FRAXA
(DXS98, DXS369, DXS297, and DXS292) have proved
uninformative in this family, we cannot at present dis¬
tinguish between these alternatives; it is not possible to
say whether a recombination has occurred in the inter¬
val between DXS105 (proximal to the putative HSAS2
gene) and DXS296 (distal), in the first generation.
Second, the disease segregates with an unusual CGG
repeat number at the FRAXA locus. This allele (coded
"1" in fig. 1) was estimated to consist of 41 CGG trinu¬
cleotides (not shown). Alleles of n > 41 account for
<2% of normal chromosomes (Fu et al. 1991). How¬
ever, this allele is still within the normal size range (the
range not showing any meiotic instability) (Fu et al.
1991). The faint possibility that instability of the repeat
could be involved in the disease was eliminated by
Southern blotting using the probe StB 12.3 (Hbzdlll di¬
gest) (Oberle et al. 1991; Rousseau et al. 1991). This
showed homogeneous, normal sized bands in the sur¬
viving affected boy and his mother (IV-8 and 111-8).
Third, markers within Xq28 showed an unexpect¬
edly high frequency of recombination in this family. In
particular, in three cases (111-2/3, 111-10, and 111-12)
there is recombination in the interval between DXS304
and DXS52 (9 = .12), and in one case (111-8) there is
recombination in the interval between DXS52 and
DXS15 (0 = .005). As expected from this observation,
two-point intermarker analysis fails to show evidence
for significant linkage between some pairs of loci (data
not shown). Nonetheless, significantly negative LOD
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scores at the true value of 0 were not observed between
any adjacent pair of the markers shown in figure 2 (data
not shown). Also, no obligatory double-recombination
events have occurred in this family within the 38-cM
interval covered by these markers. Because we initially
suspected that the high number of recombinants might
indicate incorrect pedigree structure, all individuals on
the pedigree were rebled and reanalyzed for most of the
markers. No discordant analyses were found, which
eliminated sample identification errors. The entire ped¬
igree was also analyzed by multilocus fingerprinting us¬
ing the probe 33.6 (Jeffreys et al. 1985; Ferrie et al.
1991), which verified the pedigree structure as shown.
(This analysis also demonstrated that III-2 and III-3
were MZ twins, as indicated.) Trivial explanations for
the unusual recombination frequencies have thus been
eliminated. However, we appreciate the theoretical pos¬
sibility that in our family local peculiarities of the
Xq27-q28 region have affected the segregation of al¬
leles in this region. Because of this, detailed cytogenetic
analysis of the carrier female III-8 was performed (see
Material and Methods), with no evidence found for any
abnormality of Xq28.
Case reports indicate that rapid ventricular dilatation
in HSAS1 may occur only late in pregnancy or even
postnatally (Jansen 1975). Since, as a result, prenatal
diagnosis of X-linked hydrocephalus by obstetric ultra¬
sound is very unsatisfactory, genetic diagnosis would be
of great value. Willems et al. (1990, 1992) have advo¬
cated the use of Xq28 markers for this purpose. How¬
ever, the lack of linkage to this region, in our family,
suggests that caution must be exercised and that prena¬
tal diagnosis should only be offered if linkage or muta¬
tion studies within the individual family support link¬
age to a particular marker. Our experience also suggests
that clinical criteria are unlikely to be of any help in
discriminating between genetic types of X-linked hydro¬
cephalus.
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Re: Diagnostic potential of fetal renal biopsy
This interesting paper by Greco et al. (1993) has
demonstrated that fetal renal biopsy is technically
feasible, but it gave no indication that pain relief
was provided for the fetuses (who were not ben¬
efited by the investigation). In our nursery, it
would not be considered civilized to put a 20-gauge
needle into the kidney of a 25-week infant without
analgesia; why should it be acceptable for a fetus
of the same age?
The question of the age at which a fetus feels
pain is difficult. Thalamo-cortical connections are
established by 24 weeks, and pain fibres to the
brain stem and thalamus are fully myelinated by 30
weeks (Anand and Hickey, 1987; Porter, 1989).
Even a second-trimester fetus moves away, at least
as a reflex, from a needle tip.
1 feel strongly that consideration should be given
to adequate fetal analgesia in all procedures
involving invasion of the fetus itself, whether they
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Prenatal diagnosis of X-linked hydrocephalus
Serville et al. (1993) report the successful predic¬
tion of normal outcome in two pregnancies at 25
per cent risk for X-linked hydrocephalus (HSAS;
McKusick catalogue No. 307000). They advocate
the use of Xq28 polymorphisms (particularly those
in the interval DXS52-F8C) for prenatal diagnosis
of this disorder. The HSAS1 locus is allelic with
LI CAM, encoding a neural cell adhesion molecule,
which lies within this interval (Rosenthal et al.,
1992).
In one family, the prenatal diagnosis rested on
firm ground, since linkage of the disease to the
Xq28 markers used for prenatal diagnosis had
already been established by a study of this family.
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However, the second family was small, with only
weak evidence in favour of Xq28 linkage. In this
situation, as discussed by the authors, prenatal
diagnostic accuracy depends on the supposition of
locus homogeneity for HSAS1IL1CAM.
We would like to caution against unguarded
application of the approach advocated by Serville
et al. We have recently studied two Scottish
families.
In one (Strain et al., 1994) there have been four
cases of severe X-linked hydrocephalus, with three
perinatal deaths, and, in the surviving baby, severe
hydrocephalus at birth with high morbidity. A full
neuropathological study of one infant confirmed
typical HSAS with severe aqueductal stenosis.
Negative LOD scores were obtained with all Xq28
markers tested, ruling out the involvement of the
Xq28 locus in this family, despite the classical
clinicopathological presentation.
We have also restudied a previously reported
family (Fried, 1972) in which variable mental
retardation, gait abnormalities, spasticity, and, in
some affected individuals, hydrocephalus are
inherited in an X-linked pattern. The condition in
this family bears a close resemblance to the MASA
syndrome, now believed to be allelic to HSAS1I
LI CAM. Again, we found no evidence for Xq28
linkage, with small negative LOD scores against all
markers in this region.
In addition, one other small HSAS family
reported by Willems et al. (1992) also exhibited
recombination events between an entire Xq28 hap-
lotype and the disease locus, but is not mentioned
in the discussion by Serville et al.
Their own study, which Serville et al. cite in
support of genetic homogeneity (Lyonnet et al.,
1992), actually only involved five families. Their
impressively large family 1 (family 13 of Willems et
al., 1992) is linked to Xq28, with a LOD score of
4-57 against DXS52, but this family alone accounts
for most of the total LOD score of 7-2 in the five
families. Altogether, linkage data have now been
reported on about 20 families (13 in Willems et al.,
1992; 4 in Jouet et al., 1993; 3 in Lyonnet et al.,
1992). Only family 12 of Willems et al. (1992) and
our own family 1 appear clearly to fit the criteria
for HSAS without showing linkage to Xq28, but
this alone may mean that up to 10 per cent of
families could be unlinked to Xq28. This possibil¬
ity was discussed by Willems et al. (1992). The lack
of linkage to Xq28 in the Fried family (Fried,
1972; Fried and Sanger, 1973) similarly suggests
caution in assessment of families where the MASA
syndrome is part of the differential diagnosis. We
feel that there is an appreciable risk of error in
DNA-based prenatal diagnosis of HSAS/MASA
unless mutational or linkage studies have con¬
firmed involvement of LI CAM in the individual
family.
Lisa Strain, David J. H. Brock
and David T. Bonthron
Human Genetics Unit,
Department of Medicine (WGH)
University of Edinburgh.
Western General Hospital.
Edinburgh EH4 2XU. U.K.
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Discordant segregation of Xq28 markers
and a mutation in the LI gene in a family with
X linked hydrocephalus
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X linked recessive hydrocephalus is the
most common hereditary form of hydro¬
cephalus. Genetic analysis indicates that
the majority of cases are caused by mut¬
ations in a single gene in Xq28, recently
identified as the gene for neural cell ad¬
hesion molecule LI. Genetic heterogeneity
for this disorder was suggested following
the description of a single large pedigree
where X linked hydrocephalus showed lack
of linkage to Xq28 markers flanking the
LI gene. Mutation analysis in this family
shows a single base pair deletion within
the coding sequence of the LI gene that
would result in truncation of the mature
protein. The nature of the mutation and
its segregation with the disease through
the pedigree indicate that it is the cause
of X linked hydrocephalus in this family.
These results are at odds with data ob¬
tained through segregation of alleles for
markers flanking the LI gene. Somatic and
germline mosaicism is the most plausible
explanation for these data, which also pro¬
vide further evidence for genetic homo¬
geneity of X linked hydrocephalus.
{J Med Genet 1996;33:248-250)
Key words: X linked hydrocephalus; Xq28 markers; LI
gene.
X linked recessive hydrocephalus is char¬
acterised by enlarged cerebral ventricles,
mental retardation, spastic paraplegia, and,
frequently, flexion deformities of the thumbs.'
Genetic linkage analysis has placed the gene
for this disorder within Xq28.2 Recently we
and others showed that X linked hydrocephalus
and the related disorders MASA syndrome
(mental retardation, aphasia, shuffling gait, and
adducted thumbs) and spastic paraplegia type
1 (SPG1) result from mutations in the gene
for neural cell adhesion molecule LI.3~" Link¬
age data indicate that X linked hydrocephalus
is genetically homogeneous.121' One exception
was reported by Strain et a/16 where two re¬
combination events were observed between
Xq28 markers that flank the LI locus and the
disease gene within a single pedigree (fig 1A).
Repeated sampling and DNA fingerprinting
were used to eliminate the possibility of sample
misidentification, and thus the existence of a
second gene for X linked hydrocephalus was
suggested. Germinal mosaicism, a higher than
usual recombination rate, or a chromosomal
rearrangement in Xq28 could also explain these
data and in view of these possibilities mutation
analysis of the LI gene was undertaken.
The 28 exons of the LI gene from subject
19 (fig 1A) were screened using SSCP (single
strand conformation polymorphism) and het-
eroduplex analysis" and a single mobility shift
observed for exon 23. Sequencing showed de¬
letion of a single adenosine at position 3088
within the coding sequence1' (fig 2). The con¬
sequence of this mutation for LI protein struc¬
ture is illustrated in fig 3. A frameshift would
lead to insertion of 72 new amino acids after
amino acid 1029 of the mature protein and
premature termination owing to creation of a
downstream stop codon (UGA). Truncation
of the protein would occur before the trans¬
membrane domain, eliminating the potential
for normal cell surface expression of LI.
This mutation was most easily visualised by
heteroduplex analysis which was therefore used
to show complete segregation of the deletion
with the disorder within the pedigree (fig IB).
Heteroduplexes are visible for the two affected
boys and four obligate carrier females, whereas
none of six healthy sons of carrier mothers has
the mutation. This includes the two healthy
brothers (9 and 14) who had previously been
shown to have inherited the same Xq28 haplo-
type as their carrier sisters for markers flanking
the LI gene (fig 1A). One possible explanation
for the genetic results obtained with this family
is gonadal mosaicism of subject 3. However,
using DNA from blood samples obtained on
two separate occasions, this person was re¬
peatedly identified as a somatic carrier of the
deletion.
Two lines of evidence indicate that the muta¬
tion identified in the LI gene causes the dis¬
order in this family. Firstly, the mutation
segregates with the disease despite discordant
segregation of alleles for flanking markers. Sec¬
ondly, the nature of the mutation is similar to
that observed in other families with severe X
linked hydrocephalus. We have identified three
additional mutations in three independent
families that would result in truncation of the
LI protein before the transmembrane domain"
(unpublished observations). All three families
represent the severe end of the clinical spectrum
observed for this disorder.
An explanation is required for the discordant
genetic data described for this family. One
possibility is the occurrence of double re-
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Figure 1(A) Genetic analysis showing that subjects 9 and 14 have inherited the same haplotype for markers flanking
LI as carrier females and affected boys (LI lies between DXS15 and F8C). Data for DXS52, DXS15, and F8C are
from Strain et al.'6 Data for DXS1177 and DXS1108 were derived for this report and confirm the original observations.
(B) Segregation of the mutation throughout the pedigree as shown by heteroduplex analysis. The presence of the upper
heteroduplex band is diagnostic of the presence of the 1 bp deletion.
combination events between Xq28 poly¬
morphic markers DXS52 and F8C. The
genetic distance between F8C and DXS52 is
approximately 1% recombination.18 The prob¬
ability of two recombination events within this
interval is very small and would have to have
occurred twice to account for the haplotypes
of subjects 9 and 14. A further unlikely ex¬
planation is that local rearrangement of LI in
this family has displaced LI from its flanking
loci which could be addressed by multicolour
FISH analysis. The most parsimonious and
likely explanation is that subject 3 is a somatic
and germinal mosaic for the deletion owing to
mutation in early embryogenesis and, as a
result, has contributed the same haplotype,
with a mutation, to carrier daughters 5, 6, and
11, and without a mutation to healthy sons 9
and 14. This hypothesis is supported by the
observation that there has clearly been a new
mutation in . the genesis of subject 3 as all
haplotypes inherited by affected or carrier sub¬
jects are grandpaternal. Furthermore, com¬
bined somatic and germinal mosacism has been
well documented previously.1920
Whatever the explanation for the disparity,
these data have a bearing on genetic counselling
of this family and provide further evidence for






















Figure 2 Sequence analysis of exon 23 from patient and
healthy subject DNA. Exon 23 zuas amplified with
primers G39 and g40 and primer G39 was used for
sequencing.
Ig type C2 Fn type III TM C
NH -COOH
1029
Figure 3 Structure of the LI protein showing immunoglobulin type C2 (IgC2),
fibronect.in (Fn) type III, transmembrane (TM), and cytoplasmic (C) domains. The
position of amino acid 1029 is indicated by an arrow.
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